
<html lang="en"     class="pb-page"  data-request-id="c4798e1f-9a08-46f4-b98b-16dc7ba9d510"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-11;article:article:10.1021/acs.jmedchem.5b01938;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)" /></meta><meta name="dc.Creator" content="James D.  Osborne" /></meta><meta name="dc.Creator" content="Thomas P.  Matthews" /></meta><meta name="dc.Creator" content="Tatiana  McHardy" /></meta><meta name="dc.Creator" content="Nicolas  Proisy" /></meta><meta name="dc.Creator" content="Kwai-Ming J.  Cheung" /></meta><meta name="dc.Creator" content="Michael  Lainchbury" /></meta><meta name="dc.Creator" content="Nathan  Brown" /></meta><meta name="dc.Creator" content="Michael I.  Walton" /></meta><meta name="dc.Creator" content="Paul D.  Eve" /></meta><meta name="dc.Creator" content="Katherine J.  Boxall" /></meta><meta name="dc.Creator" content="Angela  Hayes" /></meta><meta name="dc.Creator" content="Alan T.  Henley" /></meta><meta name="dc.Creator" content="Melanie R.  Valenti" /></meta><meta name="dc.Creator" content="Alexis K.  De Haven Brandon" /></meta><meta name="dc.Creator" content="Gary  Box" /></meta><meta name="dc.Creator" content="Yann  Jamin" /></meta><meta name="dc.Creator" content="Simon P.  Robinson" /></meta><meta name="dc.Creator" content="Isaac M.  Westwood" /></meta><meta name="dc.Creator" content="Rob L. M.  van Montfort" /></meta><meta name="dc.Creator" content="Philip M.  Leonard" /></meta><meta name="dc.Creator" content="Marieke B. A. C.  Lamers" /></meta><meta name="dc.Creator" content="John C.  Reader" /></meta><meta name="dc.Creator" content="G. Wynne  Aherne" /></meta><meta name="dc.Creator" content="Florence I.  Raynaud" /></meta><meta name="dc.Creator" content="Suzanne A.  Eccles" /></meta><meta name="dc.Creator" content="Michelle D.  Garrett" /></meta><meta name="dc.Creator" content="Ian  Collins" /></meta><meta name="dc.Description" content="Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidat..." /></meta><meta name="Description" content="Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidat..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 23, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01938" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01938" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01938" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01938" /></link>
        
    
    

<title>Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01938" /></meta><meta property="og:title" content="Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0016.jpeg" /></meta><meta property="og:description" content="Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic–pharmacodynamic (PK–PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01938"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01938">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01938&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01938&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01938&amp;href=/doi/10.1021/acs.jmedchem.5b01938" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5221-5237</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01571" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b02016" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (<i>R</i>)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=James+D.++Osborne">James D. Osborne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Thomas+P.++Matthews">Thomas P. Matthews</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tatiana++McHardy">Tatiana McHardy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicolas++Proisy">Nicolas Proisy</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kwai-Ming+J.++Cheung">Kwai-Ming J. Cheung</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Lainchbury">Michael Lainchbury</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nathan++Brown">Nathan Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+I.++Walton">Michael I. Walton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+D.++Eve">Paul D. Eve</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+J.++Boxall">Katherine J. Boxall</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Angela++Hayes">Angela Hayes</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alan+T.++Henley">Alan T. Henley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Melanie+R.++Valenti">Melanie R. Valenti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Alexis+K.++De+Haven+Brandon">Alexis K. De Haven Brandon</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Box">Gary Box</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yann++Jamin">Yann Jamin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon+P.++Robinson">Simon P. Robinson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Isaac+M.++Westwood">Isaac M. Westwood</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rob+L.+M.++van+Montfort">Rob L. M. van Montfort</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Philip+M.++Leonard">Philip M. Leonard</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marieke+B.+A.+C.++Lamers">Marieke B. A. C. Lamers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+C.++Reader">John C. Reader</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=G.+Wynne++Aherne">G. Wynne Aherne</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Florence+I.++Raynaud">Florence I. Raynaud</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suzanne+A.++Eccles">Suzanne A. Eccles</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+D.++Garrett">Michelle D. Garrett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ian++Collins">Ian Collins</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Cancer Research UK Cancer Therapeutics Unit and <sup>‡</sup>Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Sareum Ltd., Cambridge CB22 3FX, U.K.</span></div><div class="corresp-info"><strong>*</strong>Phone: +44 2087224000. Fax: +44 2087224126. E-mail: <a href="/cdn-cgi/l/email-protection#b0d9d1de9ed3dfdcdcd9dec3f0d9d3c29ed1d39ec5db"><span class="__cf_email__" data-cfemail="0c656d62226f63606065627f4c656f7e226d6f227967">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01938&amp;href=/doi/10.1021%2Facs.jmedchem.5b01938" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5221–5237</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 11, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 December 2015</li><li><span class="item_label"><b>Published</b> online</span>23 May 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 June 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01938" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01938</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by text">with CC-BY<a href="/page/policy/authorchoice_ccby_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01938"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5163</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">13</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01938" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;James&quot;,&quot;last_name&quot;:&quot;D. Osborne&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;P. Matthews&quot;},{&quot;first_name&quot;:&quot;Tatiana&quot;,&quot;last_name&quot;:&quot;McHardy&quot;},{&quot;first_name&quot;:&quot;Nicolas&quot;,&quot;last_name&quot;:&quot;Proisy&quot;},{&quot;first_name&quot;:&quot;Kwai-Ming&quot;,&quot;last_name&quot;:&quot;J. Cheung&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Lainchbury&quot;},{&quot;first_name&quot;:&quot;Nathan&quot;,&quot;last_name&quot;:&quot;Brown&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;I. Walton&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;D. Eve&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;J. Boxall&quot;},{&quot;first_name&quot;:&quot;Angela&quot;,&quot;last_name&quot;:&quot;Hayes&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;T. Henley&quot;},{&quot;first_name&quot;:&quot;Melanie&quot;,&quot;last_name&quot;:&quot;R. Valenti&quot;},{&quot;first_name&quot;:&quot;Alexis&quot;,&quot;last_name&quot;:&quot;K. De Haven Brandon&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Box&quot;},{&quot;first_name&quot;:&quot;Yann&quot;,&quot;last_name&quot;:&quot;Jamin&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;P. Robinson&quot;},{&quot;first_name&quot;:&quot;Isaac&quot;,&quot;last_name&quot;:&quot;M. Westwood&quot;},{&quot;first_name&quot;:&quot;Rob&quot;,&quot;last_name&quot;:&quot;L. M. van Montfort&quot;},{&quot;first_name&quot;:&quot;Philip&quot;,&quot;last_name&quot;:&quot;M. Leonard&quot;},{&quot;first_name&quot;:&quot;Marieke&quot;,&quot;last_name&quot;:&quot;B. A. C. Lamers&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;C. Reader&quot;},{&quot;first_name&quot;:&quot;G.&quot;,&quot;last_name&quot;:&quot;Wynne Aherne&quot;},{&quot;first_name&quot;:&quot;Florence&quot;,&quot;last_name&quot;:&quot;I. Raynaud&quot;},{&quot;first_name&quot;:&quot;Suzanne&quot;,&quot;last_name&quot;:&quot;A. Eccles&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;D. Garrett&quot;},{&quot;first_name&quot;:&quot;Ian&quot;,&quot;last_name&quot;:&quot;Collins&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;23&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;5221-5237&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01938&quot;},&quot;abstract&quot;:&quot;Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic–pharmacodynamic (PK–PD) properties gave a compound with low predicted doses and exposures in humans which mitigated th&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01938&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01938" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01938&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01938" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01938&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01938" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01938&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01938&amp;href=/doi/10.1021/acs.jmedchem.5b01938" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01938" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01938" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01938%26sid%3Dliteratum%253Aachs%26pmid%3D27167172%26genre%3Darticle%26aulast%3DOsborne%26date%3D2016%26atitle%3DMultiparameter%2BLead%2BOptimization%2Bto%2BGive%2Ban%2BOral%2BCheckpoint%2BKinase%2B1%2B%2528CHK1%2529%2BInhibitor%2BClinical%2BCandidate%253A%2B%2528R%2529-5-%2528%25284-%2528%2528Morpholin-2-ylmethyl%2529amino%2529-5-%2528trifluoromethyl%2529pyridin-2-yl%2529amino%2529pyrazine-2-carbonitrile%2B%2528CCT245737%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D11%26spage%3D5221%26epage%3D5237%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/jmcmar.2016.59.issue-11/20160609/jmcmar.2016.59.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic–pharmacodynamic (PK–PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84742" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84742" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The serine-threonine kinase CHK1 is a critical component of the cellular response to DNA damage, especially the repair of DNA breaks arising during replication or caused by DNA-damaging chemotherapies and ionizing radiation.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> CHK1 is activated by the upstream kinases ataxia telangiectasia and Rad3-related (ATR), and, to a lesser extent, ataxia telangiectasia mutated (ATM).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> CHK1 is phosphorylated on residues S317 and S345 by ATR and undergoes autophosphorylation on S296.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The activated enzyme phosphorylates a range of substrates, including the cell division cycle 25 (CDC25) family of phosphatases that regulate cell cycle progression, with the result that the cell cycle is halted at checkpoints in Synthesis (S) or Gap 2 (G2) phase.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> At the same time, CHK1 initiates DNA repair by homologous recombination through signaling to the repair protein RAD51.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The cell cycle checkpoints controlled by CHK1 therefore provide an opportunity for repair of the damaged DNA before the replicating cell enters mitosis. If the damage is resolved, the checkpoint is released and cell growth and division recommence, while prolonged activation of the checkpoint leads to senescence or cell death.</div><div class="NLM_p">The DNA damage response (DDR) mediated by ATR-CHK1 provides a mechanism for cancer cells to resist DNA-damaging anticancer therapies and is an attractive point of intervention for new treatments.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A strong body of evidence shows that inhibition of CHK1 with small molecules, or depletion by ribonucleic acid (RNA) interference, selectively sensitizes tumor cells to genotoxic drugs and ionizing radiation.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Normal cells have multiple DNA-damage checkpoints, including the important p53-dependent Gap 1 (G1) phase checkpoint. However, many cancer cells harbor defects in one or more of these checkpoints, for example, due to frequent deletion, mutation, and loss of function of the tumor suppressor p53, and rely on the S and G2 checkpoints mediated by CHK1 to effect repair of DNA damage.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">The potential of CHK1 inhibition as a monotherapy has been demonstrated in tumor cells with replication stress. These tumors rely on the CHK1-mediated DDR to repair intrinsically high levels of DNA strand breaks, for example, arising from increased replication fork stalling in S phase, and include cancers driven by v-myc avian myelocytomatosis viral oncogene homologue (MYC) and v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homologue (MYCN) oncogenes<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> as well as some melanomas and triple-negative breast cancers.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a></div><div class="NLM_p">There has been substantial activity in developing CHK1 inhibitors for clinical study in combination with various DNA-damaging agents.<a onclick="showRef(event, 'ref7 ref13'); return false;" href="javascript:void(0);" class="ref ref7 ref13">(7, 13)</a> While the first clinical studies have demonstrated the tolerability of CHK1 inhibition, further progression has often been challenging and development of several agents has been halted after early phase clinical trials. Some of the first-generation inhibitors have low selectivity for CHK1 and were developed as intravenous agents. Subsequent to the identification of these compounds, studies showed that maximum potentiation of gemcitabine efficacy in preclinical models was associated with exposure to the CHK1 inhibitor during a window beginning some 24 h after administration of the genotoxic agent.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> Consequently, an oral compound would offer advantages of ease of administration and flexibility of scheduling. In addition, preclinical data on the emerging contexts for CHK1 monotherapy suggests that daily dosing may be needed, for which an oral drug would again be favored. The oral CHK1 inhibitors GDC-0425 and GDC-0575 have been reported in phase I clinical trials.<a onclick="showRef(event, 'ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref16 ref17">(16, 17)</a> There remains a clear need for highly selective oral CHK1 inhibitors from different chemical series to advance to clinical studies.</div><div class="NLM_p">We previously reported the discovery and optimization of the first published selective oral CHK1 inhibitor (<i>R</i>)-3-((1-(dimethylamino)propan-2-yl)oxy)-5-((4-methoxy-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (<b>1</b>)<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> through a scaffold hybridization strategy starting from potent, selective, but highly metabolized inhibitor (<i>R</i>)-5-((8-chloroisoquinolin-3-yl)amino)-3-((1-(dimethylamino)propan-2-yl)oxy)pyrazine-2-carbonitrile (<b>2</b>) and the less potent but metabolically stable 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitrile <b>3</b> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>).<a onclick="showRef(event, 'ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref19 ref20">(19, 20)</a> While effective in preclinical models, compound <b>1</b> was suboptimal due to low metabolic stability in human hepatocytes, leading to predictions of poor human pharmacokinetics (PK) and a requirement for high doses. In parallel with the discovery of <b>1</b>, we pursued the multiparameter optimization of the 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles based on <b>3</b>, described herein, resulting in the identification of the potent and highly selective oral CHK1 clinical candidate, (<i>R</i>)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (<b>4</b>; CCT245737).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0001.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Summary of the evolution of the oral inhibitor tool compound <b>1</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and oral clinical development candidate <b>4</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07280" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07280" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Assay Cascade and Target Candidate Profile</h3><div class="NLM_p">The desired candidate profile was developed based on our experience with compounds <b>1</b> and <b>2</b>. Potent biochemical inhibition of CHK1 (IC<sub>50</sub> < 10 nM) was required. We measured CHK1 inhibition using a dissociation-enhanced lanthanide fluorescent immunoassay (DELFIA) format and also developed a microfluidic assay for CHK1 substrate phosphorylation with a larger dynamic range to accurately assess tight-binding compounds. High selectivity for CHK1 over other kinases was considered essential. In particular, inhibition of the structurally distinct DDR protein, checkpoint kinase 2 (CHK2), has been shown to be detrimental to the potentiation of the cytotoxicity of DNA damaging agents and radiotherapy by CHK1 inhibition.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> In contrast to <i>CHEK1</i>, encoding for the CHK1 protein, the <i>CHEK2</i> gene is a tumor susceptibility gene and selective inhibition of CHK2 does not sensitize cancer cells to a range of DNA-damaging agents.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> We also monitored compounds for inhibition of the cell cycle regulatory kinase, cyclin dependent kinase 1 (CDK1). Continued cell cycle progression into mitosis is necessary to expose cancer cells to the deleterious effects of enhanced DNA damage through checkpoint abrogation. Inhibition of cell cycle regulatory kinases such as CDK1, itself an indirect downstream target of activated CHK1, would lead to CHK1-independent cell cycle arrest that would confound interpretation of the cellular activity of the compounds. In both cases, we considered biochemical selectivity of >100-fold a minimum requirement. As lipophilic bases present a general risk of ion channel inhibition, we monitored hERG inhibition as a representative and clinically relevant off-target during lead optimization.</div><div class="NLM_p">Potent and highly selective inhibition of CHK1-dependent effects in human cancer cells was considered essential, and we specified an IC<sub>50</sub> < 100 nM for the abrogation of a CHK1-dependent etoposide-induced G2/M checkpoint in p53-deficient HT29 human colon cancer cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> To measure CHK1 selective effects in cells, the potency for the CHK1-specific checkpoint abrogation was compared with the nonspecific antiproliferative effect of the inhibitors in the same cell line, with a minimum requirement of 5-fold cellular selectivity.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> We used this ratio of cellular effects as an integrated surrogate for kinome-wide or other large scale biochemical profiling of multiple compounds during lead optimization. The growth of HT29 cells is not highly sensitive to selective inhibition of CHK1, thus the ratio of the potency for this CHK1-independent effect to that for the CHK1-dependent checkpoint abrogation informs on the target selectivity of the compounds. Compounds with sufficient cellular potency and selectivity were assessed for their ability to potentiate the cytotoxicity of the DNA-damaging agent gemcitabine in SW620 human colon cancer cells. CHK1 inhibition has been shown to synergize maximally with antimetabolites such as gemcitabine compared with other classes of DNA-damaging chemotherapies.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p last">Cellular studies of the tool compound <b>1</b> had shown that sustained inhibition of CHK1 signaling after administration of the DNA-damaging agent was required for maximal potentiation of the efficacy of the cytotoxic agent.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Therefore, compounds with sufficient metabolic stability, plasma concentration, and pharmacodynamic (PD) duration of action to give 24 h inhibition of the target following a single oral dose were sought. Inhibition of the autophosphorylation of CHK1 on S296 in HT29 human tumor xenografts was used as a PD measure of target protein engagement.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Optimization of in Vitro and PK Properties</h3><div class="NLM_p">Compound <b>3</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) presented an encouraging starting point for realization of the desired clinical candidate profile. While requiring increases in cellular potency and selectivity, the compound showed more than 400-fold selectivity for in vitro inhibition of CHK1 over CHK2 and was stable in mouse liver microsomes (MLM) (9% metabolized after 30 min; <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). To improve on <b>3</b>, we chose to retain the 5-aminopyrazine-2-carbonitrile group, as our extensive structural biology studies to develop the series had shown this group to interact optimally with unique protein-bound water molecules in CHK1, conferring high selectivity over other kinases.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Basic substitution at <i>C</i>-4 of the pyridine core was retained to maximize affinity through potential interactions with polar residues in the ribose binding pocket of the CHK1 active site, as we had previously shown for 5-((6-((piperidin-4-ylmethyl)amino)pyrimidin-4-yl)amino)pyrazine-2-carbonitrile (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM7">2YM7</a>) and other compounds prepared during the identification of <b>3</b>.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro Properties of Selected 4-Amino-Substituted Methyl 6-((5-Cyanopyrazin-2-yl)amino)nicotinates</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0013.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">CHK1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CHK2 IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">checkpoint abrogation IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">cellular selectivity (fold)<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (% inhibition @ 10 μM)<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left"><i>A</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">21 (±6)</td><td class="colsep0 rowsep0" align="center">9.6 (±2.4)</td><td class="colsep0 rowsep0" align="center">825 (±125)</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">11 (±0.1)</td><td class="colsep0 rowsep0" align="center">9.8 (±1.3)</td><td class="colsep0 rowsep0" align="center">440 (±130)</td><td class="colsep0 rowsep0" align="char" char=".">5.1</td><td class="colsep0 rowsep0" align="char" char=".">55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left"><i>A</i></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">19 (±1)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">850 (±450)</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">82</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left"><i>C</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">2.9 (±0.1)</td><td class="colsep0 rowsep0" align="center">14<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">129 (±62)</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">(<i>s</i>)-<i>D</i></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="center">1.0<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">11 (±5)</td><td class="colsep0 rowsep0" align="center">21<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">6.2</td><td class="colsep0 rowsep0" align="char" char=".">58</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left"><i>D</i><a class="ref internalNav" href="#t1fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="center">0.5<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a>,<a class="ref internalNav" href="#t1fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="center">2.2<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">12 (±6)</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">91</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">(<i>s</i>)-<i>E</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">7.0 (±0.3)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">2500<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">6.8</td><td class="colsep0 rowsep0" align="char" char=".">60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left"><i>rac</i>-<i>F</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">56<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>,<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="center">1100<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">42</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" align="left"><i>rac</i>-<i>G</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">2.2 (±0.3)</td><td class="colsep0 rowsep0" align="center">5.0<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">310<a class="ref internalNav" href="#t1fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">Determined in Caliper microfluidic assay, mean (±SD) for <i>n</i> = 2.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Determined in DELFIA, mean (±SD) for <i>n</i> = 2.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Abrogation of etoposide-induced G2 checkpoint arrest in HT29 human colon cancer cells, mean (±SD) for <i>n</i> = 2.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Ratio of antiproliferative GI<sub>50</sub> (measured in duplicate by sulforhodamine B (SRB) assay) to IC<sub>50</sub> for CHK1-mediated abrogation of etoposide-induced G2 checkpoint arrest in HT29 human cancer cells.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">Inhibition of hERG ion current in HEK cells overexpressing hERG ion channel (PatchExpress, Millipore Inc.), single determination at 10 μM.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Single determination.</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">Prepared as a mixture of (3<i>s</i>) and (3<i>r</i>) isomers.</p></div><div class="footnote" id="t1fn8"><sup>h</sup><p class="last">Below tight-binding limit of assay.</p></div></div></div><div class="NLM_p">Initially, we examined a range of 4-amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates to determine the scope for replacing the 4-(piperidine-4-methyl) substituent of <b>3</b>, with selected examples shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. Homologation (<b>5</b>) or truncation (<b>7</b>) of the linking alkyl chain, and <i>N</i>-methylation (<b>6</b> and <b>7</b>) of the piperidine were tolerated, with increased CHK1 inhibition and cellular potency for <b>7</b>. The tropane derivatives <b>8</b>, <b>9</b>, and <b>10</b> showed potent inhibition of CHK1 activity (IC<sub>50</sub> < 10 nM), translating to cellular potency of <100 nM for <b>8</b> and <b>9</b> and cellular selectivity exceeding the target threshold of 5-fold. The racemic piperidin-2-methyl analogue <b>11</b> retained the profile of <b>3</b>, while the racemic morpholin-2-yl-methyl derivative <b>12</b> had enhanced biochemical inhibition compared to the piperidines <b>3</b> and <b>11</b>, with more potent checkpoint abrogation in cells but a greater differential between biochemical and cellular activities.</div><div class="NLM_p">While the increased lipophilicity of the tropane derivatives led to improved potency and cellular selectivity, it was also associated with more potent hERG inhibition, particularly for the <i>N</i>-methyl derivative <b>9</b>. In contrast, the racemic morpholin-2-yl-methyl derivative <b>12</b> delivered enhanced CHK1 affinity with minimal hERG inhibition. Reductions of amine lipophilicity or basicity are documented as strategies for reducing hERG activity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> hERG inhibition by a wider group of 4-amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates prepared during this study, including those exemplified in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, showed a correlation with calculated ALogP (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Less potent hERG inhibition was more frequently associated with secondary amines with a total of three hydrogen bond donors (HBD) in the molecule, as shown by compounds <b>3</b>, <b>11</b>, and <b>12</b>, compared to tertiary amines (2 HBD). This indicated that an increased risk of hERG inhibition would be associated with compounds with higher calculated AlogP in this series, but this would need to be balanced with the potential for improved CHK1 cellular potency and selectivity with more lipophilic amines.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0002.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Relationship of hERG inhibition to calculated AlogP and HBD count for 4-amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates including examples specified in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">During the optimization of the series, selected compounds were screened for metabolic stability in MLM and typically showed <30% metabolism of the parent compound after 30 min (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). The mouse PK profiles of the esters <b>5</b> and <b>7</b> were determined (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Compound <b>5</b> showed moderate oral bioavailability (44%), high volume of distribution, and clearance greater than liver blood flow. In vivo clearance was substantially increased for the <i>N</i>-methylpiperidine analogue <b>7</b> despite similar MLM in vitro stability (26% and 28% metabolized after 30 min for <b>5</b> and <b>7</b>, respectively; <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S1</a>, Supporting Information). A number of methyl ester-substituted analogues in the related 3-alkoxy-5-(pyridin-2-ylamino)pyrazine-2-carbonitrile scaffold<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> were assessed for stability in human plasma, but no evidence for degradation was seen during a 60 min incubation (data not shown). To efficiently discriminate compounds on the basis of PK performance, we used a limited sampling strategy that compared plasma levels at 1 and 6 h after iv and po dosing<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> to assess compounds in vivo with promising in vitro potency and selectivity or with structural features important to the development of structure–activity relationships. This strategy provided a useful ranking of relative oral bioavailability and clearance. Selected compounds were subsequently progressed to full PK determinations (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vivo Mouse PK Properties of Selected Compounds Following Intravenous (iv) or Oral (po) Dosing</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center" char=".">iv dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (L/h/kg)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">Vss<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (L/kg)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (h)</th><th class="colsep0 rowsep0" align="center" char=".">po dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">8.45</td><td class="colsep0 rowsep0" align="char" char=".">60.5</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">54.7</td><td class="colsep0 rowsep0" align="char" char=".">20.2</td><td class="colsep0 rowsep0" align="char" char=".">0.36</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">7.85</td><td class="colsep0 rowsep0" align="char" char=".">7.25</td><td class="colsep0 rowsep0" align="char" char=".">1.6</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">6.75</td><td class="colsep0 rowsep0" align="char" char=".">26.8</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="char" char=".">1</td><td class="colsep0 rowsep0" align="char" char=".">0.50</td><td class="colsep0 rowsep0" align="char" char=".">1.15</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">8.25</td><td class="colsep0 rowsep0" align="char" char=".">10.4</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">6.35</td><td class="colsep0 rowsep0" align="char" char=".">14.8</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">6.70</td><td class="colsep0 rowsep0" align="char" char=".">43.9</td><td class="colsep0 rowsep0" align="char" char=".">8.1</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2.75</td><td class="colsep0 rowsep0" align="char" char=".">10.1</td><td class="colsep0 rowsep0" align="char" char=".">3.4</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">84</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">2.65</td><td class="colsep0 rowsep0" align="char" char=".">9.25</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">105</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Parameters from iv PK profile.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Calculated based on a 20 g mouse body weight.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Oral bioavailability.</p></div></div></div><div class="NLM_p">The crystal structure of <b>12</b> bound to CHK1 was determined (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N">5F4N</a>, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The 2-aminopyridine core formed hydrogen bonds with Glu85 and Cys87 in the kinase hinge region, as seen previously for compounds such as <b>2</b> (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM8">2YM8</a>).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The cyanopyrazine was positioned close to the side chain of Lys38. Importantly, both the nitrile and <i>N</i>-4 of the pyrazine ring were positioned to interact with bound water at the entrance to the pocket beyond the gatekeeper residue, one of a network of conserved water molecules resulting from the presence of the unique polar residue Asn59 in this pocket in CHK1 instead of the more common lipophilic side chains. Interactions with these bound waters are a CHK1 selectivity determinant for this and other series of CHK1 inhibitors, including other pyrazines.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> Consistent with this, compounds <b>3</b>, <b>5</b>, <b>6</b>, <b>7</b>, <b>9</b>, and <b>12</b> did not inhibit CDK1 (IC<sub>50</sub> > 10 μM).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0003.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Detail of the crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N">5F4N</a>) showing <b>12</b> (green) bound in the CHK1 ATP site with key residues (gray) and water molecules (red spheres) shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The crystallographic model indicated only the (<i>R</i>)-enantiomer of the morpholine to be bound. The protonated amine of the morpholine engaged in direct interactions with the side chain of Glu91 and the main chain carbonyl of Glu134. In addition, water-mediated interactions to Asn135 and Ser147 were observed, illustrating the rich set of potential contacts available to basic substituents in this region of the kinase and consistent with the generally high CHK1 affinity of the amine variants in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. The morpholine projected toward the main chain of residues Leu15, Gly16, and Glu17 in the P-loop but did not form close contacts. At the entrance to the ATP-pocket, the <i>C</i>-5 methyl ester substituent lay over the selectivity surface formed by Ser88, Gly89, and Gly90. No direct polar interactions of the ester to this moderately hydrophobic surface were observed, suggesting scope for optimization of contacts to the protein. Interestingly, binding of a second molecule of the inhibitor was detected in the crystal structure at a separate hydrophobic site in the <i>N</i>-terminal domain defined by Trp9, Tyr71, and Phe83, however, no specific polar interactions of the ligand to the protein were evident and this is unlikely to represent a biologically relevant site of action.</div><div class="NLM_p">In parallel with variation of the <i>C</i>-4 substituent, investigation of substitution at the <i>C</i>-5 position of <b>3</b> was undertaken. The <i>C</i>-5 ester substituent projects toward solvent and was anticipated to provide a handle to optimize in vitro activity and allow for modulation of PK properties. A diverse set of substituents from multiple scaffolds has been shown to be capable of binding in this region of CHK1.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Compounds were chosen to explore a range of physicochemical properties, and the resulting structure–activity relationship is illustrated for specific examples of different substituent types (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro Properties of Selected Substituted 5-((4-((Piperidin-4-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0014.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">CHK1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">checkpoint abrogation IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">cellular selectivity (fold)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">hERG (% inhibition @ 10 μM)<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="center">398 (±48)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="center">8.8 (±0.7)</td><td class="colsep0 rowsep0" align="center">4400 (±400)<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="char" char=".">76</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="center">55<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a>,<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">500</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="center">54 (±4)</td><td class="colsep0 rowsep0" align="center">>10000</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="center">4.7 (±0.8)<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">4000</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">52</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="center">12 (±1)</td><td class="colsep0 rowsep0" align="center">3100</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="char" char=".">34</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="center">50<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a>,<a class="ref internalNav" href="#t3fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">440</td><td class="colsep0 rowsep0" align="char" char=".">5.9</td><td class="colsep0 rowsep0" align="char" char=".">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="center">177 (±8)</td><td class="colsep0 rowsep0" align="center">600</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="center">92 (±7)</td><td class="colsep0 rowsep0" align="center">2500</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="char" char=".">64</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">Determined in Caliper microfluidic assay, mean (±SD) for <i>n</i> = 2.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Abrogation of etoposide-induced G2 checkpoint arrest in HT29 human colon cancer cells, single determination.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Ratio of antiproliferative GI<sub>50</sub> (measured in duplicate by SRB assay) to IC<sub>50</sub> for CHK1-mediated abrogation of etoposide-induced G2 checkpoint arrest in HT29 human cancer cells.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Inhibition of hERG ion current in HEK cells overexpressing hERG ion channel (PatchExpress, Millipore Inc.), single determination at 10 μM.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Mean (±SD) for <i>n</i> = 2.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last">Determined in DELFIA assay.</p></div><div class="footnote" id="t3fn7"><sup>g</sup><p class="last">Single determination.</p></div></div></div><div class="NLM_p">Replacement of the ester with tertiary alkyl amides led to decreased CHK1 inhibition, e.g., <b>13</b> (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). Secondary alkyl amides, e.g., <b>14</b>, were better tolerated for CHK1 affinity but had poor cellular activity, presumably as a result of the increased polarity and additional HBD compared to <b>3</b>. Secondary aryl amides such as <b>15</b> offered a better range of CHK1 potencies and retained some cellular activity with increased cellular selectivity over the ester <b>3</b>. Compound <b>15</b> also showed low hERG inhibition despite the addition of the lipophilic aryl substituent. However, the PK properties of <b>15</b> were discouraging, with high clearance and no detectable oral bioavailability (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Substitution with alkyl, alkenyl, and alkynyl groups at <i>C</i>-5 was tolerated for CHK1 inhibition, with a general preference for the unsaturated functionality at <i>C</i>-5 as represented by <b>17</b> and <b>18</b> compared to <b>16</b>. Aryl and heteroaryl substitution also retained CHK1 inhibition, as for example the phenyl <b>19</b> and oxadiazole <b>21</b> analogues. CHK1 inhibition was sensitive to substitution on the <i>C</i>-5 aryl group, as exemplified by 3-fluorophenyl analogue <b>20</b>.</div><div class="NLM_p">As the inhibitors are ATP-competitive, binding to an active conformation of CHK1 kinase (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>), we expected a decrease in potency in transferring from the CHK1 biochemical assays ([ATP] = 30 μM) to cells with high endogenous [ATP]. Esters (see <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), aryl amides, and heteroaryl or aryl <i>C</i>-5 substituents generally gave the most favorable ratio of potency for G2/M checkpoint abrogation to CHK1 biochemical inhibition (<100-fold).</div><div class="NLM_p">The SAR described above showed that identifying a clinical candidate CHK1 inhibitor would require balancing the lipophilicity and basicity of the molecules to generate potent CHK1 biochemical inhibition that translated to effective cellular activity and favorable PK properties while minimizing the risk of ion channel inhibition. We focused on 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles related to morpholine <b>12</b>. To help prioritize the selection of <i>C</i>-5 substituents, three in silico classification models were generated. These considered: CHK1 biochemical potency, ratio of CHK1-dependent cellular activity to CHK1 biochemical potency, and inhibition of the hERG ion channel (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Supporting Information</a>). The CHK1 biochemical potency model classified compounds with IC<sub>50</sub> < 25 nM as active, while the model for the ratio of CHK1-dependent cellular and enzyme activities classed as desirable those compounds that had a less than 50-fold ratio of cellular to enzyme potency. The focus on the translation to cellular potency was driven by the anticipated need for highly potent compounds to achieve a low projected dose in humans. As CHK1 inhibitors will be used as potentiators of conventional cytotoxic chemotherapy, it is important to minimize non-mechanism related toxicity to achieve tolerable combination schedules. Lastly, the hERG model classified compounds as hERG-inactive if their percentage inhibition was less than 40% @ 10 μM. Virtual molecules were constructed from two chemotypes that varied in one substituent position (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Figure S1</a>, Supporting Information). The first structure, relevant to this work, was based on morpholine <b>12</b> with variation of the <i>C</i>-5 substituent. The other structure considered was for the previously described series related to compound <b>1</b>.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Of the substituents selected to replace the <i>C</i>-5 group in the virtual library, 135 were selected by medicinal chemists and 1514 were extracted from commercially available building blocks. The combinatorial library was enumerated and, after the application of Lipinski Rule-of-Five heuristics, 1649 virtual structures were taken forward for prediction in the three models. The resulting predictions for each of these virtual molecules were used to aid selection of compounds for synthesis, using the normalized probabilities of satisfying the objectives of each of the three models and visual inspection.</div><div class="NLM_p">Representative 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles related to morpholine <b>12</b> are described in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Replacing the ester of <b>12</b> with substituted phenyl groups led to the single enantiomers <b>22</b>–<b>29</b>. In vitro inhibition of CHK1 was higher for the morpholine (<i>R</i>)-enantiomers (compare <b>22</b> vs <b>23</b> and <b>25</b> vs <b>26</b>), consistent with the observation of the (<i>R</i>)-enantiomer of <b>12</b> bound to CHK1 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Compounds <b>22</b>, <b>23</b>, <b>25</b>, and <b>26</b> were tested for inhibition of CHK2 and retained >100-fold selectivity for CHK1. The cellular profiles of these compounds were similar to <b>12</b>, with no improvement in cellular potency except for the 3-fluorophenyl analogue <b>25</b>. hERG inhibition was increased over <b>12</b> for these lipophilic analogues. Replacing the <i>C</i>-5-aryl groups by monocyclic heteroaromatics improved cellular potency, e.g., thiazole <b>30</b> and <i>N</i>-methyl pyrazole <b>31</b>. The (<i>R</i>)-enantiomer of the morpholine was again preferred (compare <b>31</b> vs <b>32</b>). Combining the polar pyrazole and lipophilic phenyl functionalities in the <i>N</i>-methylindazoles <b>33</b> and <b>34</b> compromised the cellular potency and selectivity compared to the corresponding pyrazole <b>31</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Properties of Selected Substituted 5-((4-((Morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0015.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">no.</th><th class="colsep0 rowsep0" align="center">R<sup>1</sup></th><th class="colsep0 rowsep0" align="center">R<sup>2</sup></th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center">CHK1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">checkpoint abrogation IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">cellular selectivity (fold)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">cellular efficacy (fold)<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center">hERG % inhibition (IC<sub>50</sub>, μM)<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="center">6.4 (±0.1)</td><td class="colsep0 rowsep0" align="center">900</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="center">11<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="center">1500</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">4-F</td><td class="colsep0 rowsep0" align="center">25 (±1)</td><td class="colsep0 rowsep0" align="center">800</td><td class="colsep0 rowsep0" align="char" char=".">6</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="center">6.4 (±0.6)</td><td class="colsep0 rowsep0" align="center">120</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">7.9</td><td class="colsep0 rowsep0" align="center">71 (8.8)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">3-F</td><td class="colsep0 rowsep0" align="center">17 (±4)</td><td class="colsep0 rowsep0" align="center">390</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">4.8</td><td class="colsep0 rowsep0" align="center">71 (8.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="center">5.2 (±1)</td><td class="colsep0 rowsep0" align="center">600</td><td class="colsep0 rowsep0" align="char" char=".">2.2</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">3,4-F<sub>2</sub></td><td class="colsep0 rowsep0" align="center">14 (±0.5)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>B</i></td><td class="colsep0 rowsep0" align="left">3,5-F<sub>2</sub></td><td class="colsep0 rowsep0" align="center">12 (±2)</td><td class="colsep0 rowsep0" align="center">630</td><td class="colsep0 rowsep0" align="char" char=".">6.7</td><td class="colsep0 rowsep0" align="char" char=".">7.6</td><td class="colsep0 rowsep0" align="center">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>C</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">0.5<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a>,<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">13</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">8.2</td><td class="colsep0 rowsep0" align="center">38 (56)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>D</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">0.9<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a> (±0.1)</td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">7.4</td><td class="colsep0 rowsep0" align="center">67 (8.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>D</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">3.2 (±0.8)</td><td class="colsep0 rowsep0" align="center">400</td><td class="colsep0 rowsep0" align="char" char=".">3.5</td><td class="colsep0 rowsep0" align="char" char=".">8</td><td class="colsep0 rowsep0" align="center">26 (22)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>E</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">8.5 (±1)</td><td class="colsep0 rowsep0" align="center">1000</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="center">51 (16)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>F</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">4.6 (±0.4)</td><td class="colsep0 rowsep0" align="center">240</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">1.9</td><td class="colsep0 rowsep0" align="center">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>G</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">0.5<a class="ref internalNav" href="#t4fn6" aria-label="f">f</a>,<a class="ref internalNav" href="#t4fn7" aria-label="g">g</a></td><td class="colsep0 rowsep0" align="center">280</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">39</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>G</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">2.2 (±0.4)</td><td class="colsep0 rowsep0" align="center">180</td><td class="colsep0 rowsep0" align="char" char=".">9.2</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td><td class="colsep0 rowsep0" align="center">28 (26)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left"><i>H</i></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">2.1 (±0.1)</td><td class="colsep0 rowsep0" align="center">72</td><td class="colsep0 rowsep0" align="char" char=".">12</td><td class="colsep0 rowsep0" align="char" char=".">5.6</td><td class="colsep0 rowsep0" align="center">47 (16)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left">–C≡CH</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">5.2 (±0.8)</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="char" char=".">29</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="center">68 (8.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left"><i>rac</i>-(<i>A</i>)</td><td class="colsep0 rowsep0" align="left">–C≡N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">23 (±3)</td><td class="colsep0 rowsep0" align="center">1600</td><td class="colsep0 rowsep0" align="char" char=".">24</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">(<i>S</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left">–<i>cyc</i>-Pr</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">7.4 (±1.4)</td><td class="colsep0 rowsep0" align="center">100</td><td class="colsep0 rowsep0" align="char" char=".">9</td><td class="colsep0 rowsep0" align="char" char=".">7.3</td><td class="colsep0 rowsep0" align="center">79 (6.6)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left">–CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">1.3 (±0.4)</td><td class="colsep0 rowsep0" align="center">30 (±11)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">23</td><td class="colsep0 rowsep0" align="char" char=".">17</td><td class="colsep0 rowsep0" align="center">76 (6.2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left">–Cl</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">1.9 (±0.8)</td><td class="colsep0 rowsep0" align="center">157 (±37)<a class="ref internalNav" href="#t4fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">14</td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="center">83 (6.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">(<i>R</i>)-<i>A</i></td><td class="colsep0 rowsep0" align="left">–F</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="center">14 (±1)</td><td class="colsep0 rowsep0" align="center"> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="center">39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">Determined in Caliper microfluidic assay, mean (±SD) for <i>n</i> ≥ 2.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Abrogation of etoposide-induced G2 checkpoint arrest in HT29 human colon cancer cells, single determination.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">Ratio of antiproliferative GI<sub>50</sub> (measured in duplicate by SRB assay) to IC<sub>50</sub> for CHK1-mediated abrogation of etoposide-induced G2 checkpoint arrest in HT29 human cancer cells.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Fold-potentiation of gemcitabine cytotoxicity in SW620 human colon cancer cells, determined as the ratio of GI<sub>50</sub> (test compound)/GI<sub>50</sub> (test compound + fixed dose Gemcitabine) in an SRB assay (ref <a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">19</a>).</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last">Inhibition of hERG ion current in HEK cells overexpressing hERG ion channel (PatchExpress, Millipore Inc.), single determination at test concentration of 10 μM, IC<sub>50</sub> determination (<i>n</i> = 1) in parentheses.</p></div><div class="footnote" id="t4fn6"><sup>f</sup><p class="last">Single determination in DELFIA assay.</p></div><div class="footnote" id="t4fn7"><sup>g</sup><p class="last">Below tight-binding limit of assay.</p></div><div class="footnote" id="t4fn8"><sup>h</sup><p class="last">Mean (±SD), <i>n</i> ≥ 3.</p></div></div></div><div class="NLM_p">The ability of selected compounds to potentiate the efficacy of the cytotoxic drug gemcitabine in p53-deficient SW620 human colon cancer cells was investigated (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The cell active <i>C</i>-5-aryl analogues <b>25</b> and <b>26</b> had moderate cellular selectivity, and both potentiated the efficacy of gemcitabine. While the thiazole and pyrazole analogues <b>30</b>–<b>32</b> strongly potentiated gemcitabine cytotoxicity in cells, the indazoles <b>33</b> and <b>34</b> surprisingly showed minimal activity. The cellular selectivities of <b>33</b> and <b>34</b> were reduced compared with other analogues, suggesting that off-target activities may be confounding the CHK1-dependent effects.</div><div class="NLM_p">Key <i>C</i>-5-aryl and <i>C</i>-5-heteroaryl analogues were screened for in vivo PK properties (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The 3-fluorophenyl derivative <b>25</b> showed a similar in vivo clearance and bioavailability to the ester <b>5</b>. The thiazole <b>30</b> had low in vivo clearance but poor oral bioavailability, presumed to be due to poor absorption and consistent with the 20-fold lower volume of distribution for this compound. The potent pyrazole <b>31</b> was assessed in vivo by limited sampling PK, where a drop in plasma levels at 6 h to <20% of those at 1 h indicated a high clearance relative to <b>5</b> and the compound was not profiled further.</div><div class="NLM_p">In tandem with (hetero)aryl groups, non-aryl <i>C</i>-5-substituents were prepared in the 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitrile series (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). The 2-methylbut-3-yn-2-ols <b>35</b> and <b>36</b> potently inhibited CHK1 with cellular activity and selectivity similar to the aryl substituted analogues. The 1-ethynylcyclopentan-1-ol analogue <b>37</b> increased potency in vitro and in cells. Both <b>36</b> and <b>37</b> potentiated the efficacy of gemcitabine in SW620 cells, but the PK profile of <b>36</b> showed high clearance and low oral bioavailability (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_p">The terminal alkyne derivative <b>38</b> was found to retain cellular activity and to have exceptionally high cellular selectivity compared to other compounds in this series. The potentiation of the antiproliferative effects of gemcitabine by the alkyne <b>38</b> was also increased. The nitrile analogue <b>39</b> gave very high cellular selectivity but with reduced biochemical and cellular potency. Other small substituents at <i>C</i>-5 were investigated (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), and the structure–activity relationship for the potentiation of gemcitabine cytoxicity in SW620 human colon cancer cells revealed an inverse correlation to the size of the <i>C</i>-5 substituent, as measured by molecular weight or heavy atom count (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The cellular selectivity for CHK1-mediated effects followed a similar trend. The crystal structure of <b>12</b> bound to CHK1 (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) indicated that substitution at the <i>C</i>-5-position would become directed into solvent with increasing size rather than making contacts with the CHK1 protein. We therefore speculate that the structure–activity relationships for high cellular efficacy and selectivity reflected confounding off-target interactions, possibly one or more kinases, that increased with increasing size of the <i>C</i>-5-substituent and interfered with the ability of the CHK1 inhibitor to potentiate genotoxic efficacy.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0004.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Relationship of efficacy and selectivity in SW620 colon cancer cells to molecular weight for 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles with <i>C</i>-5 substituents of various sizes, exemplified in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Points are color-coded by CHK1 cellular selectivity (red, low; green, high) and labeled with compound identifiers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Among the smaller substituents investigated at <i>C</i>-5, the cyclopropyl analogue <b>40</b> maintained potency but with decreased cellular selectivity and efficacy. In contrast, both the trifluoromethyl- <b>4</b> and chloro-derivative <b>41</b> had excellent potency and cellular selectivity and were strong potentiators of gemcitabine efficacy in cancer cells. Consistent with the cellular profile, these compounds were more than 1000-fold selective for CHK1 over CHK2 and CDK1. The importance of the presence of a suitable <i>C</i>-5 substituent for CHK1 affinity was shown by the fluoro analogue <b>42</b>, which was 10-fold less potent than <b>4</b>. Although more potent and efficacious in cells, the smaller and more lipophilic <i>C</i>-5 substituents were associated with micromolar hERG inhibition. This was balanced by an improvement in PK properties. Thus, the terminal alkyne <b>38</b> and cyclopropane <b>40</b> had improved oral bioavailability compared to <b>5</b>, while both the trifluoromethyl <b>4</b> and chloro analogue <b>41</b> had substantially reduced in vivo clearance and increased oral bioavailability (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Inhibition of CYP450 enzymes was determined for selected analogues, and compounds <b>36</b>, <b>38</b>, <b>40</b>, <b>41</b>, and <b>4</b> all showed IC<sub>50</sub> > 10 μM against the six isoforms tested (1A2, 2A6, 2C9, 2C19, 2D6, 3A4).</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Optimization of in Vivo Target Engagement and Efficacy</h3><div class="NLM_p">In parallel with the optimization of in vitro and PK properties, the PD properties of this series of CHK1 inhibitors were assessed in vivo. Following DNA damage, CHK1 is activated through phosphorylation on Ser317 and Ser345 by the upstream kinase ATR and undergoes autophosphorylation on Ser296. We therefore chose inhibition of the gemcitabine-induced CHK1 Ser296 autophosphorylation as a direct PD biomarker of CHK1 inhibition in vivo. Selected compounds with moderate to good oral bioavailability, high cellular selectivity, and gemcitabine-potentiating efficacy were assessed for tolerability in mice when administered in combination with gemcitabine (60 mg/kg iv). The compounds were then tested at the maximum tolerated combination dose for their ability to inhibit gemcitabine-induced pSer296 CHK1 in SW620 human colon cancer xenografts. It has been shown that maximum potentiation of genotoxic efficacy in cells and in vivo requires sustained inhibition of CHK1 signaling to prevent effective tumor cell DNA repair, and inhibition of CHK1 for at least 24–48 h following administration may be desirable.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14, 15)</a> We therefore sought compounds showing robust pSer296 inhibition up to 24 h following a single oral dose.</div><div class="NLM_p">The dose of compound <b>25</b> (80 mg/kg) was restricted by toxicity, although a partial inhibition of the CHK1 pSer296 signal was seen at 6 h (data not shown). In contrast, single doses of compounds <b>38</b> (300 mg/kg), <b>41</b> (300 mg/kg), and <b>4</b> (300 mg/kg) were very well tolerated. Compound <b>38</b> inhibited the gemcitabine-induced autophosphorylation of CHK1 at 6 h (not shown), but CHK1 kinase activity had recovered by 24 h (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>A). In contrast, the two compounds <b>41</b> and <b>4</b> inhibited gemcitabine-induced pS296 CHK1 for up to 24 h (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>B,C).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0005.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of gemcitabine (60 mg/kg iv) induced pSer296 CHK1 autophosphorylation at 24 h by 300 mg/kg po of (A) <b>38</b>, (B) <b>41</b>, and (C) <b>4</b> in SW620 human colon cancer xenografts. Dashed line indicates where Western blot image has been cut. (D) Total inhibitor concentrations of <b>38</b>, <b>41</b>, and <b>4</b> in plasma and SW620 tumor xenografts at 24 h after a single 300 mg/kg po dose (mean ± SD, <i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Inhibitor concentrations at 24 h were measured in plasma and the tumor xenografts (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>D). Plasma levels of between 4–8 μM were seen for <b>38</b>, <b>41</b>, and <b>4</b>. Similar levels of <b>38</b> were observed despite the higher clearance of this compound compared with <b>41</b> and <b>4</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Distribution to tumor tissue was seen for all compounds, with <b>4</b> achieving the highest tumor concentration.</div><div class="NLM_p">The antitumor efficacies of <b>41</b> and <b>4</b> were investigated in combination with gemcitabine in HT29 human colon cancer xenografts. The dosing schedule was selected based on our previous studies of the oral CHK1 tool compound <b>1</b><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> and involved the administration of two doses of the CHK1 inhibitors at 24 and 48 h after gemcitabine (100 mg/kg iv) in each of three weekly treatment cycles. Compounds <b>41</b> and <b>4</b> were dosed at their maximum tolerated dose (MTD) (150 mg·kg po) for this schedule in the xenograft tumor model (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Both compounds were well tolerated in combination with no significant decrease in body weight. A strong potentiation of the antitumor effect of gemcitabine was seen, consistent with the cell-based studies (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>), with minimal effects of the CHK1 inhibitors alone in this model. At these doses, tumor regressions were observed in 83% (<b>41</b>) and 100% (<b>4</b>) of the combination-treated cohorts at day 17 immediately following completion of the final treatment cycle.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0006.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacies of <b>41</b> (150 mg/kg po) and <b>4</b> (150 mg/kg po) in combination with gemcitabine (100 mg/kg iv) in HT29 colon cancer xenografts. The CHK1 inhibitors were administered as suspensions in DMSO–Tween80–PEG400–water (0.05:0.2:0.65:0.1) 24 and 48 h after gemcitabine in each of three weekly treatment cycles. Inset: body weights of cohorts as described in main figure. <i>N</i> = 4–6 per cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The in vitro and in vivo PK properties of <b>41</b> and <b>4</b> were investigated further (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). Both compounds had low oral bioavailability in rats. Although both were high clearance compounds, <b>4</b> had a lower clearance than <b>41</b>. Pleasingly, determination of the intrinsic clearance (CLint) in hepatocytes showed both compounds were substantially more stable in human hepatocytes than mouse, and <b>4</b> was more stable in human than rat and dog hepatocytes. In particular, <b>4</b> had a favorable low human hepatocyte CL<sub>int</sub>. Predictions of human clearance were made using physiological-based PK (PBPK) modeling<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and suggested that <b>4</b> would have a clearance in humans of 6% liver blood flow.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Additional in Vivo and in Vitro PK Data for <b>41</b> and <b>4</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><b>41</b></th><th class="colsep0 rowsep0" align="center"><b>4</b></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat PK</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CL (L/h/kg)</td><td class="colsep0 rowsep0" align="left">5.17</td><td class="colsep0 rowsep0" align="left">3.50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Vss (L/kg)</td><td class="colsep0 rowsep0" align="left">7.45</td><td class="colsep0 rowsep0" align="left">4.60</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hepatocyte CL<sub>int</sub> (μL/min/10<sup>6</sup> cells)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">22.1 (±2.6)</td><td class="colsep0 rowsep0" align="left">25.7 (±3.4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">43.4 (±9.96)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">nd<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">55.0 (±2.1)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">4.82 (±0.91)</td><td class="colsep0 rowsep0" align="left">2.72 (±0.61)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Determined at Cyprotex. Incubations at 3 μM. Mean (±SE).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Incubations in male CD-1 mouse hepatocytes.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">Not determined.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Incubations in mixed gender human hepatocytes.</p></div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> In Vitro and in Vivo Profile of Compound <b>4</b></h3><div class="NLM_p">Compound <b>4</b> was further profiled in vitro and in vivo. The solubility of <b>4</b> in pure water was 0.09 mg mL<sup>–1</sup>, rising to 1.5 mg mL<sup>–1</sup> in pH 6.5 phosphate buffer, consistent with the moderate basicity (p<i>K</i><sub>a</sub> = 7.87 ± 0.07)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and lipophilicity (Log <i>D</i><sub>7.4</sub> = 1.47 ± 0.04)<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and indicating good prospects for formulation as a salt. Compound <b>4</b> showed passive permeability across a CaCo2 cell monolayer (<i>P</i><sub>e</sub> = 25 × 10<sup>–6</sup> cms<sup>–1</sup>). The plasma protein binding of <b>4</b> was moderate (mouse <i>F</i><sub>u</sub> = 0.19, human <i>F</i><sub>u</sub> = 0.21, measured using dialysis with pH control). No change in the metabolic stability of <b>4</b> was observed in human liver microsomes in the presence and absence of glutathione, indicating that <b>4</b> does not undergo metabolic activation. While some electron-deficient heterocyclic nitriles have been reported to be chemically reactive under physiological conditions,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> we speculate that the balanced electronic donor–acceptor substitution pattern of the 5-aminopyrazine-2-carbonitrile prevents this reactivity. Compound <b>4</b> was not metabolized by human aldehyde oxidase.</div><div class="NLM_p">The kinome selectivity of <b>4</b> was assessed against a panel of 124 representative kinases in substrate phosphorylation assays ([ATP] = <i>K</i><sub>m,ATP</sub>).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Compound <b>4</b> showed <50% inhibition at 10 μM for 85/121 kinases, representing a selectivity for CHK1 inhibition of >5000-fold over these enzymes, while 12/124 (including CHK1) showed >80% inhibition at 10 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S2</a>, Supporting Information). The activity of these enzymes, along with the potential off-targets CDK1/2 and 5′-AMP-activated protein kinase (AMPK),<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> were titrated (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S3</a>, Supporting Information). Submicromolar activity was identified for seven kinases in this panel, with <b>4</b> showing 100-fold selectivity for CHK1 over the most potent off-target kinase activity identified (mitogen-activated protein kinase 15, ERK8) and more than 200-fold selectivity for CHK1 over other kinases tested. These data confirmed the expectation of high CHK1 selectivity from the cellular selectivity of <b>4</b>. While medium-throughput whole-kinome profiling during lead optimization is feasible, interpretation of the functional relevance of off-target binding assays remains difficult.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Our experience with this inhibitor series shows that appropriate cell-based mechanistic assays can drive compounds toward high kinome selectivity based on an integrative assessment of on- vs off-target outcomes in cancer cell lines.</div><div class="NLM_p">The ability of compound <b>4</b> to potentiate the anticancer efficacy of DNA-damaging agents was determined in a wider range of cancer cell lines (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S4</a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Potentiation of the efficacy of the antimetabolite gemcitabine (8–23-fold) was significantly greater than that for SN38 (1.8–3-fold), the active metabolite of the clinical topoisomerase 1 inhibitor irinotecan. Importantly, in addition to efficacy in colon cancer cell lines, compound <b>4</b> strongly potentiated gemcitabine efficacy in non-small cell lung cancer (NSCLC) and pancreatic cancer cell lines. These represent clinical indications where gemcitabine is part of current chemotherapy regimens and where tumors have a high frequency of p53 mutation or loss-of-function.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> Compromise of the p53-dependent DDR checkpoint may enhance the effectiveness of CHK1 inhibition in combination with genotoxic agents.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> The inhibition of CHK1 and antitumor efficacy of <b>4</b> was confirmed in NSCLC and pancreatic cancer tumor xenografts. In particular, <b>4</b> potentiated the efficacy of a gemcitabine and carboplatin combination in RAS mutant Calu6 human NSCLC xenografts.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> In vivo efficacy in combination with gemcitabine was further demonstrated in the KPC1 genetically engineered mouse model (GEMM) of p53- and V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue (KRAS)-deficient pancreatic ductal adenocarcinoma.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In cells derived from this model, <b>4</b> potentiated the antiproliferative effect of gemcitabine 18-fold in vitro. Allografts from established KPC1 mouse tumors were grown subcutaneously in female NCr athymic mice and treated with gemcitabine and three dose levels of <b>4</b> using the schedule developed during lead optimization. Some single agent efficacy of the highest dose of CHK1 inhibitor was observed in this model in addition to dose-dependent potentiation of gemcitabine efficacy (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0007.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>4</b> (150 mg/kg po) potentiates the tumor growth delay of gemcitabine in allograft KPC1 p53- and KRAS-deficient mouse pancreatic adenocarcinomas.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><i>N</i> = 8 per cohort. Red arrow = gemcitabine dosed; blue arrow = <b>4</b> dosed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Single-agent CHK1 inhibition has recently been identified as a potential therapeutic strategy for MYC-driven tumors that rely on the CHK1-mediated DDR pathway as a result of replication stress.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> We therefore assessed the efficacy of compound <b>4</b> in vivo in a GEMM of pediatric MYCN-driven neuroblastoma.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> After treatment for 7 days with compound <b>4</b> (150 mg/kg po UID), the weights of excised abdominal tumors were reduced compared with vehicle treated cohorts (T/C = 13%), and an individual mouse assessed by magnetic resonance imaging (MRI)<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> before and after dosing of <b>4</b> showed 85% reduction in the pretreatment tumor volume (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). Single-agent efficacy of <b>4</b> was also demonstrated in an Eμ-Myc driven mouse model of B-cell lymphoma.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0008.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>4</b> (150 mg/kg po UID for 7 d) inhibits tumor growth in the TH-MYCN GEMM of neuroblastoma.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (A) Comparison of tumor weights for vehicle- and compound-treated cohorts (mean ± SEM, <i>n</i> = 8). (B) Pre- and post-treatment T<sub>2</sub>-weighted MRI<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> assessment of an abdominal tumor in a single mouse treated with <b>4</b>. k = kidney.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Dose titration of <b>4</b> in combination with gemcitabine (100 mg/kg iv) was carried out in HT29 colon cancer xenografts to establish in vivo PK–PD relationships and determine a minimum effective dose in this preclinical tumor model. Compound <b>4</b> showed an increase in plasma and tumor concentrations between 3–100 mg/kg po.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Modulation of the pSer296 CHK1 autophosphorylation was assessed by Western blot from tumor lysates at 24 h after a single dose of <b>4</b>, administered 24 h after gemcitabine. Inhibition of pSer296 CHK1 at this time point was observed from 12.5–100 mg/kg dose of <b>4</b> with no effect for lower doses. Dose-dependent potentiation of gemcitabine efficacy in this model was also observed from doses of 12.5 mg/kg upward.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> Calculation of the plasma free drug levels of <b>4</b> from the PD dose titration suggested that complete CHK1 inhibition for 24 h after dosing of <b>4</b> was associated with achieving free drug levels of at least 15 nM at 24 h. Single species scaling from mouse<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and PBPK methods using Simcyp with limited and full simulations were used to predict human clearance and a dose equivalent to the minimum effective dose of 12.5 mg/kg in mice. Both methods predicted that <b>4</b> would show CHK1-dependent effects below 1 mg/kg in humans. For example, the simulated PK profile for a 25 mg total dose in humans predicted a plasma <i>C</i><sub>max,free</sub> of ca. 70 nM and <i>C</i><sub>24h,free</sub> of ca. 30 nM, suggesting an acceptable window over the in vitro potential for hERG inhibition existed at doses predicted to give free concentrations exceeding those relevant to preclinical biological activity in the human tumor model. Further profiling of cardiac ion channel inhibition was conducted, and <b>4</b> showed no inhibition (IC<sub>50</sub> > 10 μM) for seven other K, Ca, and Na ion channels (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Table S5</a>, Supporting Information).<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> The therapeutic window over potential cardiovascular effects was confirmed by an in vivo cardiovascular pharmacology study (data not shown). Compound <b>4</b> was selected for progression to preclinical development.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Chemistry</h3><div class="NLM_p">General procedures were developed for the synthesis of the <i>C</i>-4 amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates <b>3</b> and <b>5</b>–<b>12</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Methyl 4,6-dichloronicotinate (<b>43</b>) underwent selective S<sub>N</sub>Ar reaction with a range of amines to give the methyl 4-amino-6-chloronicotinate derivatives (<b>44</b>). The substituted pyrazine was introduced by Buchwald couplings of the chlorides <b>44</b> with 5-aminopyrazine-2-carbonitrile. The majority of compounds were prepared using tris(dibenzylideneacetone)dipalladium(0) and xantphos as the catalyst precursors and cesium carbonate as the base. When these conditions gave poor yields, we found that using tris(dibenzylideneacetone)dipalladium(0), 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl) (BINAP), and sodium <i>tert</i>-butoxide was successful. Deprotection of <i>N</i>-<i>tert</i>-butyloxycarbonyl (<i>N</i>-Boc) groups with trifluoroacetic acid was applied where required to generate the test compounds.</div><figure id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>3</b>, <b>5</b>–<b>15</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sup>1</sup>NH<sub>2</sub>, Et<sub>3</sub>N, <sup><i>n</i></sup>BuOH, 120 °C (microwave irradiation), 1.5 h; (ii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, NaO<sup><i>t</i></sup>Bu, toluene, 130 °C (microwave irradiation), 30 min; (iii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 130 °C (microwave irradiation), 30 min; (iv) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (v) NaOH, H<sub>2</sub>O, MeOH, rt, 3 h; (vi) MeNH<sub>2</sub> (2M, THF), HATU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt, 18 h; (vii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene/DMF (1:1), 130 °C (microwave irradiation), 120 min; (viii) (a) LiOH, H<sub>2</sub>O, <sup><i>t</i></sup>BuOH, rt, 4 d, (b) R<sup>2</sup>NH<sub>2</sub>, TBTU, rt, 18 h; (ix) (a) LiI, pyridine, 150 °C (microwave irradiation), 2.5 h, (b) <i>N</i>′-hydroxyacetimidamide, HATU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt, 18 h, (c) pyridine, 120 °C (microwave irradiation), 1 h.</p></p></figure><div class="NLM_p">The above procedures were adapted for the synthesis of the <i>C</i>-5 amide substituted analogues <b>13</b>–<b>15</b> and the <i>C</i>-5 1,2,4-oxadiazole substituted analogue <b>21</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The appropriate methyl 4-amino-6-chloronicotinate (<b>44</b>; R<sup>1</sup> = <i>N</i>-Boc-piperidin-4-ylmethyl) was hydrolyzed to the acid <b>45</b>. The acid <b>45</b> was converted to the amide under standard conditions and the pyrazine introduced by Buchwald reaction as before, to give <b>13</b> after deprotection. Secondary amides <b>14</b> and <b>15</b> were prepared from the intermediate ester (<b>44</b>; R<sup>1</sup> = <i>N</i>-Boc-piperidin-4-ylmethyl) through conversion to <b>46</b> before hydrolysis and coupling of the crude acid to aniline or ethylamine. Deprotection gave <b>14</b> and <b>15</b>. Alternatively, the intermediate methyl ester <b>46</b> was converted to the acid by S<sub>N</sub>2 dealkylation with lithium iodide in pyridine. The crude acid was coupled with <i>N</i>′-hydroxyacetimidamide and cyclized at high temperature to yield the 1,2,4-oxadiazole <b>21</b>.</div><div class="NLM_p">General procedures were developed for the synthesis of the <i>C</i>-5 alkenyl, aryl, and heteroaryl substituted analogues <b>17</b>, <b>19</b>, <b>20</b>, and <b>22</b>–<b>34</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). 2-Chloropyridin-4-amine (<b>47</b>) was iodinated to give 2-chloro-5-iodopyridin-4-amine (<b>48</b>).<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Introduction of <i>C</i>-4 amine substituents was effected by alkylation of the sodium anion of <b>48</b> with either <i>tert</i>-butyl 4-(bromomethyl)piperidine-1-carboxylate or the appropriate enantiomerically pure <i>tert</i>-butyl 2-((tosyloxy)methyl)morpholine-4-carboxylates to give the substituted iodopyridines <b>49</b>. Suzuki couplings to the iodides <b>49</b> using vinyl, aryl, and heteroaryl boronic acids or boronate esters generated the chloropyridines <b>50</b>. In turn, these were subject to Buchwald coupling with 5-aminopyrazine-2-carbonitrile followed by <i>N</i>-Boc deprotection to give the test compounds. For the thiazole analogue <b>30</b>, the Suzuki coupling step was replaced with a Stille coupling using 5-methyl-2-(tributylstannyl)thiazole.</div><figure id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0010.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>16</b>–<b>20</b> and <b>22</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ICl, KOAc, AcOH, 70 °C, 5 h; (ii) R<sup>1</sup>Br or R<sup>1</sup>OTs, NaH, DMF, 80 °C, 2 h; (iii) R<sup>2</sup>B(OR)<sub>2</sub>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub> (0.5M, H<sub>2</sub>O), MeCN, 100 °C (microwave irradiation), 20 min; (iv) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 150 °C (microwave irradiation), 1 h; (v) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (vi) 5-methyl-2-(tributylstannyl)thiazole, (Ph<sub>3</sub>P)<sub>4</sub>Pd, toluene, 90 °C, 18 h; (vii) HCl, dioxane, rt, 1 h; (viii) R<sup>3</sup>CCH, CuI, Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 120 °C (microwave irradiation), 10 min; (ix) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 18 h.</p></p></figure><div class="NLM_p">The above procedures were adapted for the synthesis of the <i>C</i>-5 alkynyl substituted analogues <b>18</b> and <b>35</b>–<b>38</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The iodopyridines <b>49</b> were subject to Sonogashira couplings to give the alkynylpyridines <b>52</b>, followed by introduction of the pyrazine by Buchwald reaction and <i>N</i>-deprotection. Synthesis of the <i>C</i>-5 alkyl substituted analogue <b>16</b> was achieved starting from the appropriate protected 5-alkynyl-2-chloropyridine (<b>52</b>; R<sup>1</sup> = <i>N</i>-Boc-piperidin-4-yl-methyl, R<sup>3</sup> = <sup><i>t</i></sup>BuMe<sub>2</sub>SiOCH<sub>2</sub>), which was coupled to 5-aminopyrazine-2-carbonitrile using Buchwald conditions, followed by hydrogenation of the alkyne to the saturated alkyl chain (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The <i>N</i>-Boc and <i>O</i>-<i>tert</i>-butyl-dimethylsilyl protecting groups were removed using trifluoroacetic acid.</div><div class="NLM_p">Synthesis of the <i>C</i>-5 nitrile analogue <b>39</b> was begun by selective S<sub>N</sub>Ar displacement of 4,6-dichloronicotinamide <b>53</b> using <i>tert</i>-butyl (<i>rac</i>)-2-(aminomethyl)morpholine-4-carboxylate to yield the chloropyridine <b>54</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The nitrile was then introduced by dehydration of the primary amide using trifluoroacetic anhydride. Buchwald coupling to install the pyrazine and <i>N</i>-deprotection followed as before.</div><figure id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0011.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>39</b> and <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>tert</i>-butyl (<i>rac</i>)-2-(aminomethyl)morpholine-4-carboxylate, Et<sub>3</sub>N, <sup><i>n</i></sup>BuOH, 120 °C (microwave irradiation), 1.5 h; (ii) (CF<sub>3</sub>CO)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (iii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, K<sub>3</sub>PO<sub>4</sub>, dioxane, 150 °C (microwave irradiation), 1 h; (iv) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (v) cyclopropylboronic acid pinacol ester, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub> (0.5M, H<sub>2</sub>O), MeCN, 130 °C (microwave irradiation), 1.5 h; (vi) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 130 °C (microwave irradiation), 45 min.</p></p></figure><div class="NLM_p">Synthesis of the <i>C</i>-5 cyclopropyl analogue <b>40</b> was achieved by reacting the appropriate 5-iodopyridine (<b>49</b>; R<sup>1</sup> = (<i>R</i>)-<i>N</i>-Boc-morpholin-2-yl-methyl) with cyclopropylboronic acid pinacol ester under Suzuki coupling conditions to give <b>55</b>, followed by Buchwald coupling of the pyrazine and <i>N</i>-deprotection (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><div class="NLM_p">General procedures were developed for the synthesis of the <i>C</i>-5 chloro- and fluoro-substituted analogues <b>41</b> and <b>42</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Commercially available pyridines <b>56</b> and <b>57</b> were <i>N</i>-alkylated with <i>tert</i>-butyl (<i>R</i>)-2-((tosyloxy)methyl)morpholine-4-carboxylate to give the chloropyridines <b>58</b> and <b>59</b>, respectively, which were subject to Buchwald coupling and <i>N</i>-deprotection to generate <b>41</b> and <b>42</b>.</div><figure id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0012.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds <b>4</b>, <b>41</b>, and <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>tert</i>-butyl (<i>R</i>)-2-((tosyloxy)methyl)morpholine-4-carboxylate, NaH, DMF, 80 °C, 2.5 h; (ii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 150 °C (microwave irradiation), 60 min; (iii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (iv) diphenyl phosphorazidate, Et<sub>3</sub>N, <sup><i>t</i></sup>BuOH, toluene, 105 °C, 5 h; (v) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 150 °C (microwave irradiation), 1 h; (vi) CF<sub>3</sub>CO<sub>2</sub>H, <sup><i>i</i></sup>Pr<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h.</p></p></figure><div class="NLM_p last">Synthesis of the <i>C</i>-5 trifluoromethyl substituted analogue <b>4</b> was begun by conversion of the commercially available 2-chloro-5-(trifluoromethyl)isonicotinic acid (<b>60</b>) to the 4-aminopyridine <b>61</b> by a Curtius–Hoffman reaction sequence<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). <i>N</i>-Alkylation using <i>tert</i>-butyl (<i>R</i>)-2-((tosyloxy)methyl)morpholine-4-carboxylate, followed by Buchwald coupling of 5-aminopyrazine-2-carbonitrile and morpholine <i>N</i>-deprotection, completed the synthesis of <b>4</b>.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51724" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51724" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Multiparameter lead optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles was conducted to identify potent and selective CHK1 inhibitors that potentiated the efficacy of genotoxic agents in vitro and in vivo. The use of cellular mechanism of action assays to give an integrated assessment of compound selectivity was critical to drive the in vitro optimization of the series and resulted in a highly CHK1 selective and ATP-competitive inhibitor. In particular, selective effects in cells were dependent on the size of a substituent directed away from the CHK1 kinase active site. Lipophilicity and basicity were observed to drive both CHK1 potency and off-target hERG ion channel activity with some overlapping structure–activity relationships. An acceptable therapeutic window over hERG inhibition was achieved by identifying molecules which gave potent CHK1 affinity and cellular activity through minimizing the size of the <i>C</i>-5 substituent.</div><div class="NLM_p last">Augmenting in vitro assays with an efficient in vivo PK screening strategy was important to select compounds with favorable oral PK properties from this series. In tandem, in vivo PD studies identified compounds giving prolonged target engagement following single oral dose, which is anticipated as important for the clinical success of CHK1 inhibition in combination with genotoxic drugs. Compounds with the desired PK–PD profile demonstrated efficacy in vivo in this setting. Compound <b>4</b> was profiled in depth and showed a favorable physicochemical, PK, and PD-efficacy profile. The high affinity and low predicted human clearance of the compound supported predictions of low doses to humans. This mitigated the residual in vitro hERG activity, confirmed by an in vivo cardiovascular pharmacology study (data not shown). Compound <b>4</b> (CCT245737) was selected for progression to preclinical development.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34328" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34328" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Chemistry: General Information</h3><div class="NLM_p last">Reactions were carried out under N<sub>2</sub>. Organic solutions were dried over magnesium sulfate or sodium sulfate. Starting materials and solvents were purchased from commercial suppliers and were used without further purification. Reactions heated by microwave irradiation were carried out using a Biotage Initiator microwave reactor. Flash silica column chromatography was performed using Merck silica gel 60 (0.025–0.04 mm). Gradient silica column chromatography was performed with a Biotage SP1 medium pressure chromatography system, using prepacked silica gel cartridges. Ion exchange chromatography was performed using Isolute Flash SCX-II (acidic) or Flash NH2 (basic) resin cartridges. <sup>1</sup>H NMR spectra were recorded on a Bruker AMX500 instrument at 500 MHz or on a Bruker Avance instrument at 400 MHz using internal deuterium locks. Chemical shifts (δ) are reported relative to TMS (δ = 0) and/or referenced to the solvent in which they were measured. Compounds were assessed for purity by tandem HPLC-MS. Combined HPLC-MS analyses were recorded using a Waters Alliance 2795 separation module and Waters/Micromass LCT mass detector with HPLC performed using Supelco DISCOVERY C18, 50 mm × 4.6 mm or 30 mm × 4.6 mm i.d. columns or using an Agilent 6210 TOF HPLC-MS with a Phenomenex Gemini 3 μm C18 (3 cm × 4.6 mm i.d.) column. Both HPLC systems were run at a temperature of 22 °C with gradient elution of 10–90% MeOH/0.1% aqueous formic acid at a flow rate of 1 mL/min and a run time of 3.5, 4, or 6 min. UV detection was at 254 nm and ionization was by positive or negative ion electrospray. The molecular weight scan range was 50–1000 amu. Biologically evaluated compounds gave >95% purity as determined by these methods.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Synthesis of Compound <b>4</b></h3><div id="sec4_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> (<i>R</i>)-5-(4-(Morpholin-2-ylmethylamino)-5-(trifluoromethyl)pyridin-2-ylamino)pyrazine-2-carbonitrile (<b>4</b>)</h4><div class="NLM_p last">NaH (60% in oil, 33 mg, 0.81 mmol) was added to a solution of 2-chloro-5-(trifluoromethyl)pyridin-4-amine (<b>61</b>) (80 mg, 0.41 mmol) in DMF (4 mL), and the mixture was stirred at rt for 10 min. The temperature was raised to 80 °C, and (<i>R</i>)-<i>tert</i>-butyl 2-(tosyloxymethyl)morpholine-4-carboxylate (181 mg, 0.488 mmol) was added portionwise. The reaction mixture was stirred at 80 °C for 2 h, then cooled to rt. The mixture was partitioned between saturated aqueous NaHCO<sub>3</sub> and EtOAc. The combined organic layers were washed with brine, dried, filtered, and concentrated. Flash column chromatography, eluting with a gradient of 10–20% EtOAc–hexanes, gave (<i>S</i>)-<i>tert</i>-butyl 2-((2-chloro-5-(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate (118 mg, 0.30 mmol, 73%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 8.24 (s, 1H), 6.61 (s, 1H), 5.32 (br s, 1H), 3.96–3.94 (m, 3H), 3.70–3.65 (m, 1H), 3.58 (ddd, <i>J</i> = 11.5, 11.5, and 2.6 Hz, 1H), 3.37–3.32 (m, 1H), 3.21–3.18 (m, 1H), 2.99 (br s, 1H), 2.77 (br s, 1H), 1.49 (s, 9H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz) δ 155.4, 154.3, 152.6, 147.4 (q, <i>J</i><sub>CF</sub> = 6.1 Hz), 124.7 (q, <i>J</i><sub>CF</sub> = 269.8 Hz), 108.6 (q, <i>J</i><sub>CF</sub> = 30.2 Hz), 106.0, 79.6, 73.8, 66.2, 46.2 (br), 44.5, 45.0 (br), 28.4 (3C). LCMS (3.5 min) <i>t</i><sub>R</sub> = 2.62 min; <i>m</i>/<i>z</i> (ESI<sup>+</sup>) 396 (M + H<sup>+</sup>). HRMS <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>22</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>3</sub> (M + H) 396.1296, found 396.1292. Dioxane (2.53 mL) was added to a mixture of (<i>S</i>)-<i>tert</i>-butyl 2-((2-chloro-5-(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate (100 mg, 0.25 mmol), 5-aminopyrazine-2-carbonitrile (42.5 mg, 0.35 mmol), Pd<sub>2</sub>dba<sub>3</sub> (19 mg, 0.02 mmol), Cs<sub>2</sub>CO<sub>3</sub> (165 mg, 0.50 mmol), and BINAP (25 mg, 0.04 mmol). Argon was bubbled through the suspension for 5 min. The mixture was heated by microwave irradiation at 150 °C for 1 h. The reaction mixture was cooled to rt and purified by ion exchange chromatography on SCX-II acidic resin, eluting with MeOH then 2 M NH<sub>3</sub> in MeOH. The basic fractions were combined and concentrated. Preparative thin layer chromatography, eluting with 2% MeOH–CH<sub>2</sub>Cl<sub>2</sub>, gave (<i>S</i>)-<i>tert</i>-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(trifluoromethyl)pyridin-4-ylamino)methyl)morpholine-4-carboxylate (69 mg, 0.144 mmol, 57%). <sup>1</sup>H NMR (CD<sub>3</sub>OD, 500 MHz) δ 8.97 (br s, 1H), 8.66 (br s, 1H), 8.19 (s, 1H), 7.34 (br s, 1H), 4.04 (br d, <i>J</i> = 12.9 Hz, 1H), 3.94 (br d, <i>J</i> = 10.5 Hz, 1H), 3.86 (ddd, <i>J</i> = 13.4, 1.3, and 1.3 Hz, 1H), 3.72–3.71 (m, 1H), 3.54 (ddd, <i>J</i> = 11.7, 11.7, and 2.5 Hz, 1H), 3.46–3.39 (m, 2H), 3.00 (br s, 1H), 2.77 (br s, 1H), 1.47 (s, 9H). <sup>13</sup>C NMR ((CD<sub>3</sub>)<sub>2</sub>SO, 125 MHz) δ 156.2, 154.3, 152.3, 152.0, 147.6, 146.4 (q, <i>J</i><sub>CF</sub> = 5.2 Hz), 137.3, 125.2 (q, <i>J</i><sub>CF</sub> = 271.8 Hz), 119.2, 117.5, 104.9 (q, <i>J</i><sub>CF</sub> = 21.0 Hz), 93.9, 79.6, 73.0, 66.3, 46.7 (br), 44.9 (br), 43.7 (br), 28.4 (3C). LCMS (3.5 min) <i>t</i><sub>R</sub> = 2.51 min; <i>m</i>/<i>z</i> (ESI<sup>+</sup>) 480 (M + H<sup>+</sup>). HRMS calcd for C<sub>21</sub>H<sub>25</sub>F<sub>3</sub>N<sub>7</sub>O<sub>3</sub> (M + H) 480.1966, found 480.1971. The above procedures were repeated to produce additional starting material for the next stage: CF<sub>3</sub>CO<sub>2</sub>H (4.7 mL, 61 mmol) was added to a solution of (<i>S</i>)-<i>tert</i>-butyl 2-((2-(5-cyanopyrazin-2-ylamino)-5-(trifluoromethyl)pyridin-4-ylamino)methyl)-morpholine-4-carboxylate (206 mg, 0.4 mmol) and (<sup><i>i</i></sup>Pr)<sub>3</sub>SiH (0.56 mL, 2.8 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (50 mL). The solution was stirred at rt for 1 h then solvents were removed by evaporation. The residue was purified by ion exchange chromatography on SCX-II acidic resin, eluting with MeOH then 2 M NH<sub>3</sub> in MeOH. The basic fractions were combined and concentrated. Trituration with 10% MeOH–CH<sub>2</sub>Cl<sub>2</sub> gave <b>4</b> (116 mg) as an amorphous solid. Purification of the mother liquids by preparative thin layer chromatography, eluting with 5% MeOH–CH<sub>2</sub>Cl<sub>2</sub>, gave additional material (22 mg) of similar purity. The two batches of material obtained were combined, redissolved in MeOH, and the solvent removed by evaporation to give <b>4</b> (138 mg, 0.364 mmol, 85%) as a pale-yellow amorphous solid. <sup>1</sup>H NMR ((CD<sub>3</sub>)<sub>2</sub>SO, 500 MHz) δ 10.7 (br s, 1H), 9.10 (d, <i>J</i> = 1.4 Hz, 1H), 8.77 (d, <i>J</i> = 1.4 Hz, 1H), 8.20 (s, 1H), 7.19 (s, 1H), 6.32 (br t, <i>J</i> = 5.5 Hz, 1H), 3.75 (br d, <i>J</i> = 11.0 Hz, 1H), 3.64–3.59 (m, 1H), 3.43 (ddd, <i>J</i> = 10.7, 10.7, and 3.4 Hz, 1H), 3.22 (m, 2H), 2.82 (dd, <i>J</i> = 12.1 and 2.1 Hz, 1H), 2.67–2.59 (m, 2H), 2.42 (dd, <i>J</i> = 12.1 and 10.0 Hz, 1H). <sup>13</sup>C NMR ((CD<sub>3</sub>)<sub>2</sub>SO, 125 MHz) δ 155.7, 151.9, 151.6, 147.2, 145.9 (q, <i>J</i><sub>CF</sub> = 6.3 Hz), 136.8, 124.8 (q, <i>J</i><sub>CF</sub> = 270.9 Hz), 118.9, 117.1, 104.4 (q, <i>J</i><sub>CF</sub> = 30.0 Hz), 93.2, 73.6, 67.2, 48.9, 45.4, 44.9. LCMS (3.5 min) <i>t</i><sub>R</sub> = 1.17 min; <i>m</i>/<i>z</i> (ESI<sup>+</sup>) 380 (M + H<sup>+</sup>).HRMS <i>m</i>/<i>z</i> calcd for C<sub>16</sub>H<sub>17</sub>F<sub>3</sub>N<sub>7</sub>O (M + H) 380.1441, found 380.1438.</div></div><div id="sec4_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-Chloro-5-(trifluoromethyl)pyridin-4-amine (<b>61</b>)</h4><div class="NLM_p last">Et<sub>3</sub>N (2.80 mL, 20 mmol) was added to a solution of 2-chloro-5-(trifluoromethyl)isonicotinic acid (<b>60</b>; 1.5 g, 6.6 mmol) and diphenyl phosphorazidate (2.14 mL, 9.9 mmol) in <sup><i>t</i></sup>BuOH (12 mL) and toluene (13.5 mL). The solution was stirred at 105 °C for 5 h. The reaction mixture was cooled to rt, and solvents were evaporated. The residue was partitioned between water and EtOAc. The combined organic layers were washed with brine, dried, filtered, and concentrated. Flash column chromatography, eluting with 10% EtOAc–hexanes, gave <i>tert</i>-butyl (2-chloro-5-(trifluoromethyl)pyridin-4-yl)carbamate (1.24 g, 4.2 mmol, 63%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 8.50 (s, 1H), 8.45 (s, 1H), 7.00 (br s, 1H), 1.57 (s, 9H). <sup>13</sup>C NMR (CDCl<sub>3</sub>, 125 MHz) δ 156.3, 150.4, 146.8 (q, <i>J</i><sub>CF</sub> = 7.1 Hz), 144.9, 123.0 (q, <i>J</i><sub>CF</sub> = 275.8 Hz), 112.7, 111.5 (q, <i>J</i><sub>CF</sub> = 31.2 Hz), 82.9, 27.6 (3C). LCMS (3.5 min) <i>t</i><sub>R</sub> = 2.77 min; <i>m</i>/<i>z</i> (ESI+) 297 (M + H<sup>+</sup>). HRMS calcd for C<sub>11</sub>H<sub>13</sub>ClF<sub>3</sub>N<sub>2</sub>O<sub>2</sub> (M + H) 297.0612, found 297.0627. CF<sub>3</sub>CO<sub>2</sub>H (6.44 mL, 84 mmol) was added to a solution of <i>tert</i>-butyl (2-chloro-5-(trifluoromethyl)pyridin-4-yl)carbamate (1.24 g, 4.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (16.5 mL). The solution was stirred at rt for 5 h. Solvents were removed by evaporation, and the residue was purified by ion exchange chromatography on SCX-II acidic resin, eluting with MeOH then 2 M NH<sub>3</sub> in MeOH. The basic fractions were combined to give 2-chloro-5-(trifluoromethyl)pyridin-4-amine (<b>61</b>; 0.736 g, 3.8 mmol, 90%). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 500 MHz) δ 8.30 (s, 1H), 6.66 (s, 1H), 4.77 (br s, 2H). <sup>13</sup>C NMR (CD<sub>3</sub>OD, 125 MHz) δ 154.0, 146.8 (q, <i>J</i><sub>CF</sub> = 6.2 Hz), 124.2 (q, <i>J</i><sub>CF</sub> = 268.0 Hz), 108.9, 108.7 (q, <i>J</i><sub>CF</sub> = 30.8 Hz), (one quaternary carbon not observed). LCMS (3.5 min) <i>t</i><sub>R</sub> = 1.82 min; <i>m</i>/<i>z</i> (ESI<sup>+</sup>) 197 (M + H<sup>+</sup>). HRMS <i>m</i>/<i>z</i> calcd for C<sub>6</sub>H<sub>5</sub>ClF<sub>3</sub>N<sub>2</sub> (M + H) 197.0088, found 197.0082.</div></div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Biochemical Assays</h3><div class="NLM_p last">In vitro assays for inhibition of CHK1 and CHK2 were carried out as described previously.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18, 19)</a></div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Cellular Assays</h3><div class="NLM_p last">Assays for the determination of checkpoint abrogation, antiproliferative activity, and potentiation of genotoxic drug efficacy in cancer cell lines were carried out as described previously.<a onclick="showRef(event, 'ref19 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref21">(19, 21)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Crystallography</h3><div class="NLM_p last">Crystallography of CHK1 kinase domain was carried out as described previously.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Data were integrated with XDS,<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> imported with POINTLESS, then scaled and merged with AIMLESS.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Following molecular replacement as previously described, the structure was refined with COOT<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> and BUSTER.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> TLS parameters were generated with PHENIX.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Ligand geometry restraints were generated with GRADE<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a>/MOGUL.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vivo Assays</h3><div class="NLM_p last">All experiments using animals were performed in accordance with the local Animal Welfare and Ethical Review Board, the UK Home Office Animals Scientific Procedures Act 1986, and with the United Kingdom National Cancer Research Institute guidelines for the welfare of animals in cancer research.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The ICR does not undertake research in nonrodent species and requires internal ethical review when such studies are sponsored by organizations with whom we collaborate. Collaborator-sponsored nonrodent pharmacology studies of compound <b>4</b> necessary for the prediction of therapeutic window were approved by the ICR Animal Welfare and Ethics Review Board and were conducted in full compliance with national regulations at AAALAC accredited R&D sites. Detailed experimental procedures are reported in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01938">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01938" class="ext-link">10.1021/acs.jmedchem.5b01938</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Mouse liver microsome stability of selected compounds; kinase inhibition profile of <b>4</b>; potentiation of genotoxic efficacy in cancer cell lines by <b>4</b>; cardiac ion channel inhibition profile of <b>4</b>; experimental methods for the synthesis of compounds <b>3</b> and <b>5</b>–<b>42</b>; experimental methods for in silico classification model; experimental methods for in vivo procedures; experimental methods for MRI; data collection and refinement statistics for the crystal structure of CHK1 with <b>12</b>; HPLC data for key compounds; <sup>1</sup>H and <sup>13</sup>C NMR spectra for compounds <b>3</b>–<b>42</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf">jm5b01938_si_001.pdf (7.78 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_002.csv">jm5b01938_si_002.csv (3.52 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N">5F4N</a>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01938" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56014" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56014" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ian Collins</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9bf2faf5b5f8f4f7f7f2f5e8dbf2f8e9b5faf8b5eef0"><span class="__cf_email__" data-cfemail="4c252d22622f23202025223f0c252f3e622d2f623927">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">James D. Osborne</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas P. Matthews</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tatiana McHardy</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicolas Proisy</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kwai-Ming J. Cheung</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Lainchbury</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathan Brown</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael I. Walton</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul D. Eve</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine J. Boxall</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Angela Hayes</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan T. Henley</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Melanie R. Valenti</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alexis K. De Haven Brandon</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Box</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yann Jamin</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon P. Robinson</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Isaac M. Westwood</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rob L. M. van Montfort</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Philip M. Leonard</span> - <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marieke B. A. C. Lamers</span> - <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John C. Reader</span> - <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">G. Wynne Aherne</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florence I. Raynaud</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suzanne A. Eccles</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle D. Garrett</span> - <span class="hlFld-Affiliation affiliation">†Cancer Research UK
Cancer Therapeutics Unit and ‡Division of Radiotherapy and Imaging, The Institute of Cancer Research, London SM2 5NG, U.K.</span>; 
    <span class="hlFld-Affiliation affiliation">Sareum
Ltd., Cambridge CB22 3FX, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): The authors JDO, TPM, TM, NP, KJC, ML, NB, MIW, PDE, KJB, AH, ATH, MRV, AKdHB, GB, YJ, SPR, IMW, RvM, GWA, FIR, SAE, MDG and IC are, or have been, employees of The Institute of Cancer Research which has a commercial interest in CHK1 inhibitors.  Intellectual property arising from the CHK1 inhibitor programme has been licensed to the Cancer Research Technology Pioneer Fund. Please note that all authors who are, or have been, employed by The Institute of Cancer Research are subject to a 'Rewards to Inventors Scheme' which may reward contributors to a programme that is subsequently licensed.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5224-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53683" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53683" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Dr. Amin Mirza, Dr. Maggie Liu, and Meirion Richards for assistance in analytical chemistry and spectroscopy, Professor Owen Samson for the provision of KPC1 GEMM pancreatic tumor cells, and Professor Louis Chesler for provision of TH-MYCN mice. We acknowledge Simcyp Ltd for license to use the Simcyp population-based ADME Simulator. This work was supported by Cancer Research UK [CUK] grant numbers C309/A8274 and C309/A11566, the Cancer Research UK and EPSRC Cancer Imaging Centre, in association with the MRC and Department of Health (England) grant number C1060/A10334, the Institute of Cancer Research, and Sareum Ltd.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i31" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i31"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i32" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i32"> Abbreviations Used</h2><tr><td class="NLM_term">AMPK</td><td class="NLM_def"><p class="first last">5′-AMP-activated protein kinase</p></td></tr><tr><td class="NLM_term">ATM</td><td class="NLM_def"><p class="first last">ataxia telangiectasia mutated</p></td></tr><tr><td class="NLM_term">ATR</td><td class="NLM_def"><p class="first last">ataxia telangiectasia and Rad3-related</p></td></tr><tr><td class="NLM_term">BINAP</td><td class="NLM_def"><p class="first last">2,2′-bis(diphenylphosphino)-1,1′-binaphthyl)</p></td></tr><tr><td class="NLM_term">CDC25</td><td class="NLM_def"><p class="first last">cell division cycle 25</p></td></tr><tr><td class="NLM_term">CHK1</td><td class="NLM_def"><p class="first last">checkpoint kinase 1</p></td></tr><tr><td class="NLM_term">CHK2</td><td class="NLM_def"><p class="first last">checkpoint kinase 2</p></td></tr><tr><td class="NLM_term">CDK1</td><td class="NLM_def"><p class="first last">cyclin dependent kinase 1</p></td></tr><tr><td class="NLM_term">CL<sub>int</sub></td><td class="NLM_def"><p class="first last">intrinsic clearance</p></td></tr><tr><td class="NLM_term">DDR</td><td class="NLM_def"><p class="first last">DNA damage response</p></td></tr><tr><td class="NLM_term">DELFIA</td><td class="NLM_def"><p class="first last">dissociation-enhanced lanthanide fluorescent immunoassay</p></td></tr><tr><td class="NLM_term">DNA</td><td class="NLM_def"><p class="first last">DNA</p></td></tr><tr><td class="NLM_term">G1</td><td class="NLM_def"><p class="first last">Gap1 phase</p></td></tr><tr><td class="NLM_term">G2</td><td class="NLM_def"><p class="first last">Gap 2 phase</p></td></tr><tr><td class="NLM_term">GEMM</td><td class="NLM_def"><p class="first last">genetically engineered mouse model</p></td></tr><tr><td class="NLM_term">HBD</td><td class="NLM_def"><p class="first last">hydrogen bond donors</p></td></tr><tr><td class="NLM_term">hERG</td><td class="NLM_def"><p class="first last">human ether-a-go-go-related gene</p></td></tr><tr><td class="NLM_term">KRAS</td><td class="NLM_def"><p class="first last">V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue</p></td></tr><tr><td class="NLM_term">MLM</td><td class="NLM_def"><p class="first last">mouse liver microsomes</p></td></tr><tr><td class="NLM_term">MRI</td><td class="NLM_def"><p class="first last">magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">MTD</td><td class="NLM_def"><p class="first last">maximum tolerated dose</p></td></tr><tr><td class="NLM_term">MYC</td><td class="NLM_def"><p class="first last">v-myc avian myelocytomatosis viral oncogene homologue</p></td></tr><tr><td class="NLM_term">MYCN</td><td class="NLM_def"><p class="first last">v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homologue</p></td></tr><tr><td class="NLM_term"><i>N</i>-Boc</td><td class="NLM_def"><p class="first last"><i>N</i>-<i>tert</i>-butyloxycarbonyl</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">physiological-based pharmacokinetic</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RNA</td><td class="NLM_def"><p class="first last">ribonucleic acid</p></td></tr><tr><td class="NLM_term">S</td><td class="NLM_def"><p class="first last">synthesis phase</p></td></tr><tr><td class="NLM_term">SRB</td><td class="NLM_def"><p class="first last">sulforhodamine B</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15518" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15518" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S.</span><span> </span><span class="NLM_article-title">New insights into checkpoint kinase 1 in the DNA damage response signalling network</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-09-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20068082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2qsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=376-383&author=Y.+Daiauthor=S.+Grant&title=New+insights+into+checkpoint+kinase+1+in+the+DNA+damage+response+signalling+network&doi=10.1158%2F1078-0432.CCR-09-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into checkpoint kinase 1 in the DNA damage response signaling network</span></div><div class="casAuthors">Dai, Yun; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-383</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The DNA damage response (DDR) represents a complex network of multiple signaling pathways involving cell cycle checkpoints, DNA repair, transcriptional programs, and apoptosis, through which cells maintain genomic integrity following various endogenous (metabolic) or environmental stresses.  In cancer treatment, the DDR occurs in response to various genotoxic insults by diverse cytotoxic agents and radiation, representing an important mechanism limiting chemotherapeutic and radiotherapeutic efficacy.  This has prompted the development of agents targeting DDR signaling pathways, particularly checkpoint kinase 1 (Chk1), which contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint.  Although numerous agents have been developed with the primary goal of enhancing the activity of DNA-damaging agents or radiation, the therapeutic outcome of this strategy remains to be detd.  Recently, new insights into DDR signaling pathways support the notion that Chk1 represents a core component central to the entire DDR, including direct involvement in DNA repair and apoptotic events in addn. to checkpoint regulation.  Together, these new insights into the role of Chk1 in the DDR machinery could provide an opportunity for novel approaches to the development of Chk1 inhibitor strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP9oCivdYOLbVg90H21EOLACvtfcHk0lhcjG4drNJKqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2qsb8%253D&md5=37b8cf16a1a136372f1c1ee6d42b6988</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1029%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DNew%2520insights%2520into%2520checkpoint%2520kinase%25201%2520in%2520the%2520DNA%2520damage%2520response%2520signalling%2520network%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D376%26epage%3D383%26doi%3D10.1158%2F1078-0432.CCR-09-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tho, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, D. A.</span><span> </span><span class="NLM_article-title">The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/B978-0-12-380888-2.00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2FB978-0-12-380888-2.00003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21034966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2010&pages=73-112&author=J.+Smithauthor=L.+M.+Thoauthor=N.+Xuauthor=D.+A.+Gillespie&title=The+ATM-Chk2+and+ATR-Chk1+pathways+in+DNA+damage+signaling+and+cancer&doi=10.1016%2FB978-0-12-380888-2.00003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer</span></div><div class="casAuthors">Smith, Joanne; Tho, Lye Mun; Xu, Naihan; Gillespie, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-112</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  DNA damage is a key factor both in the evolution and treatment of cancer.  Genomic instability is a common feature of cancer cells, fuelling accumulation of oncogenic mutations, while radiation and diverse genotoxic agents remain important, if imperfect, therapeutic modalities.  Cellular responses to DNA damage are coordinated primarily by two distinct kinase signaling cascades, the ATM-Chk2 and ATR-Chk1 pathways, which are activated by DNA double-strand breaks (DSBs) and single-stranded DNA resp.  Historically, these pathways were thought to act in parallel with overlapping functions; however, more recently it has become apparent that their relationship is more complex.  In response to DSBs, ATM is required both for ATR-Chk1 activation and to initiate DNA repair via homologous recombination (HRR) by promoting formation of single-stranded DNA at sites of damage through nucleolytic resection.  Interestingly, cells and organisms survive with mutations in ATM or other components required for HRR, such as BRCA1 and BRCA2, but at the cost of genomic instability and cancer predisposition.  By contrast, the ATR-Chk1 pathway is the principal direct effector of the DNA damage and replication checkpoints and, as such, is essential for the survival of many, although not all, cell types.  Remarkably, deficiency for HRR in BRCA1- and BRCA2-deficient tumors confers sensitivity to cisplatin and inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme required for repair of endogenous DNA damage.  In addn., suppressing DNA damage and replication checkpoint responses by inhibiting Chk1 can enhance tumor cell killing by diverse genotoxic agents.  Here, we review current understanding of the organization and functions of the ATM-Chk2 and ATR-Chk1 pathways and the prospects for targeting DNA damage signaling processes for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKlkmzDBDD7Vg90H21EOLACvtfcHk0lhcjG4drNJKqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlSlug%253D%253D&md5=f9d9d807519bb88afed9ecffc85bd99f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-380888-2.00003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-380888-2.00003-0%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DTho%26aufirst%3DL.%2BM.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DGillespie%26aufirst%3DD.%2BA.%26atitle%3DThe%2520ATM-Chk2%2520and%2520ATR-Chk1%2520pathways%2520in%2520DNA%2520damage%2520signaling%2520and%2520cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2010%26volume%3D108%26spage%3D73%26epage%3D112%26doi%3D10.1016%2FB978-0-12-380888-2.00003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Clarke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. R.</span><span> </span><span class="NLM_article-title">DNA-dependent phosphorylation of CHK1 and claspin in human cell-free system</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span><span class="refDoi"> DOI: 10.1042/BJ20041966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1042%2FBJ20041966" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2005&pages=705-712&author=C.+A.+Clarkeauthor=P.+R.+Clarke&title=DNA-dependent+phosphorylation+of+CHK1+and+claspin+in+human+cell-free+system&doi=10.1042%2FBJ20041966"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBJ20041966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20041966%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DC.%2BA.%26aulast%3DClarke%26aufirst%3DP.%2BR.%26atitle%3DDNA-dependent%2520phosphorylation%2520of%2520CHK1%2520and%2520claspin%2520in%2520human%2520cell-free%2520system%26jtitle%3DBiochem.%2520J.%26date%3D2005%26volume%3D388%26spage%3D705%26epage%3D712%26doi%3D10.1042%2FBJ20041966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunasekera, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span> </span><span class="NLM_article-title">Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">21767</span><span class="NLM_x">–</span> <span class="NLM_lpage">21773</span><span class="refDoi"> DOI: 10.1074/jbc.M300229200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1074%2Fjbc.M300229200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=21767-21773&author=Z.+Xiaoauthor=Z.+Chenauthor=A.+H.+Gunasekeraauthor=T.+J.+Sowinauthor=S.+H.+Rosenbergauthor=S.+Fesikauthor=H.+Zhang&title=Chk1+mediates+S+and+G2+arrests+through+Cdc25A+degradation+in+response+to+DNA-damaging+agents&doi=10.1074%2Fjbc.M300229200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M300229200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M300229200%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGunasekera%26aufirst%3DA.%2BH.%26aulast%3DSowin%26aufirst%3DT.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DFesik%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DChk1%2520mediates%2520S%2520and%2520G2%2520arrests%2520through%2520Cdc25A%2520degradation%2520in%2520response%2520to%2520DNA-damaging%2520agents%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D21767%26epage%3D21773%26doi%3D10.1074%2Fjbc.M300229200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Sorensen, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziegielewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syljuasen, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">The cell-cycle checkpoint kinase chk1 is required for mammalian homologous recombination repair</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1038/ncb1212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fncb1212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15665856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1CjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=195-201&author=C.+S.+Sorensenauthor=L.+T.+Hansenauthor=J.+Dziegielewskiauthor=R.+G.+Syljuasenauthor=C.+Lundinauthor=J.+Bartekauthor=T.+Helleday&title=The+cell-cycle+checkpoint+kinase+chk1+is+required+for+mammalian+homologous+recombination+repair&doi=10.1038%2Fncb1212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair</span></div><div class="casAuthors">Sorensen, Claus Storgaard; Hansen, Lasse Tengbjerg; Dziegielewski, Jaroslaw; Syljuasen, Randi G.; Lundin, Cecilia; Bartek, Jiri; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-201</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The essential checkpoint kinase Chk1 is required for cell-cycle delays after DNA damage or blocked DNA replication.  However, it is unclear whether Chk1 is involved in the repair of damaged DNA.  Here we establish that Chk1 is a key regulator of genome maintenance by the homologous recombination repair (HRR) system.  Abrogation of Chk1 function with small interfering RNA or chem. antagonists inhibits HRR, leading to persistent unrepaired DNA double-strand breaks (DSBs) and cell death after replication inhibition with hydroxyurea or DNA-damage caused by camptothecin.  After hydroxyurea treatment, the essential recombination repair protein RAD51 is recruited to DNA repair foci performing a vital role in correct HRR.  We demonstrate that Chk1 interacts with RAD51, and that RAD51 is phosphorylated on Thr 309 in a Chk1-dependent manner.  Consistent with a functional interplay between Chk1 and RAD51, Chk1-depleted cells failed to form RAD51 nuclear foci after exposure to hydroxyurea, and cells expressing a phosphorylation-deficient mutant RAD51T309A were hypersensitive to hydroxyurea.  These results highlight a crucial role for the Chk1 signalling pathway in protecting cells against lethal DNA lesions through regulation of HRR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSb0kSyc0XLVg90H21EOLACvtfcHk0lhcjG4drNJKqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1CjsA%253D%253D&md5=27d6e602266199bad4ff44e2d13b491d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncb1212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1212%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DC.%2BS.%26aulast%3DHansen%26aufirst%3DL.%2BT.%26aulast%3DDziegielewski%26aufirst%3DJ.%26aulast%3DSyljuasen%26aufirst%3DR.%2BG.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520cell-cycle%2520checkpoint%2520kinase%2520chk1%2520is%2520required%2520for%2520mammalian%2520homologous%2520recombination%2520repair%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D195%26epage%3D201%26doi%3D10.1038%2Fncb1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Targeting the S and G2 checkpoint to treat cancer</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.drudis.2011.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=22192883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Gnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=194-202&author=T.+Chenauthor=P.+A.+Stephensauthor=F.+K.+Middletonauthor=N.+J.+Curtin&title=Targeting+the+S+and+G2+checkpoint+to+treat+cancer&doi=10.1016%2Fj.drudis.2011.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the S and G2 checkpoint to treat cancer</span></div><div class="casAuthors">Chen, Tao; Stephens, Peter A.; Middleton, Fiona K.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">194-202</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell survival following DNA damage depends on activating checkpoints to arrest proliferation.  Most cancer cells have dysregulated G1 checkpoints making them dependent on their S and G2 checkpoints, which are activated by ATR/Chk1 signalling.  Thus, inhibiting ATR or Chk1 should selectively sensitize cancer cells to DNA damage.  Genetic inactivation of ATR and Chk1 abrogates cell cycle arrest and enhances cytotoxicity following exposure to DNA-damaging agents.  Similar effects were seen with small-mol. Chk1 inhibitors in preclin. studies, and clin. trial data are starting to emerge.  Recently, potent ATR inhibitors have been identified that also sensitize cancer cells in vitro.  ATR and Chk1 inhibitors might also cause synthetic lethality' in tumor cells defective in defined DNA repair pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-ZLlmsYspbVg90H21EOLACvtfcHk0ljtYuGuCgGw8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Gnu7s%253D&md5=23724baf6f2ba1a2e622e2f6b44b2e40</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DStephens%26aufirst%3DP.%2BA.%26aulast%3DMiddleton%26aufirst%3DF.%2BK.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DTargeting%2520the%2520S%2520and%2520G2%2520checkpoint%2520to%2520treat%2520cancer%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D194%26epage%3D202%26doi%3D10.1016%2Fj.drudis.2011.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Anticancer therapy with checkpoint inhibitors: what, when and where?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1016/j.tips.2011.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.tips.2011.02.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=308-316&author=M.+D.+Garrettauthor=I.+Collins&title=Anticancer+therapy+with+checkpoint+inhibitors%3A+what%2C+when+and+where%3F&doi=10.1016%2Fj.tips.2011.02.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DAnticancer%2520therapy%2520with%2520checkpoint%2520inhibitors%253A%2520what%252C%2520when%2520and%2520where%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2011.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwnica-Worms, H.</span><span> </span><span class="NLM_article-title">Death by releasing the breaks: Chk1 inhibitors as cancer therapeutics</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.molmed.2010.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.molmed.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21087899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=88-96&author=C.+X.+Maauthor=J.+W.+Janetkaauthor=H.+Piwnica-Worms&title=Death+by+releasing+the+breaks%3A+Chk1+inhibitors+as+cancer+therapeutics&doi=10.1016%2Fj.molmed.2010.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span></div><div class="casAuthors">Ma, Cynthia X.; Janetka, James W.; Piwnica-Worms, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-96</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Defects in p53 function, which occur frequently in human cancers due to mutations in TP53 or disruptions in the p53 regulatory pathway, render cells dependent on CHK1 (Checkpoint Kinase 1) to activate cell cycle checkpoints.  In the presence of DNA damage or replication stress, inhibition of CHK1 leads to "mitotic catastrophe" and cell death in p53-deficient tumors while sparing p53-proficient cells.  CHK1 inhibitors sensitize tumors to a variety of DNA-damaging agents or antimetabolites in preclin. models and are being evaluated in early phase clin. trials.  In this review, we summarize recent advances and controversies in the development and application of CHK1 inhibitors as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAxtqrXv9ZqbVg90H21EOLACvtfcHk0ljtYuGuCgGw8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D&md5=e53c01cf0016d5be069913a041d67a08</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DPiwnica-Worms%26aufirst%3DH.%26atitle%3DDeath%2520by%2520releasing%2520the%2520breaks%253A%2520Chk1%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.molmed.2010.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huggins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulderman, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diskin, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3336</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1073/pnas.1012351108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1073%2Fpnas.1012351108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21289283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislGgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=3336-3341&author=K.+A.+Coleauthor=J.+Hugginsauthor=M.+Laquagliaauthor=C.+E.+Huldermanauthor=M.+R.+Russellauthor=K.+Bosseauthor=S.+J.+Diskinauthor=E.+F.+Attiyehauthor=R.+Sennettauthor=G.+Norrisauthor=M.+Laudenslagerauthor=A.+C.+Woodauthor=P.+A.+Mayesauthor=J.+Jagannathanauthor=C.+Winterauthor=Y.+P.+Mosseauthor=J.+M.+Maris&title=RNAi+screen+of+the+protein+kinome+identifies+checkpoint+kinase+1+%28CHK1%29+as+a+therapeutic+target+in+neuroblastoma&doi=10.1073%2Fpnas.1012351108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma</span></div><div class="casAuthors">Cole, Kristina A.; Huggins, Jonathan; Laquaglia, Michael; Hulderman, Chase E.; Russell, Mike R.; Bosse, Kristopher; Diskin, Sharon J.; Attiyeh, Edward F.; Sennett, Rachel; Norris, Geoffrey; Laudenslager, Marci; Wood, Andrew C.; Mayes, Patrick A.; Jagannathan, Ayanti; Winter, Cynthia; Mosse, Yael P.; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3336-3341, S3336/1-S3336/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that is often fatal despite intense multimodality therapy.  In an effort to identify therapeutic targets for this disease, we performed a comprehensive loss-of-function screen of the protein kinome.  Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the cell cycle checkpoint kinase 1 (CHK1/CHEK1) being the most potent.  CHK1 mRNA expression was higher in MYC-Neuroblastoma-related (MYCN)-amplified (P < 0.0001) and high-risk (P = 0.03) tumors.  Western blotting revealed that CHK1 was constitutively phosphorylated at the ataxia telangiectasia response kinase target site Ser345 and the autophosphorylation site Ser296 in neuroblastoma cell lines.  This pattern was also seen in six of eight high-risk primary tumors but not in control nonneuroblastoma cell lines or in seven of eight low-risk primary tumors.  Neuroblastoma cells were sensitive to the two CHK1 inhibitors SB21807 and TCS2312, with median IC50 values of 564 nM and 548 nM, resp.  In contrast, the control lines had high micromolar IC50 values, indicating a strong correlation between CHK1 phosphorylation and CHK1 inhibitor sensitivity (P = 0.0004).  Furthermore, cell cycle anal. revealed that CHK1 inhibition in neuroblastoma cells caused apoptosis during S-phase, consistent with its role in replication fork progression.  CHK1 inhibitor sensitivity correlated with total MYC(N) protein levels, and inducing MYCN in retinal pigmented epithelial cells resulted in CHK1 phosphorylation, which caused growth inhibition when inhibited.  These data show the power of a functional RNAi screen to identify tractable therapeutical targets in neuroblastoma and support CHK1 inhibition strategies in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5veQlVyIXEbVg90H21EOLACvtfcHk0ljYTyW8dj0rQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislGgtL0%253D&md5=650a9bbb555bc05eefa19f2b22acd476</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012351108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012351108%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DHuggins%26aufirst%3DJ.%26aulast%3DLaquaglia%26aufirst%3DM.%26aulast%3DHulderman%26aufirst%3DC.%2BE.%26aulast%3DRussell%26aufirst%3DM.%2BR.%26aulast%3DBosse%26aufirst%3DK.%26aulast%3DDiskin%26aufirst%3DS.%2BJ.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DNorris%26aufirst%3DG.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DJagannathan%26aufirst%3DJ.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DRNAi%2520screen%2520of%2520the%2520protein%2520kinome%2520identifies%2520checkpoint%2520kinase%25201%2520%2528CHK1%2529%2520as%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D3336%26epage%3D3341%26doi%3D10.1073%2Fpnas.1012351108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Höglund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muralidharan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasvold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudelius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. A.</span><span> </span><span class="NLM_article-title">Therapeutic implications for the induced levels of Chk1 in Myc expressing cancer cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7067</span><span class="NLM_x">–</span> <span class="NLM_lpage">7079</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-11-1198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21933891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3MbpvFyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7067-7079&author=A.+H%C3%B6glundauthor=L.+M.+Nilssonauthor=S.+V.+Muralidharanauthor=L.+A.+Hasvoldauthor=P.+Mertaauthor=M.+Rudeliusauthor=V.+Nikolovaauthor=U.+Kellerauthor=J.+A.+Nilsson&title=Therapeutic+implications+for+the+induced+levels+of+Chk1+in+Myc+expressing+cancer+cells&doi=10.1158%2F1078-0432.CCR-11-1198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells</span></div><div class="casAuthors">Hoglund Andreas; Nilsson Lisa M; Muralidharan Somsundar Veppil; Hasvold Lisa A; Merta Philip; Rudelius Martina; Nikolova Viktoriya; Keller Ulrich; Nilsson Jonas A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7067-79</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  The transcription factor c-Myc (or "Myc") is a master regulator of pathways driving cell growth and proliferation.  MYC is deregulated in many human cancers, making its downstream target genes attractive candidates for drug development.  We report the unexpected finding that B-cell lymphomas from mice and patients exhibit a striking correlation between high levels of Myc and checkpoint kinase 1 (Chk1).  EXPERIMENTAL DESIGN:  By in vitro cell biology studies as well as preclinical studies using a genetically engineered mouse model, we evaluated the role of Chk1 in Myc-overexpressing cells.  RESULTS:  We show that Myc indirectly induces Chek1 transcript and protein expression, independently of DNA damage response proteins such as ATM and p53.  Importantly, we show that inhibition of Chk1, by either RNA interference or a novel highly selective small molecule inhibitor, results in caspase-dependent apoptosis that affects Myc-overexpressing cells in both in vitro and in vivo mouse models of B-cell lymphoma.  CONCLUSION:  Our data suggest that Chk1 inhibitors should be further evaluated as potential drugs against Myc-driven malignancies such as certain B-cell lymphoma/leukemia, neuroblastoma, and some breast and lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKm-xnHGUIDGgRQsDqrjW_fW6udTcc2ebL9iAaNDv6S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbpvFyluw%253D%253D&md5=03f3e4e0366e0d05147dd6381bf0016c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1198%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25B6glund%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DL.%2BM.%26aulast%3DMuralidharan%26aufirst%3DS.%2BV.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DRudelius%26aufirst%3DM.%26aulast%3DNikolova%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DU.%26aulast%3DNilsson%26aufirst%3DJ.%2BA.%26atitle%3DTherapeutic%2520implications%2520for%2520the%2520induced%2520levels%2520of%2520Chk1%2520in%2520Myc%2520expressing%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7067%26epage%3D7079%26doi%3D10.1158%2F1078-0432.CCR-11-1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Brooks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beamish, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrielli, B.</span><span> </span><span class="NLM_article-title">A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1038/onc.2012.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fonc.2012.72" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=788-796&author=K.+Brooksauthor=V.+Oakesauthor=B.+Edwardsauthor=M.+Ranallauthor=P.+Leoauthor=S.+Paveyauthor=A.+Pinderauthor=H.+Beamishauthor=P.+Mukhopadhyayauthor=D.+Lambieauthor=B.+Gabrielli&title=A+potent+Chk1+inhibitor+is+selectively+cytotoxic+in+melanomas+with+high+levels+of+replicative+stress&doi=10.1038%2Fonc.2012.72"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.72%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DK.%26aulast%3DOakes%26aufirst%3DV.%26aulast%3DEdwards%26aufirst%3DB.%26aulast%3DRanall%26aufirst%3DM.%26aulast%3DLeo%26aufirst%3DP.%26aulast%3DPavey%26aufirst%3DS.%26aulast%3DPinder%26aufirst%3DA.%26aulast%3DBeamish%26aufirst%3DH.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DLambie%26aufirst%3DD.%26aulast%3DGabrielli%26aufirst%3DB.%26atitle%3DA%2520potent%2520Chk1%2520inhibitor%2520is%2520selectively%2520cytotoxic%2520in%2520melanomas%2520with%2520high%2520levels%2520of%2520replicative%2520stress%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D788%26epage%3D796%26doi%3D10.1038%2Fonc.2012.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Albiges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goubar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefèbvre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsafadi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghatchian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaloge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">André, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quidville, V.</span><span> </span><span class="NLM_article-title">Chk1 as a new therapeutic target in triple-negative breast cancer</span> <span class="citation_source-journal">Breast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1016/j.breast.2014.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.breast.2014.02.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=250-258&author=L.+Albigesauthor=A.+Goubarauthor=V.+Scottauthor=C.+Vicierauthor=C.+Lef%C3%A8bvreauthor=S.+Alsafadiauthor=F.+Commoauthor=M.+Saghatchianauthor=V.+Lazarauthor=P.+Dessenauthor=S.+Delalogeauthor=F.+Andr%C3%A9author=V.+Quidville&title=Chk1+as+a+new+therapeutic+target+in+triple-negative+breast+cancer&doi=10.1016%2Fj.breast.2014.02.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.breast.2014.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.breast.2014.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlbiges%26aufirst%3DL.%26aulast%3DGoubar%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DVicier%26aufirst%3DC.%26aulast%3DLef%25C3%25A8bvre%26aufirst%3DC.%26aulast%3DAlsafadi%26aufirst%3DS.%26aulast%3DCommo%26aufirst%3DF.%26aulast%3DSaghatchian%26aufirst%3DM.%26aulast%3DLazar%26aufirst%3DV.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DQuidville%26aufirst%3DV.%26atitle%3DChk1%2520as%2520a%2520new%2520therapeutic%2520target%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%26date%3D2014%26volume%3D23%26spage%3D250%26epage%3D258%26doi%3D10.1016%2Fj.breast.2014.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">McNeely, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bence Lin, A. K.</span><span> </span><span class="NLM_article-title">CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.pharmthera.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=24140082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=1-10&author=S.+McNeelyauthor=R.+Beckmannauthor=A.+K.+Bence+Lin&title=CHEK+again%3A+revisiting+the+development+of+CHK1+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.pharmthera.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy</span></div><div class="casAuthors">McNeely, S.; Beckmann, R.; Bence Lin, A. K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  CHEK1 encodes the serine/threonine kinase CHK1, a central component of the DNA damage response.  CHK1 regulates cell cycle checkpoints following genotoxic stress to prevent the entry of cells with damaged DNA into mitosis and coordinates various aspects of DNA repair.  Accordingly, CHK1 has become a target of considerable interest in oncol.  CHK1 inhibitors potentiate the efficacy of DNA-damaging chemotherapeutics by abrogating CHK1-mediated cell cycle arrest and preventing repair of damaged DNA.  In addn., CHK1 inhibitors interfere with the biol. role of CHK1 as a principal regulator of the cell cycle that controls the initiation of DNA replication, stabilizes replication forks, and coordinates mitosis.  Since these functions of CHK1 facilitate progression through an unperturbed cell cycle, CHK1 inhibitors are being developed not only as chemopotentiators, but also as single-agent therapies.  This review is intended to provide information on the current progress of CHK1 inhibitors in pre-clin. and clin. development and will focus on mechanisms of single-agent activity and potential strategies for patient tailoring and combinations with non-genotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnRvVVC1dCbVg90H21EOLACvtfcHk0lixX16e4MUdfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWqtr8%253D&md5=38db1812b9cd93c1f210c4985b53b4b5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeely%26aufirst%3DS.%26aulast%3DBeckmann%26aufirst%3DR.%26aulast%3DBence%2BLin%26aufirst%3DA.%2BK.%26atitle%3DCHEK%2520again%253A%2520revisiting%2520the%2520development%2520of%2520CHK1%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pharmthera.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallsworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">CCT244747 is a novel, potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-12-1322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=22929806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC38bitVCksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5650-5661&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+De+Haven+Brandonauthor=G.+Boxauthor=A.+Hallsworthauthor=E.+L.+Smithauthor=K.+J.+Boxallauthor=M.+Lainchburyauthor=T.+P.+Matthewsauthor=Y.+Jaminauthor=S.+P.+Robinsonauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=L.+Cheslerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=I.+Collinsauthor=M.+D.+Garrett&title=CCT244747+is+a+novel%2C+potent+and+selective+CHK1+inhibitor+with+oral+efficacy+alone+and+in+combination+with+genotoxic+anticancer+drugs&doi=10.1158%2F1078-0432.CCR-12-1322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs</span></div><div class="casAuthors">Walton Mike I; Eve Paul D; Hayes Angela; Valenti Melanie R; De Haven Brandon Alexis K; Box Gary; Hallsworth Albert; Smith Elizabeth L; Boxall Kathy J; Lainchbury Michael; Matthews Thomas P; Jamin Yann; Robinson Simon P; Aherne G Wynne; Reader John C; Chesler Louis; Raynaud Florence I; Eccles Suzanne A; Collins Ian; Garrett Michelle D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5650-61</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stress.  CHK1 is critically involved in the DNA damage response and maintenance of replication fork stability.  We have therefore discovered a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor, CCT244747, and present its preclinical pharmacology and therapeutic activity.  EXPERIMENTAL DESIGN:  Cellular CHK1 activity was assessed using an ELISA assay, and cytotoxicity a SRB assay.  Biomarker modulation was measured using immunoblotting, and cell-cycle effects by flow cytometry analysis.  Single-agent oral CCT244747 antitumor activity was evaluated in a MYCN-driven transgenic mouse model of neuroblastoma by MRI and in genotoxic combinations in human tumor xenografts by growth delay.  RESULTS:  CCT244747 inhibited cellular CHK1 activity (IC(50) 29-170 nmol/L), significantly enhanced the cytotoxicity of several anticancer drugs, and abrogated drug-induced S and G(2) arrest in multiple tumor cell lines.  Biomarkers of CHK1 (pS296 CHK1) activity and cell-cycle inactivity (pY15 CDK1) were induced by genotoxics and inhibited by CCT244747 both in vitro and in vivo, producing enhanced DNA damage and apoptosis.  Active tumor concentrations of CCT244747 were obtained following oral administration.  The antitumor activity of both gemcitabine and irinotecan were significantly enhanced by CCT244747 in several human tumor xenografts, giving concomitant biomarker modulation indicative of CHK1 inhibition.  CCT244747 also showed marked antitumor activity as a single agent in a MYCN-driven neuroblastoma.  CONCLUSION:  CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.  Clin Cancer Res; 18(20); 5650-61.  ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYuNWGWhNoVzMsgLhIoICsfW6udTcc2eaYEo4QWH4ZnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bitVCksg%253D%253D&md5=ae2b2c532939e201d741d8caf3aac8e2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1322%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%2BL.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCCT244747%2520is%2520a%2520novel%252C%2520potent%2520and%2520selective%2520CHK1%2520inhibitor%2520with%2520oral%2520efficacy%2520alone%2520and%2520in%2520combination%2520with%2520genotoxic%2520anticancer%2520drugs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5650%26epage%3D5661%26doi%3D10.1158%2F1078-0432.CCR-12-1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelista, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowanetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramiscal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubiak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">Combination drug scheduling defines a ″window of opportunity″ for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1968</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-12-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=23873850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1968-1980&author=E.+Blackwoodauthor=J.+Eplerauthor=I.+Yenauthor=M.+Flagellaauthor=T.+O%E2%80%99Brienauthor=M.+Evangelistaauthor=S.+Schmidtauthor=Y.+Xiaoauthor=J.+Choiauthor=K.+Kowanetzauthor=J.+Ramiscalauthor=K.+Wongauthor=D.+Jakubiakauthor=S.+Yeeauthor=G.+Cainauthor=L.+Gazzardauthor=K.+Williamsauthor=J.+Halladayauthor=P.+K.+Jacksonauthor=S.+Malek&title=Combination+drug+scheduling+defines+a+%E2%80%B3window+of+opportunity%E2%80%B3+for+chemopotentiation+of+gemcitabine+by+an+orally+bioavailable%2C+selective+ChK1+inhibitor%2C+GNE-900&doi=10.1158%2F1535-7163.MCT-12-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900</span></div><div class="casAuthors">Blackwood, Elizabeth; Epler, Jennifer; Yen, Ivana; Flagella, Michael; O'Brien, Tom; Evangelista, Marie; Schmidt, Stephen; Xiao, Yang; Choi, Jonathan; Kowanetz, Kaska; Ramiscal, Judi; Wong, Kenton; Jakubiak, Diana; Yee, Sharon; Cain, Gary; Gazzard, Lewis; Williams, Karen; Halladay, Jason; Jackson, Peter K.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1968-1980</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (ChK1) is a serine/threonine kinase that functions as a central mediator of the intra-S and G2-M cell-cycle checkpoints.  Following DNA damage or replication stress, ChK1-mediated phosphorylation of downstream effectors delays cell-cycle progression so that the damaged genome can be repaired.  As a therapeutic strategy, inhibition of ChK1 should potentiate the antitumor effect of chemotherapeutic agents by inactivating the postreplication checkpoint, causing premature entry into mitosis with damaged DNA resulting in mitotic catastrophe.  Here, we describe the characterization of GNE-900, an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor.  In combination with chemotherapeutic agents, GNE-900 sustains ATR/ATM signaling, enhances DNA damage, and induces apoptotic cell death.  The kinetics of checkpoint abrogation seems to be more rapid in p53-mutant cells, resulting in premature mitotic entry and/or accelerated cell death.  Importantly, we show that GNE-900 has little single-agent activity in the absence of chemotherapy and does not grossly potentiate the cytotoxicity of gemcitabine in normal bone marrow cells.  In vivo scheduling studies show that optimal administration of the ChK1 inhibitor requires a defined lag between gemcitabine and GNE-900 administration.  On the refined combination treatment schedule, gemcitabine's antitumor activity against chemotolerant xenografts is significantly enhanced and dose-dependent exacerbation of DNA damage correlates with extent of tumor growth inhibition.  In summary, we show that in vivo potentiation of gemcitabine activity is mechanism based, with optimal efficacy obsd. when S-phase arrest and release is followed by checkpoint abrogation with a ChK1 inhibitor.  Mol Cancer Ther; 12(10); 1968-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JdTj7IGGxLVg90H21EOLACvtfcHk0lixX16e4MUdfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurrO&md5=9698b1e41f9e0710174c00ea80bf68d2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1218%26sid%3Dliteratum%253Aachs%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DEpler%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DKowanetz%26aufirst%3DK.%26aulast%3DRamiscal%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DJakubiak%26aufirst%3DD.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DCain%26aufirst%3DG.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DCombination%2520drug%2520scheduling%2520defines%2520a%2520%25E2%2580%25B3window%2520of%2520opportunity%25E2%2580%25B3%2520for%2520chemopotentiation%2520of%2520gemcitabine%2520by%2520an%2520orally%2520bioavailable%252C%2520selective%2520ChK1%2520inhibitor%252C%2520GNE-900%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1968%26epage%3D1980%26doi%3D10.1158%2F1535-7163.MCT-12-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Infante, J. R.; Hollebecque, A.; Postel-Vinay, S.; Bauer, T.; Blackwood, B.; Evangelista, M.; Mahrus, S.; Peale, F.; Lu, X.; Sahasranaman, S.; Zhu, R.; Chen, Y.; Ding, X.; Murray, E.; Schutzman, J.; Lauchle, J.; Soria, J.; LoRusso, P.</span><span> </span><span class="NLM_article-title">Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors</span>. In Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 18–22, 2015; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>. Abstract no.  <span class="NLM_fpage">CT139</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=CT139&author=J.+R.+Infante&author=A.+Hollebecque&author=S.+Postel-Vinay&author=T.+Bauer&author=B.+Blackwood&author=M.+Evangelista&author=S.+Mahrus&author=F.+Peale&author=X.+Lu&author=S.+Sahasranaman&author=R.+Zhu&author=Y.+Chen&author=X.+Ding&author=E.+Murray&author=J.+Schutzman&author=J.+Lauchle&author=J.+Soria&author=P.+LoRusso&title=Phase+I+study+of+GDC-0425%2C+a+checkpoint+kinase+1+inhibitor%2C+in+combination+with+gemcitabine+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DPhase%2520I%2520study%2520of%2520GDC-0425%252C%2520a%2520checkpoint%2520kinase%25201%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DProceedings%2520of%2520the%2520106th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%252C%2520Philadelphia%252C%2520PA%252C%2520April%252018%25E2%2580%259322%252C%25202015%26pub%3DAACR%26date%3D2015%26spage%3DCT139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Stumpf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelaud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span> </span><span class="NLM_article-title">Development of an expedient process for the multi-kilogram synthesis of Chk1 inhibitor GDC-0425</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=661-672&author=A.+Stumpfauthor=Z.+K.+Chengauthor=B.+Wongauthor=M.+Reynoldsauthor=R.+Angelaudauthor=J.+Girottiauthor=A.+Deeseauthor=C.+Guauthor=L.+Gazzard&title=Development+of+an+expedient+process+for+the+multi-kilogram+synthesis+of+Chk1+inhibitor+GDC-0425&doi=10.1021%2Facs.oprd.5b00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425</span></div><div class="casAuthors">Stumpf, Andreas; Cheng, Zhigang Ken; Wong, Brian; Reynolds, Mark; Angelaud, Remy; Girotti, James; Deese, Alan; Gu, Christine; Gazzard, Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-672</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A process leading to the multikilogram GMP synthesis of Chk1 inhibitor GDC-0425 (I) was developed.  Highlights of the synthesis include protection of the pyrrole ring of a 1,7-diazacarbazole as Pr Et ether, an efficient Pd catalyzed cyanation of an aryl chloride, aryl ether formation by SNAr fluoride displacement, and development of a controlled crystn. providing the API with the required polymorphic form.  The process delivered high-quality GDC-0425 with low levels of impurities and residual metals in five steps and 31% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWjKZthxSBP7Vg90H21EOLACvtfcHk0liW-bKkN57euw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChtrY%253D&md5=3aa319ef1b9059e30f4b464a1e36be58</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00105%26sid%3Dliteratum%253Aachs%26aulast%3DStumpf%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DZ.%2BK.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DAngelaud%26aufirst%3DR.%26aulast%3DGirotti%26aufirst%3DJ.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DGazzard%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520an%2520expedient%2520process%2520for%2520the%2520multi-kilogram%2520synthesis%2520of%2520Chk1%2520inhibitor%2520GDC-0425%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D661%26epage%3D672%26doi%3D10.1021%2Facs.oprd.5b00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10229</span><span class="NLM_x">–</span> <span class="NLM_lpage">10240</span><span class="refDoi"> DOI: 10.1021/jm3012933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10229-10240&author=M.+Lainchburyauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=K.+J.+Boxallauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+de+Haven+Brandonauthor=G.+Boxauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+3-alkoxyamino-5-%28pyridin-2-ylamino%29pyrazine-2-carbonitriles+as+selective%2C+orally+bioavailable+CHK1+inhibitors&doi=10.1021%2Fjm3012933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm3012933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012933%26sid%3Dliteratum%253Aachs%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25203-alkoxyamino-5-%2528pyridin-2-ylamino%2529pyrazine-2-carbonitriles%2520as%2520selective%252C%2520orally%2520bioavailable%2520CHK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10229%26epage%3D10240%26doi%3D10.1021%2Fjm3012933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proisy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8328</span><span class="NLM_x">–</span> <span class="NLM_lpage">8342</span><span class="refDoi"> DOI: 10.1021/jm2007326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8328-8342&author=J.+C.+Readerauthor=T.+P.+Matthewsauthor=S.+Klairauthor=K.+J.+Cheungauthor=J.+Scanlonauthor=N.+Proisyauthor=G.+Addisonauthor=J.+Ellardauthor=N.+Pitonauthor=S.+Taylorauthor=M.+Cherryauthor=M.+Fisherauthor=K.+Boxallauthor=S.+Burnsauthor=M.+I.+Waltonauthor=I.+M.+Westwoodauthor=A.+Hayesauthor=P.+Eveauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=G.+Boxauthor=R.+L.+van+Montfortauthor=D.+H.+Williamsauthor=G.+W.+Aherneauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Structure-guided+evolution+of+potent+and+selective+CHK1+inhibitors+through+scaffold+morphing&doi=10.1021%2Fjm2007326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing</span></div><div class="casAuthors">Reader, John C.; Matthews, Thomas P.; Klair, Suki; Cheung, Kwai-Ming J.; Scanlon, Jane; Proisy, Nicolas; Addison, Glynn; Ellard, John; Piton, Nelly; Taylor, Suzanne; Cherry, Michael; Fisher, Martin; Boxall, Kathy; Burns, Samantha; Walton, Michael I.; Westwood, Isaac M.; Hayes, Angela; Eve, Paul; Valenti, Melanie; de Haven Brandon, Alexis; Box, Gary; van Montfort, Rob L. M.; Williams, David H.; Aherne, G. Wynne; Raynaud, Florence I.; Eccles, Suzanne A.; Garrett, Michelle D.; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8328-8342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolopyridine lead inhibitors with micromolar affinities for the checkpoint kinase CHK1 and selective for CHK1 against CHK2 were refined by fragment-growing and scaffold morphing strategies to generate the isoquinolinylaminopyrazinecarbonitrile I as a potent and selective inhibitor of CHK1 [IC50 (CHK1) = 13 nM, IC50 (CHK2) = > 100 μM] as a potential antitumor agent.  Scaffold morphing was used to improve the CHK1 potency and selectivity, synthetic accessibility, and novelty of the inhibitors; the inhibitor core was changed from pyrimido[2,3-b]azaindole to pyrazinylpyrimidinamine to imidazo[4,5-c]pyridine and isoquinoline.  The toxicities, lipophilicities, and polar surface areas of selected compds. were detd., while ligand efficiencies were detd. for the compds. prepd. and tested; the microsomal stability and oral bioavailability of I in mice were detd.  I potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice but had no effect on its own.  The structures of six kinase inhibitors including I bound to the CHK1 kinase domain were detd. by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNwXjNh9xLdLVg90H21EOLACvtfcHk0lh4rp66JA0Igw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO&md5=927c82ade2efd6df0db154e9009368f8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm2007326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007326%26sid%3Dliteratum%253Aachs%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DKlair%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.%2BJ.%26aulast%3DScanlon%26aufirst%3DJ.%26aulast%3DProisy%26aufirst%3DN.%26aulast%3DAddison%26aufirst%3DG.%26aulast%3DEllard%26aufirst%3DJ.%26aulast%3DPiton%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DEve%26aufirst%3DP.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-guided%2520evolution%2520of%2520potent%2520and%2520selective%2520CHK1%2520inhibitors%2520through%2520scaffold%2520morphing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8328%26epage%3D8342%26doi%3D10.1021%2Fjm2007326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven-Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-09-0938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20053762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=89-100&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+Valentiauthor=A.+De+Haven-Brandonauthor=G.+Boxauthor=K.+J.+Boxallauthor=G.+W.+Aherneauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=D.+H.+Williamsauthor=J.+C.+Readerauthor=I.+Collinsauthor=M.+D.+Garrett&title=The+preclinical+pharmacology+and+therapeutic+activity+of+the+novel+CHK1+inhibitor+SAR-020106&doi=10.1158%2F1535-7163.MCT-09-0938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106</span></div><div class="casAuthors">Walton, Michael I.; Eve, Paul D.; Hayes, Angela; Valenti, Melanie; De Haven Brandon, Alexis; Box, Gary; Boxall, Kathy J.; Aherne, G. Wynne; Eccles, Suzanne A.; Raynaud, Florence I.; Williams, David H.; Reader, John C.; Collins, Ian; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-100</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Genotoxic antitumor agents continue to be the mainstay of current cancer chemotherapy.  These drugs cause DNA damage and activate numerous cell cycle checkpoints facilitating DNA repair and the maintenance of genomic integrity.  Most human tumors lack functional p53 and consequently have compromised G1-S checkpoint control.  This has led to the hypothesis that S and G2-M checkpoint abrogation may selectively enhance genotoxic cell killing in a p53-deficient background, as normal cells would be rescued at the G1-S checkpoint.  CHK1 is a serine/threonine kinase assocd. with DNA damage-linked S and G2-M checkpoint control.  SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.  This compd. abrogates an etoposide-induced G2 arrest with an IC50 of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion.  Biomarker studies have shown that SAR-020106 inhibits cytotoxic drug-induced autophosphorylation of CHK1 at S296 and blocks the phosphorylation of CDK1 at Y15 in a dose-dependent fashion both in vitro and in vivo.  Cytotoxic drug combinations were assocd. with increased γH2AX and poly ADP ribose polymerase cleavage consistent with the SAR-020106-enhanced DNA damage and tumor cell death.  Irinotecan and gemcitabine antitumor activity was enhanced by SAR-020106 in vivo with minimal toxicity.  SAR-020106 represents a novel class of CHK1 inhibitors that can enhance antitumor activity with selected anticancer drugs in vivo and may therefore have clin. utility.  Mol Cancer Ther; 9(1); 89-100.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodRgZ8gsmTGbVg90H21EOLACvtfcHk0lh4rp66JA0Igw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOhuw%253D%253D&md5=395ce9fc39b4a465597e82d59e413f14</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0938%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven-Brandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DThe%2520preclinical%2520pharmacology%2520and%2520therapeutic%2520activity%2520of%2520the%2520novel%2520CHK1%2520inhibitor%2520SAR-020106%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D89%26epage%3D100%26doi%3D10.1158%2F1535-7163.MCT-09-0938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T. M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swales, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2329</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span><span class="refDoi"> DOI: 10.18632/oncotarget.4919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.18632%2Foncotarget.4919" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2329-2342&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=A.+T.+M.+R.+Henleyauthor=A.+K.+De+Haven+Brandonauthor=G.+Boxauthor=K.+J.+Boxallauthor=M.+Tallauthor=K.+Swalesauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=M.+Lainchburyauthor=J.+Osborneauthor=J.+E.+Hunterauthor=N.+D.+Perkinsauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=I.+Collinsauthor=M.+D.+Garrett&title=The+clinical+development+candidate+CCT245737+is+an+orally+active+CHK1+inhibitor+with+preclinical+activity+in+RAS+mutant+NSCLC+and+E%CE%BC-MYC+driven+B-cell+lymphoma&doi=10.18632%2Foncotarget.4919"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4919%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%2BM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DTall%26aufirst%3DM.%26aulast%3DSwales%26aufirst%3DK.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DOsborne%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%2BE.%26aulast%3DPerkins%26aufirst%3DN.%2BD.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DThe%2520clinical%2520development%2520candidate%2520CCT245737%2520is%2520an%2520orally%2520active%2520CHK1%2520inhibitor%2520with%2520preclinical%2520activity%2520in%2520RAS%2520mutant%2520NSCLC%2520and%2520E%25CE%25BC-MYC%2520driven%2520B-cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D2329%26epage%3D2342%26doi%3D10.18632%2Foncotarget.4919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Guzi, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paruch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labroli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanahan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taricani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaflor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D.</span><span> </span><span class="NLM_article-title">Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-10-0928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21321066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=591-602&author=T.+J.+Guziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=M.+Labroliauthor=F.+Shanahanauthor=N.+Davisauthor=L.+Taricaniauthor=D.+Wiswellauthor=W.+Seghezziauthor=E.+Penaflorauthor=B.+Bhagwatauthor=W.+Wangauthor=D.+Guauthor=Y.+Hsiehauthor=S.+Leeauthor=M.+Liuauthor=D.+Parry&title=Targeting+the+replication+checkpoint+using+SCH+900776%2C+a+potent+and+functionally+selective+CHK1+inhibitor+identified+via+high+content+screening&doi=10.1158%2F1535-7163.MCT-10-0928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening</span></div><div class="casAuthors">Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Shanahan, Frances; Davis, Nicole; Taricani, Lorena; Wiswell, Derek; Seghezzi, Wolfgang; Penaflor, Ervin; Bhagwat, Bhagyashree; Wang, Wei; Gu, Danling; Hsieh, Yunsheng; Lee, Suining; Liu, Ming; Parry, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-602</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (CHK1) is an essential serine/threonine kinase that responds to DNA damage and stalled DNA replication.  CHK1 is essential for maintenance of replication fork viability during exposure to DNA antimetabolites.  In human tumor cell lines, ablation of CHK1 function during antimetabolite exposure led to accumulation of double-strand DNA breaks and cell death.  Here, we extend these observations and confirm ablation of CHK2 does not contribute to these phenotypes and may diminish them.  Furthermore, concomitant suppression of cyclin-dependent kinase (CDK) activity is sufficient to completely antagonize the desired CHK1 ablation phenotypes.  These mechanism-based observations prompted the development of a high-content, cell-based screen for γ-H2AX induction, a surrogate marker for double-strand DNA breaks.  This mechanism-based functional approach was used to optimize small mol. inhibitors of CHK1.  Specifically, the assay was used to mechanistically define the optimal in-cell profile with compds. exhibiting varying degrees of CHK1, CHK2, and CDK selectivity.  Using this approach, SCH 900776 was identified as a highly potent and functionally optimal CHK1 inhibitor with minimal intrinsic antagonistic properties.  SCH 900776 exposure phenocopies short interfering RNA-mediated CHK1 ablation and interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce dsDNA breaks and cell death in tumor cell backgrounds.  Mol Cancer Ther; 10(4); 591-602.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_DnP2RPokHLVg90H21EOLACvtfcHk0lhP4Awy5Pfl5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSrt7o%253D&md5=884137ebd69d0959b583a6338a89b87a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0928%26sid%3Dliteratum%253Aachs%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DLabroli%26aufirst%3DM.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DTaricani%26aufirst%3DL.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DPenaflor%26aufirst%3DE.%26aulast%3DBhagwat%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DD.%26atitle%3DTargeting%2520the%2520replication%2520checkpoint%2520using%2520SCH%2520900776%252C%2520a%2520potent%2520and%2520functionally%2520selective%2520CHK1%2520inhibitor%2520identified%2520via%2520high%2520content%2520screening%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D591%26epage%3D602%26doi%3D10.1158%2F1535-7163.MCT-10-0928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Anderson, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F0008-5472.CAN-10-1252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21239475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=463-472&author=V.+E.+Andersonauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=K.+J.+Boxallauthor=L.+Antoniauthor=J.+J.+Caldwellauthor=W.+Aherneauthor=L.+H.+Pearlauthor=A.+W.+Oliverauthor=I.+Collinsauthor=M.+D.+Garrett&title=CCT241533+is+a+potent+and+selective+inhibitor+of+CHK2+that+potentiates+the+cytotoxicity+of+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-10-1252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors</span></div><div class="casAuthors">Anderson, Victoria E.; Walton, Michael I.; Eve, Paul D.; Boxall, Katherine J.; Antoni, Laurent; Caldwell, John J.; Aherne, Wynne; Pearl, Laurence H.; Oliver, Antony W.; Collins, Ian; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">463-472</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CHK2 is a checkpoint kinase involved in the ATM-mediated response to double-strand DNA breaks.  Its potential as a drug target is still unclear, but inhibitors of CHK2 may increase the efficacy of genotoxic cancer therapies in a p53 mutant background by eliminating one of the checkpoints or DNA repair pathways contributing to cellular resistance.  We report here the identification and characterization of a novel CHK2 kinase inhibitor, CCT241533.  X-ray crystallog. confirmed that CCT241533 bound to CHK2 in the ATP pocket.  This compd. inhibits CHK2 with an IC50 of 3 nmol/L and shows minimal cross-reactivity against a panel of kinases at 1 μmol/L.  CCT241533 blocked CHK2 activity in human tumor cell lines in response to DNA damage, as shown by inhibition of CHK2 autophosphorylation at S516, band shift mobility changes, and HDMX degrdn.  CCT241533 did not potentiate the cytotoxicity of a selection of genotoxic agents in several cell lines.  However, this compd. significantly potentiates the cytotoxicity of two structurally distinct PARP inhibitors.  Clear induction of the pS516 CHK2 signal was seen with a PARP inhibitor alone, and this activation was abolished by CCT241533, implying that the potentiation of PARP inhibitor cell killing by CCT241533 was due to inhibition of CHK2.  Consequently, our findings imply that CHK2 inhibitors may exert therapeutic activity in combination with PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHyOqF2omCBbVg90H21EOLACvtfcHk0ljUqIfSZeiQAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKmuw%253D%253D&md5=42af9f0f5543674eab441e5f29f45428</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1252%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DV.%2BE.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DAntoni%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DOliver%26aufirst%3DA.%2BW.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCCT241533%2520is%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520CHK2%2520that%2520potentiates%2520the%2520cytotoxicity%2520of%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D463%26epage%3D472%26doi%3D10.1158%2F0008-5472.CAN-10-1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Carlessi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscemi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delia, D.</span><span> </span><span class="NLM_article-title">Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-06-0567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=17363488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=935-944&author=L.+Carlessiauthor=G.+Buscemiauthor=G.+Larsonauthor=Z.+Hongauthor=J.+Z.+Wuauthor=D.+Delia&title=Biochemical+and+cellular+characterization+of+VRX0466617%2C+a+novel+and+selective+inhibitor+for+the+checkpoint+kinase+Chk2&doi=10.1158%2F1535-7163.MCT-06-0567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2</span></div><div class="casAuthors">Carlessi, Luigi; Buscemi, Giacomo; Larson, Gary; Hong, Zhi; Wu, Jim Zhen; Delia, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">VRX0466617 is a novel selective small-mol. inhibitor for Chk2 discovered through a protein kinase screening program.  In this study, we provide a detailed biochem. and cellular characterization of VRX0466617.  We show that VRX0466617 blocks the enzymic activity of recombinant Chk2, as well as the ionizing radiation (IR)-induced activation of Chk2 from cells pretreated with the compd., at doses between 5 and 10 μmol/L.  These doses of VRX0466617 inhibited, to some extent, the phosphorylation of Chk2 Ser19 and Ser33-35, but not of Chk2 Thr68, which is phosphorylated by the upstream ataxia-telangiectasia mutated (ATM) kinase.  Interestingly, VRX0466617 induced the phosphorylation of Chk2 Thr68 even in the absence of DNA damage, arising from the block of its enzymic activity.  VRX0466617 prevented the IR-induced Chk2-dependent degrdn. of Hdmx, concordant with the in vivo inhibition of Chk2.  Anal. of ATM/ATM and Rad3-related substrates Smc1, p53, and Chk1 excluded a cross-inhibition of these kinases.  VRX0466617 did not modify the cell cycle phase distribution, although it caused an increase in multinucleated cells.  Whereas VRX0466617 attenuated IR-induced apoptosis, in short-term assays it did not affect the cytotoxicity by the anticancer drugs doxorubicin, Taxol, and cisplatin.  These results underscore the specificity of VRX0466617 for Chk2, both in vitro and in vivo, and support the use of this compd. as a biol. probe to study the Chk2-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYT5RvbJvcIbVg90H21EOLACvtfcHk0ljUqIfSZeiQAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur8%253D&md5=3997c4dbaf75f74fef04a171b8712f25</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0567%26sid%3Dliteratum%253Aachs%26aulast%3DCarlessi%26aufirst%3DL.%26aulast%3DBuscemi%26aufirst%3DG.%26aulast%3DLarson%26aufirst%3DG.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DDelia%26aufirst%3DD.%26atitle%3DBiochemical%2520and%2520cellular%2520characterization%2520of%2520VRX0466617%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520for%2520the%2520checkpoint%2520kinase%2520Chk2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D935%26epage%3D944%26doi%3D10.1158%2F1535-7163.MCT-06-0567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramiscal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowanetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Nagro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelista, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span> </span><span class="NLM_article-title">Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2285</span><span class="NLM_x">–</span> <span class="NLM_lpage">2295</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-13-0404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=24038068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2285-2295&author=Y.+Xiaoauthor=J.+Ramiscalauthor=K.+Kowanetzauthor=C.+Del+Nagroauthor=S.+Malekauthor=M.+Evangelistaauthor=E.+Blackwoodauthor=P.+K.+Jacksonauthor=T.+O%E2%80%99Brien&title=Identification+of+preferred+chemotherapeutics+for+combining+with+a+CHK1+inhibitor&doi=10.1158%2F1535-7163.MCT-13-0404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor</span></div><div class="casAuthors">Xiao, Yang; Ramiscal, Judi; Kowanetz, Kaska; Del Nagro, Christopher; Malek, Shiva; Evangelista, Marie; Blackwood, Elizabeth; Jackson, Peter K.; O'Brien, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2285-2295</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here we report that GNE-783, a novel checkpoint kinase-1 (CHK1) inhibitor, enhances the activity of gemcitabine by disabling the S- and G2 cell-cycle checkpoints following DNA damage.  Using a focused library of 51 DNA-damaging agents, we undertook a systematic screen using three different cell lines to det. which chemotherapeutics have their activity enhanced when combined with GNE-783.  We found that GNE-783 was most effective at enhancing activity of antimetabolite-based DNA-damaging agents; however, there was a surprisingly wide range of activity within each class of agents.  We, next, selected six different therapeutic agents and screened these in combination with GNE-783 across a panel of cell lines.  This revealed a preference for enhanced chemopotentiation of select agents within tumor types, as, for instance, GNE-783 preferentially enhanced the activity of temozolomide only in melanoma cell lines.  Addnl., although p53 mutant status was important for the overall response to combinations with some agents; our data indicate that this alone was insufficient to predict synergy.  We finally compared the ability of a structurally related CHK1 inhibitor, GNE-900, to enhance the in vivo activity of gemcitabine, CPT-11, and temozolomide in xenograft models.  GNE-900 significantly enhanced activity of only gemcitabine in vivo, suggesting that strong chemopotentiation in vitro can translate into chemopotentiation in vivo.  In conclusion, our results show that selection of an appropriate agent to combine with a CHK1 inhibitor needs to be carefully evaluated in the context of the genetic background and tumor type in which it will be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM_vkqyr9s_bVg90H21EOLACvtfcHk0ljUqIfSZeiQAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsr3P&md5=a05096579a878f8c2ff052933292058b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0404%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DRamiscal%26aufirst%3DJ.%26aulast%3DKowanetz%26aufirst%3DK.%26aulast%3DDel%2BNagro%26aufirst%3DC.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520preferred%2520chemotherapeutics%2520for%2520combining%2520with%2520a%2520CHK1%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2285%26epage%3D2295%26doi%3D10.1158%2F1535-7163.MCT-13-0404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lg83nGu99F6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1517/17460441.2013.788496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1517%2F17460441.2013.788496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=621-640&author=T.+P.+Matthewsauthor=A.+M.+Jonesauthor=I.+Collins&title=Structure-based+design%2C+discovery+and+development+of+checkpoint+kinase+inhibitors+as+potential+anticancer+therapies&doi=10.1517%2F17460441.2013.788496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.788496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.788496%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DA.%2BM.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-based%2520design%252C%2520discovery%2520and%2520development%2520of%2520checkpoint%2520kinase%2520inhibitors%2520as%2520potential%2520anticancer%2520therapies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D621%26epage%3D640%26doi%3D10.1517%2F17460441.2013.788496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Tao, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. H.</span><span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1514</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span><span class="refDoi"> DOI: 10.1021/jm061247v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061247v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1514-1527&author=Z.+F.+Taoauthor=L.+Wangauthor=K.+D.+Stewartauthor=Z.+Chenauthor=W.+Guauthor=M.+H.+Buiauthor=P.+Mertaauthor=H.+Zhangauthor=P.+Kovarauthor=E.+Johnsonauthor=C.+Parkauthor=R.+Judgeauthor=S.+Rosenbergauthor=T.+Sowinauthor=N.+H.+Lin&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+potent+and+selective+macrocyclic+checkpoint+kinase+1+inhibitors&doi=10.1021%2Fjm061247v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors</span></div><div class="casAuthors">Tao, Zhi-Fu; Wang, Le; Stewart, Kent D.; Chen, Zehan; Gu, Wendy; Bui, Mai-Ha; Merta, Philip; Zhang, Haiying; Kovar, Peter; Johnson, Eric; Park, Chang; Judge, Russell; Rosenberg, Saul; Sowin, Thomas; Lin, Nan-Horng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1514-1527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Based on the crystallog. anal. of a urea-checkpoint kinase 1 (Chk1) complex and mol. modeling, a class of macrocyclic Chk1 inhibitors were designed and their biol. activities were evaluated.  An efficient synthetic methodol. for macrocyclic ureas was developed with Grubbs metathesis macrocyclization as the key step.  The structure-activity relationship studies demonstrated that the macrocyclization retains full Chk1 inhibition activity and that the 4-position of the Ph ring can tolerate a wide variety of substituents.  These Chk1 inhibitors exhibited excellent selectivity over a panel of more than 70 kinases.  Some compds., e.g., I, were identified as ideal Chk1 inhibitors, which showed little or no single-agent activity but significantly potentiate the cytotoxicities of the DNA-damaging antitumor agents doxorubicin and camptothecin.  These Chk1 inhibitors abrogate the doxorubicin-induced G2 and camptothecin-induced S checkpoint arrests, confirming that their potent biol. activities are mechanism-based through Chk1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cDFwRBm0rbVg90H21EOLACvtfcHk0lg83nGu99F6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislags7w%253D&md5=43770dab8ec51e661400e9f9c8d4d11a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061247v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061247v%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJudge%26aufirst%3DR.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DSowin%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DN.%2BH.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520potent%2520and%2520selective%2520macrocyclic%2520checkpoint%2520kinase%25201%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1514%26epage%3D1527%26doi%3D10.1021%2Fjm061247v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Jamei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciniak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostami-Hodjegan, A.</span><span> </span><span class="NLM_article-title">The Simcyp population-based ADME simulator</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1517/17425250802691074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1517%2F17425250802691074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19199378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1elu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=211-223&author=M.+Jameiauthor=S.+Marciniakauthor=K.+Fengauthor=A.+Barnettauthor=G.+Tuckerauthor=A.+Rostami-Hodjegan&title=The+Simcyp+population-based+ADME+simulator&doi=10.1517%2F17425250802691074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The Simcyp Population-based ADME Simulator</span></div><div class="casAuthors">Jamei, Masoud; Marciniak, Steve; Feng, Kairui; Barnett, Adrian; Tucker, Geoffrey; Rostami-Hodjegan, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-223</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The Simcyp population-based absorption, distribution, metab. and excretion simulator is a platform and database for bottom-up' mechanistic modeling and simulation of the processes of oral absorption, tissue distribution, metab. and excretion of drugs and drug candidates in healthy and disease populations.  It combines exptl. data generated routinely during preclin. drug discovery and development from in vitro enzyme and cellular systems and relevant physicochem. attributes of compd. and dosage form with demog., physiol. and genetic information on different patient populations.  The mechanistic approach implemented in the Simcyp Simulator allows simulation of complex absorption, distribution, metab. and excretion outcomes, particularly those involving multiple drug interactions, parent drug and metabolite profiles and time- and dose-dependent phenomena such as auto-induction and auto-inhibition.  This review describes the framework and organization of the simulator and how it combines the different categories of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbau4KimjnBLVg90H21EOLACvtfcHk0lg83nGu99F6iA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1elu7c%253D&md5=11548b35c66fe6f07a917f0718421427</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F17425250802691074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250802691074%26sid%3Dliteratum%253Aachs%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DMarciniak%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DK.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DThe%2520Simcyp%2520population-based%2520ADME%2520simulator%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D211%26epage%3D223%26doi%3D10.1517%2F17425250802691074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><div class="note"><p class="first last">Determined at Cyprotex</p></div>: <a href="http://www.cyprotex.com" class="extLink">http://www.cyprotex.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Determined+at+Cyprotex%3A+http%3A%2F%2Fwww.cyprotex.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvakumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putlur, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span> </span><span class="NLM_article-title">Electrophilicity of pyridazine-3-carbonitrile, pyrimidine-2-carbonitrile, and pyridine-carbonitrile derivatives: a chemical model to describe the formation of thiazoline derivatives in human liver microsomes</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span><span class="refDoi"> DOI: 10.1021/tx500256j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500256j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=2052-2061&author=S.+Sinhaauthor=D.+Ahireauthor=S.+Waghauthor=D.+Mullickauthor=R.+Sistlaauthor=K.+Selvakumarauthor=J.+C.+Cortesauthor=S.+P.+Putlurauthor=S.+Mandlekarauthor=B.+M.+Johnson&title=Electrophilicity+of+pyridazine-3-carbonitrile%2C+pyrimidine-2-carbonitrile%2C+and+pyridine-carbonitrile+derivatives%3A+a+chemical+model+to+describe+the+formation+of+thiazoline+derivatives+in+human+liver+microsomes&doi=10.1021%2Ftx500256j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophilicity of Pyridazine-3-carbonitrile, Pyrimidine-2-carbonitrile, and Pyridine-carbonitrile Derivatives: A Chemical Model To Describe the Formation of Thiazoline Derivatives in Human Liver Microsomes</span></div><div class="casAuthors">Sinha, Sarmistha; Ahire, Deepak; Wagh, Santosh; Mullick, Dibakar; Sistla, Ramesh; Selvakumar, Kumaravel; Cortes, Janet Caceres; Putlur, Siva Prasad; Mandlekar, Sandhya; Johnson, Benjamin M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Certain arom. nitriles are well-known inhibitors of cysteine proteases.  The mode of action of these compds. involves the formation of a reversible or irreversible covalent bond between the nitrile and a thiol group in the active site of the enzyme.  However, the reactivity of these arom. nitrile-substituted heterocycles may lead inadvertently to nonspecific interactions with DNA, protein, glutathione, and other endogenous components, resulting in toxicity and complicating the use of these compds. as therapeutic agents.  In the present study, the intrinsic reactivity and assocd. structure-property relationships of cathepsin K inhibitors featuring substituted pyridazines [6-phenylpyridazine-3-carbonitrile, 6-(4-fluorophenyl)pyridazine-3-carbonitrile, 6-(4-methoxyphenyl)pyridazine-3-carbonitrile, 6-p-tolylpyridazine-3-carbonitrile], pyrimidines [5-p-tolylpyrimidine-2-carbonitrile, 5-(4-fluorophenyl)pyrimidine-2-carbonitrile], and pyridines [5-p-tolylpicolinonitrile and 5-(4-fluorophenyl)picolinonitrile] were evaluated using a combination of computational and anal. approaches to establish correlations between electrophilicity and levels of metabolites that were formed in glutathione- and N-acetylcysteine-supplemented human liver microsomes.  Metabolites that were characterized in this study featured substituted thiazolines that were formed following rearrangements of transient glutathione and N-acetylcysteine conjugates.  Peptidases including γ-glutamyltranspeptidase were shown to catalyze the formation of these products, which were formed to lesser extents in the presence of the selective γ-glutamyltranspeptidase inhibitor acivicin and the nonspecific peptidase inhibitors phenylmethylsulfonyl fluoride and aprotinin.  Of the chem. series mentioned above, the pyrimidine series was the most susceptible to metab. to thiazoline-contg. products, followed, in order, by the pyridazine and pyridine series.  This trend was in keeping with the diminishing electrophilicity across these series, as demonstrated by in silico modeling.  Hence, mechanistic insights gained from this study could be used to assist a medicinal chem. campaign to design cysteine protease inhibitors that were less prone to the formation of covalent adducts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_vAWzUVGE17Vg90H21EOLACvtfcHk0lic-IVqnNTqPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsLrE&md5=5953c7b27b84330b917c9bf39a3578a2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Ftx500256j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500256j%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DAhire%26aufirst%3DD.%26aulast%3DWagh%26aufirst%3DS.%26aulast%3DMullick%26aufirst%3DD.%26aulast%3DSistla%26aufirst%3DR.%26aulast%3DSelvakumar%26aufirst%3DK.%26aulast%3DCortes%26aufirst%3DJ.%2BC.%26aulast%3DPutlur%26aufirst%3DS.%2BP.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26atitle%3DElectrophilicity%2520of%2520pyridazine-3-carbonitrile%252C%2520pyrimidine-2-carbonitrile%252C%2520and%2520pyridine-carbonitrile%2520derivatives%253A%2520a%2520chemical%2520model%2520to%2520describe%2520the%2520formation%2520of%2520thiazoline%2520derivatives%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Ftx500256j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><div class="note"><p class="first last">Determined at The MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, UK</p></div>: <a href="http://www.ppu.mrc.ac.uk" class="extLink">http://www.ppu.mrc.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Determined+at+The+MRC+Protein+Phosphorylation+and+Ubiquitylation+Unit%2C+University+of+Dundee%2C+UK%3A+http%3A%2F%2Fwww.ppu.mrc.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Kerkela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woulfe, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagnozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase</span> <span class="citation_source-journal">Clin. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1111/j.1752-8062.2008.00090.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1111%2Fj.1752-8062.2008.00090.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20376335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlemtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=15-25&author=R.+Kerkelaauthor=K.+C.+Woulfeauthor=J.+B.+Durandauthor=R.+Vagnozziauthor=D.+Kramerauthor=T.+F.+Chuauthor=C.+Beahmauthor=M.+H.+Chenauthor=T.+Force&title=Sunitinib-induced+cardiotoxicity+is+mediated+by+off-target+inhibition+of+AMP-activated+protein+kinase&doi=10.1111%2Fj.1752-8062.2008.00090.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protease kinase</span></div><div class="casAuthors">Kerkela, Risto; Woulfe, Kathleen C.; Durand, Jean-Bernard; Vagnozzi, Ronald; Kramer, David; Chu, Tammy F.; Beahm, Cara; Chen, Ming Hui; Force, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has demonstrated activity against a variety of solid tumors.  Sunitinib is "multitargeted",inhibiting growth factor receptors that regulate both tumor angiogenesis and tumor cell survival.  However, cardiac dysfunction has been assocd. with its use. Identification of the target of sunitinib-assocd. cardiac dysfunction could guide future drug design to reduce toxicity while preserving anticancer activity.  Herein we identify severe mitochondrial structural abnormalities in the heart of a patient with sunitinib-induced heart failure.  In cultured cardiomyocytes, sunitinib induces loss of mitochondrial membrane potential and energy rundown.  Despite the latter, 5' adenosine monophosphate-activated protein kinase (AMPK) activity, which should be increased in the setting of energy compromise, is reduced in hearts of sunitinib-treated mice and cardiomyocytes in culture, and this is due to direct inhibition of AMPK by sunitinib.  Critically, we find that adenovirus-mediated gene transfer of an activated mutant of AMPK reduces sunitinib-induced cell death.  Our findings suggest AMPK inhibition plays a central role in sunitinib cardiomyocyte toxicity, highlighting the potential of off-target effects of TKIs contributing to cardiotoxicity.  While multitargeting can enhance tumor cell killing, this must be balanced against the potential increased risk of cardiac dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMviU6GEMVU7Vg90H21EOLACvtfcHk0lic-IVqnNTqPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlemtrY%253D&md5=9b7a885241a90b8a28073d89b924acb1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1752-8062.2008.00090.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1752-8062.2008.00090.x%26sid%3Dliteratum%253Aachs%26aulast%3DKerkela%26aufirst%3DR.%26aulast%3DWoulfe%26aufirst%3DK.%2BC.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DVagnozzi%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DT.%2BF.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DSunitinib-induced%2520cardiotoxicity%2520is%2520mediated%2520by%2520off-target%2520inhibition%2520of%2520AMP-activated%2520protein%2520kinase%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2009%26volume%3D2%26spage%3D15%26epage%3D25%26doi%3D10.1111%2Fj.1752-8062.2008.00090.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Smyth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Measuring and interpreting the selectivity of protein kinase inhibitors</span> <span class="citation_source-journal">J. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1007/s12154-009-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+interpreting+the+selectivity+of+protein+kinase+inhibitors&doi=10.1007%2Fs12154-009-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2ebCjlv4Km54nrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520interpreting%2520the%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D131%26epage%3D151%26doi%3D10.1007%2Fs12154-009-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Schneider, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R. M.</span><span> </span><span class="NLM_article-title">Genetic alterations in pancreatic carcinoma</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="refDoi"> DOI: 10.1186/1476-4598-2-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1186%2F1476-4598-2-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=12605716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BD2czltlyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=15&author=G.+Schneiderauthor=R.+M.+Schmid&title=Genetic+alterations+in+pancreatic+carcinoma&doi=10.1186%2F1476-4598-2-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic alterations in pancreatic carcinoma</span></div><div class="casAuthors">Schneider Gunter; Schmid Roland M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer of the exocrine pancreas represents the fifth leading cause of cancer death in the Western population with an average survival after diagnosis of 3 to 6 months and a five-year survival rate under 5%.  Our understanding of the molecular carcinogenesis has improved in the last few years due to the development of novel molecular biological techniques.  Pancreatic cancer is a multi-stage process resulting from the accumulation of genetic changes in the somatic DNA of normal cells.  In this article we describe major genetic alterations of pancreatic cancer, mutations in the proto-oncogene K-RAS and the tumor suppressors INK4A, TP53 and DPC4/SMAD4.  The accumulation of these genetic changes leads to a profound disturbance in cell cycle regulation and continuous growth.  The knowledge of the underlying molecular mechanisms will offer new therapeutic and diagnostic options and hopefully improve the outcome of this aggressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvHJ3qSMrH5MzK395ZObgVfW6udTcc2eY2yzrLF7tfuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czltlyhtA%253D%253D&md5=9ae0f252ae8dbf2e7f47977948f25abd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-2-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-2-15%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26atitle%3DGenetic%2520alterations%2520in%2520pancreatic%2520carcinoma%26jtitle%3DMol.%2520Cancer%26date%3D2003%26volume%3D2%26spage%3D15%26doi%3D10.1186%2F1476-4598-2-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Mogi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span> </span><span class="NLM_article-title">TP53 mutations in non-small cell lung cancer</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">583929</span><span class="refDoi"> DOI: 10.1155/2011/583929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1155%2F2011%2F583929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21331359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3M3gsVKgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=583929&author=A.+Mogiauthor=H.+Kuwano&title=TP53+mutations+in+non-small+cell+lung+cancer&doi=10.1155%2F2011%2F583929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TP53 mutations in nonsmall cell lung cancer</span></div><div class="casAuthors">Mogi Akira; Kuwano Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">583929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor suppressor gene TP53 is frequently mutated in human cancers.  Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells.  Human lung cancers are classified into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC).  The latter accounts for approximately 80% of all primary lung cancers, and the incidence of NSCLC is increasing yearly.  Most clinical studies suggest that NSCLC with TP53 alterations carries a worse prognosis and may be relatively more resistant to chemotherapy and radiation.  A deep understanding of the role of TP53 in lung carcinogenesis may lead to a more reasonably targeted clinical approach, which should be exploited to enhance the survival rates of patients with lung cancer.  This paper will focus on the role of TP53 in the molecular pathogenesis, epidemiology, and therapeutic strategies of TP53 mutation in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkBjLU7AEAUBwLZxei1HN8fW6udTcc2eY2yzrLF7tfuLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3gsVKgtw%253D%253D&md5=61547b78d036d8507b38bbdddf9efa0d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1155%2F2011%2F583929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F583929%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DA.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DTP53%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D583929%26doi%3D10.1155%2F2011%2F583929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Hingorani, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multani, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deramaudt, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruban, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span> </span><span class="NLM_article-title">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.ccr.2005.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15894267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=469-483&author=S.+R.+Hingoraniauthor=L.+Wangauthor=A.+S.+Multaniauthor=C.+Combsauthor=T.+B.+Deramaudtauthor=R.+H.+Hrubanauthor=A.+K.+Rustgiauthor=S.+Changauthor=D.+A.+Tuveson&title=Trp53R172H+and+KrasG12D+cooperate+to+promote+chromosomal+instability+and+widely+metastatic+pancreatic+ductal+adenocarcinoma+in+mice&doi=10.1016%2Fj.ccr.2005.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span></div><div class="casAuthors">Hingorani, Sunil R.; Wang, Lifu; Multani, Asha S.; Combs, Chelsea; Deramaudt, Therese B.; Hruban, Ralph H.; Rustgi, Anil K.; Chang, Sandy; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-483</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53R172H and KrasG12D to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.  The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically obsd. in mice.  No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biol. behaviors.  These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqdYCBqe-vrVg90H21EOLACvtfcHk0liiC3ghPrtfsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D&md5=fef745f04506e9e64bbc760a1d6f8cf6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMultani%26aufirst%3DA.%2BS.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DDeramaudt%26aufirst%3DT.%2BB.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DTrp53R172H%2520and%2520KrasG12D%2520cooperate%2520to%2520promote%2520chromosomal%2520instability%2520and%2520widely%2520metastatic%2520pancreatic%2520ductal%2520adenocarcinoma%2520in%2520mice%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D469%26epage%3D483%26doi%3D10.1016%2Fj.ccr.2005.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J. M.</span><span> </span><span class="NLM_article-title">Targeted expression of MYCN causes neuroblastoma in transgenic mice</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2985</span><span class="NLM_x">–</span> <span class="NLM_lpage">2995</span><span class="refDoi"> DOI: 10.1093/emboj/16.11.2985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1093%2Femboj%2F16.11.2985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=9214616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADyaK2sXktlaqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=2985-2995&author=W.+A.+Weissauthor=K.+Aldapeauthor=G.+Mohapatraauthor=B.+G.+Feuersteinauthor=J.+M.+Bishop&title=Targeted+expression+of+MYCN+causes+neuroblastoma+in+transgenic+mice&doi=10.1093%2Femboj%2F16.11.2985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted expression of MYCN causes neuroblastoma in transgenic mice</span></div><div class="casAuthors">Weiss, William A.; Aldape, Ken; Mohapatra, Gayatry; Feuerstein, Burt G.; Bishop, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2985-2995</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The proto-oncogene MYCN is often amplified in human neuroblastomas.  The assumption that the amplification contributes to tumorigenesis has never been tested directly.  The authors have created transgenic mice that over-express MYCN in neuroectodermal cells and develop neuroblastoma.  Anal. of tumors by comparative genomic hybridization revealed gains and losses of at least seven chromosomal regions, all of which are syntenic with comparable abnormalities detected in human neuroblastomas.  In addn., the authors have shown that increases in MYCN dosage or deficiencies in either of the tumor suppressor genes NF1 or RB1 can augment tumorigenesis by the transgene.  Thus, MYCN can contribute to the genesis of neuroblastoma, the genetic events involved in the genesis of neuroblastoma can be tumorigenic in more than one chronol. sequence, and the model could be used for further study of the pathogenesis and therapy of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3hLdZJ6w4wbVg90H21EOLACvtfcHk0lgLD3-R4hQqmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlaqu7o%253D&md5=5171e78c0df25a1b329ab56592b21372</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.11.2985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.11.2985%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DFeuerstein%26aufirst%3DB.%2BG.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26atitle%3DTargeted%2520expression%2520of%2520MYCN%2520causes%2520neuroblastoma%2520in%2520transgenic%2520mice%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D2985%26epage%3D2995%26doi%3D10.1093%2Femboj%2F16.11.2985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Jamin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boult, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallsworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span> </span><span class="NLM_article-title">Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma</span> <span class="citation_source-journal">Radiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1148/radiol.12120128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1148%2Fradiol.12120128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2013&pages=130-140&author=Y.+Jaminauthor=E.+R.+Tuckerauthor=E.+Poonauthor=S.+Popovauthor=L.+Vaughanauthor=J.+K.+Boultauthor=H.+Webberauthor=A.+Hallsworthauthor=L.+C.+Bakerauthor=C.+Jonesauthor=D.+M.+Kohauthor=A.+D.+Pearsonauthor=L.+Cheslerauthor=S.+P.+Robinson&title=Evaluation+of+clinically+translatable+MR+imaging+biomarkers+of+therapeutic+response+in+the+TH-MYCN+transgenic+mouse+model+of+neuroblastoma&doi=10.1148%2Fradiol.12120128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1148%2Fradiol.12120128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.12120128%26sid%3Dliteratum%253Aachs%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DVaughan%26aufirst%3DL.%26aulast%3DBoult%26aufirst%3DJ.%2BK.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DL.%2BC.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoh%26aufirst%3DD.%2BM.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26atitle%3DEvaluation%2520of%2520clinically%2520translatable%2520MR%2520imaging%2520biomarkers%2520of%2520therapeutic%2520response%2520in%2520the%2520TH-MYCN%2520transgenic%2520mouse%2520model%2520of%2520neuroblastoma%26jtitle%3DRadiology%26date%3D2013%26volume%3D266%26spage%3D130%26epage%3D140%26doi%3D10.1148%2Fradiol.12120128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0lgLD3-R4hQqmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span>CardiacProfiler; <span class="NLM_publisher-name">Eurofins Pharma Discovery Services</span>: <span class="NLM_publisher-loc">St. Charles, MO</span>; <a href="http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitro-pharmacology/ion-channels.aspx" class="extLink">http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitro-pharmacology/ion-channels.aspx</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CardiacProfiler%3B+Eurofins+Pharma+Discovery+Services%3A+St.+Charles%2C+MO%3B+http%3A%2F%2Fwww.eurofins.com%2Fpharma-services%2Fpharma-discovery-services%2Fservices%2Fin-vitro-pharmacology%2Fion-channels.aspx."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiacProfiler%26pub%3DEurofins%2520Pharma%2520Discovery%2520Services" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrader, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanford, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjerstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabuslay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span> </span><span class="NLM_article-title">Potent 4-amino-5-azaindole factor VIIa inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4567</span><span class="NLM_x">–</span> <span class="NLM_lpage">4570</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.bmcl.2006.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4567-4570&author=H.+Huauthor=A.+Kolesnikovauthor=J.+R.+Riggsauthor=K.+E.+Wessonauthor=R.+Stephensauthor=E.+M.+Leahyauthor=W.+D.+Shraderauthor=P.+A.+Sprengelerauthor=M.+J.+Greenauthor=E.+Sanfordauthor=M.+Nguyenauthor=E.+Gjerstadauthor=R.+Cabuslayauthor=W.+B.+Young&title=Potent+4-amino-5-azaindole+factor+VIIa+inhibitors&doi=10.1016%2Fj.bmcl.2006.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DWesson%26aufirst%3DK.%2BE.%26aulast%3DStephens%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DShrader%26aufirst%3DW.%2BD.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DSanford%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DGjerstad%26aufirst%3DE.%26aulast%3DCabuslay%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DPotent%25204-amino-5-azaindole%2520factor%2520VIIa%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4567%26epage%3D4570%26doi%3D10.1016%2Fj.bmcl.2006.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Mineno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimitsu, H.</span><span> </span><span class="NLM_article-title">A convergent synthesis of the imidazopyridine scaffold of fluorescent alkaloid ageladine A</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2011.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.tetlet.2011.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=3131-3132&author=T.+Minenoauthor=H.+Kansuiauthor=H.+Yoshimitsu&title=A+convergent+synthesis+of+the+imidazopyridine+scaffold+of+fluorescent+alkaloid+ageladine+A&doi=10.1016%2Fj.tetlet.2011.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DMineno%26aufirst%3DT.%26aulast%3DKansui%26aufirst%3DH.%26aulast%3DYoshimitsu%26aufirst%3DH.%26atitle%3DA%2520convergent%2520synthesis%2520of%2520the%2520imidazopyridine%2520scaffold%2520of%2520fluorescent%2520alkaloid%2520ageladine%2520A%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D3131%26epage%3D3132%26doi%3D10.1016%2Fj.tetlet.2011.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Xds</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lguvs0aT1BcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Evans, P. R.</span><span> </span><span class="NLM_article-title">Scaling and assessment of data quality</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1107/S0907444905036693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444905036693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=16369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=72-82&author=P.+R.+Evans&title=Scaling+and+assessment+of+data+quality&doi=10.1107%2FS0907444905036693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling and assessment of data quality</span></div><div class="casAuthors">Evans, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The various phys. factors affecting measured diffraction intensities are discussed, as are the scaling models which may be used to put the data on a consistent scale.  After scaling, the intensities can be analyzed to set the real resoln. of the data set, to detect bad regions (e.g. bad images), to analyze radiation damage and to assess the overall quality of the data set.  The significance of any anomalous signal may be assessed by probability and correlation anal.  The algorithms used by the CCP4 scaling program SCALA are described.  A requirement for the scaling and merging of intensities is knowledge of the Laue group and point-group symmetries: the possible symmetry of the diffraction pattern may be detd. from scores such as correlation coeffs. between observations which might be symmetry-related.  These scoring functions are implemented in a new program POINTLESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGravLSLU62RhLVg90H21EOLACvtfcHk0lguvs0aT1BcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM&md5=293d3876e534c0c57813990515bb3c76</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444905036693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905036693%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%2BR.%26atitle%3DScaling%2520and%2520assessment%2520of%2520data%2520quality%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D72%26epage%3D82%26doi%3D10.1107%2FS0907444905036693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">COOT: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=COOT%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lguvs0aT1BcRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCOOT%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O.</span>BUSTER, <span class="NLM_edition">version 2.10.1</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkóczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0ljz9vrtlpkW8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G.</span>GRADE, <span class="NLM_edition">version 1.2.1</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=O.+S.+Smart&author=T.+O.+Womack&author=A.+Sharff&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=C.+Vonrhein&author=G.+Bricogne&title=GRADE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DO.%2BS.%26jtitle%3DGRADE%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Bruno, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motherwell, W. D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkis, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orpen, A. G.</span><span> </span><span class="NLM_article-title">Retrieval of crystallographically-derived molecular geometry information</span> <span class="citation_source-journal">J. Chem. Inf. Comput. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2133</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span><span class="refDoi"> DOI: 10.1021/ci049780b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049780b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlalsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=2133-2144&author=I.+J.+Brunoauthor=J.+C.+Coleauthor=M.+Kesslerauthor=J.+Luoauthor=W.+D.+S.+Motherwellauthor=L.+H.+Purkisauthor=B.+R.+Smithauthor=R.+Taylorauthor=R.+I.+Cooperauthor=S.+E.+Harrisauthor=A.+G.+Orpen&title=Retrieval+of+crystallographically-derived+molecular+geometry+information&doi=10.1021%2Fci049780b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Retrieval of Crystallographically-Derived Molecular Geometry Information</span></div><div class="casAuthors">Bruno, Ian J.; Cole, Jason C.; Kessler, Magnus; Luo, Jie; Motherwell, W. D. Sam; Purkis, Lucy H.; Smith, Barry R.; Taylor, Robin; Cooper, Richard I.; Harris, Stephanie E.; Orpen, A. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2133-2144</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The crystallog. detd. bond length, valence angle, and torsion angle information in the Cambridge Structural Database (CSD) has many uses.  However, accessing it by conventional substructure searching requires nontrivial user intervention.  In consequence, these valuable data were underused and were not directly accessible to client applications.  The situation was remedied by development of a new program (Mogul) for automated retrieval of mol. geometry data from the CSD.  The program uses a system of keys to encode the chem. environments of fragments (bonds, valence angles, and acyclic torsions) from CSD structures.  Fragments with identical keys are deemed to be chem. identical and are grouped together, and the distribution of the appropriate geometrical parameter (bond length, valence angle, or torsion angle) is computed and stored.  Use of a search tree indexed on key values, together with a novel similarity calcn., then enables the distribution matching any given query fragment (or the distributions most closely matching, if an adequate exact match is unavailable) to be found easily and with no user intervention.  Validation expts. indicate that, with rare exceptions, search results afford precise and unbiased ests. of mol. geometrical preferences.  Such ests. may be used, for example, to validate the geometries of libraries of modeled mols. or of newly detd. crystal structures or to assist structure soln. from low-resoln. (e.g. powder diffraction) x-ray data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8AZn6w-T817Vg90H21EOLACvtfcHk0ljz9vrtlpkW8w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlalsr8%253D&md5=a7909c257045351d5bff7b78c7fba2d5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fci049780b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049780b%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DI.%2BJ.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMotherwell%26aufirst%3DW.%2BD.%2BS.%26aulast%3DPurkis%26aufirst%3DL.%2BH.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DR.%2BI.%26aulast%3DHarris%26aufirst%3DS.%2BE.%26aulast%3DOrpen%26aufirst%3DA.%2BG.%26atitle%3DRetrieval%2520of%2520crystallographically-derived%2520molecular%2520geometry%2520information%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2004%26volume%3D44%26spage%3D2133%26epage%3D2144%26doi%3D10.1021%2Fci049780b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkwill, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Double, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farningham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennie, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span> </span><span class="NLM_article-title">Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1577</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fsj.bjc.6605642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20502460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3czmvFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1555-1577&author=P.+Workmanauthor=E.+O.+Aboagyeauthor=F.+Balkwillauthor=A.+Balmainauthor=G.+Bruderauthor=D.+J.+Chaplinauthor=J.+A.+Doubleauthor=J.+Everittauthor=D.+A.+Farninghamauthor=M.+J.+Glennieauthor=L.+R.+Kellandauthor=V.+Robinsonauthor=I.+J.+Stratfordauthor=G.+M.+Tozerauthor=S.+Watsonauthor=S.+R.+Wedgeauthor=S.+A.+Eccles&title=Committee+of+the+National+Cancer+Research+Institute.+Guidelines+for+the+welfare+and+use+of+animals+in+cancer+research&doi=10.1038%2Fsj.bjc.6605642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines for the welfare and use of animals in cancer research</span></div><div class="casAuthors">Workman P; Aboagye E O; Balkwill F; Balmain A; Bruder G; Chaplin D J; Double J A; Everitt J; Farningham D A H; Glennie M J; Kelland L R; Robinson V; Stratford I J; Tozer G M; Watson S; Wedge S R; Eccles S A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1555-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer.  Excellent standards of animal care are fully consistent with the conduct of high quality cancer research.  Here we provide updated guidelines on the welfare and use of animals in cancer research.  All experiments should incorporate the 3Rs: replacement, reduction and refinement.  Focusing on animal welfare, we present recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models (e.g., genetically engineered, orthotopic and metastatic); therapy (including drugs and radiation); imaging (covering techniques, anaesthesia and restraint); humane endpoints (including tumour burden and site); and publication of best practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkVD7D529OLg5nADWVYHg1fW6udTcc2ebAge830c-ELLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmvFyhsQ%253D%253D&md5=55f4c62e16fb1ebaa1f05d59caba3989</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605642%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBalkwill%26aufirst%3DF.%26aulast%3DBalmain%26aufirst%3DA.%26aulast%3DBruder%26aufirst%3DG.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DDouble%26aufirst%3DJ.%2BA.%26aulast%3DEveritt%26aufirst%3DJ.%26aulast%3DFarningham%26aufirst%3DD.%2BA.%26aulast%3DGlennie%26aufirst%3DM.%2BJ.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DRobinson%26aufirst%3DV.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26atitle%3DCommittee%2520of%2520the%2520National%2520Cancer%2520Research%2520Institute.%2520Guidelines%2520for%2520the%2520welfare%2520and%2520use%2520of%2520animals%2520in%2520cancer%2520research%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D1555%26epage%3D1577%26doi%3D10.1038%2Fsj.bjc.6605642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 13 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Masahiro Ito, Toshio Tanaka, Akinori Toita, Noriko Uchiyama, Hironori Kokubo, Nao Morishita, Michael G. Klein, Hua Zou, Morio Murakami, Mitsuyo Kondo, Tomoya Sameshima, Shinsuke Araki, Satoshi Endo, Tomohiro Kawamoto, Gregg B. Morin, Samuel A. Aparicio, Atsushi Nakanishi, Hironobu Maezaki, <span class="NLM_string-name hlFld-ContribAuthor">Yasuhiro Imaeda</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 3-Benzyl-1-(trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7710-7728. <a href="https://doi.org/10.1021/acs.jmedchem.8b00683" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00683</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00683%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B3-Benzyl-1-%252528trans-4-%252528%2525285-cyanopyridin-2-yl%252529amino%252529cyclohexyl%252529-1-arylurea%252BDerivatives%252Bas%252BNovel%252Band%252BSelective%252BCyclin-Dependent%252BKinase%252B12%252B%252528CDK12%252529%252BInhibitors%26aulast%3DIto%26aufirst%3DMasahiro%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D30042018%26date%3D20082018%26date%3D01082018%26volume%3D61%26issue%3D17%26spage%3D7710%26epage%3D7728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Jin</span>, <span class="hlFld-ContribAuthor ">Peipei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiubing  Long</span>, <span class="hlFld-ContribAuthor ">Kailong  Jiang</span>, <span class="hlFld-ContribAuthor ">Pinrao  Song</span>, <span class="hlFld-ContribAuthor ">Wenbiao  Wu</span>, <span class="hlFld-ContribAuthor ">Gaoya  Xu</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Orally Bioavailable CHK1 Inhibitors Active against Acute Myeloid Leukemia. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (9)
                                     , 1477-1487. <a href="https://doi.org/10.1002/cmdc.202000882" title="DOI URL">https://doi.org/10.1002/cmdc.202000882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000882%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BOrally%252BBioavailable%252BCHK1%252BInhibitors%252BActive%252Bagainst%252BAcute%252BMyeloid%252BLeukemia%26aulast%3DJin%26aufirst%3DTingting%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D9%26spage%3D1477%26epage%3D1487" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rahul  Singh</span>, <span class="hlFld-ContribAuthor ">Vijay Kumar  Bhardwaj</span>, <span class="hlFld-ContribAuthor ">Jatin  Sharma</span>, <span class="hlFld-ContribAuthor ">Pralay  Das</span>, <span class="hlFld-ContribAuthor ">Rituraj  Purohit</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants. </span><span class="cited-content_cbyCitation_journal-name">Genomics</span><span> <strong>2021,</strong> <em>113 </em>
                                    (1)
                                     , 707-715. <a href="https://doi.org/10.1016/j.ygeno.2020.10.001" title="DOI URL">https://doi.org/10.1016/j.ygeno.2020.10.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ygeno.2020.10.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ygeno.2020.10.001%26sid%3Dliteratum%253Aachs%26jtitle%3DGenomics%26atitle%3DDiscovery%252Band%252Bin%252Bsilico%252Bevaluation%252Bof%252Baminoarylbenzosuberene%252Bmolecules%252Bas%252Bnovel%252Bcheckpoint%252Bkinase%252B1%252Binhibitor%252Bdeterminants%26aulast%3DSingh%26aufirst%3DRahul%26date%3D2021%26volume%3D113%26issue%3D1%26spage%3D707%26epage%3D715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao‐Feng  Xia</span>, <span class="hlFld-ContribAuthor ">Mingming  Zhao</span>, <span class="hlFld-ContribAuthor ">Wei  He</span>, <span class="hlFld-ContribAuthor ">Lianghua  Zou</span>, <span class="hlFld-ContribAuthor ">Xinxin  San</span>, <span class="hlFld-ContribAuthor ">Dawei  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Metal‐Free Oxidative [5+1] Cyclization of 1,5‐Enynes for the Synthesis of Pyrazine 1‐Oxide. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (17)
                                     , 3621-3626. <a href="https://doi.org/10.1002/adsc.202000756" title="DOI URL">https://doi.org/10.1002/adsc.202000756</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.202000756&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.202000756%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DMetal%2525E2%252580%252590Free%252BOxidative%252B%25255B5%25252B1%25255D%252BCyclization%252Bof%252B1%25252C5%2525E2%252580%252590Enynes%252Bfor%252Bthe%252BSynthesis%252Bof%252BPyrazine%252B1%2525E2%252580%252590Oxide%26aulast%3DXia%26aufirst%3DXiao%25E2%2580%2590Feng%26date%3D2020%26date%3D2020%26volume%3D362%26issue%3D17%26spage%3D3621%26epage%3D3626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nagaraja Reddy  Gangarapu</span>, <span class="hlFld-ContribAuthor ">Archakam  Ranganatham</span>, <span class="hlFld-ContribAuthor ">Eeda Koti  Reddy</span>, <span class="hlFld-ContribAuthor ">Shivaraj  Yellappa</span>, <span class="hlFld-ContribAuthor ">Kothapalli Bannoth  Chandrasekhar</span>. </span><span class="cited-content_cbyCitation_article-title">2‐Aminoaryl‐3,5‐diaryl pyrazines: Synthesis, biological evaluation against
              Mycobacterium tuberculosis
              and docking studies. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (7)
                                     , 1900368. <a href="https://doi.org/10.1002/ardp.201900368" title="DOI URL">https://doi.org/10.1002/ardp.201900368</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201900368&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201900368%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3D2%2525E2%252580%252590Aminoaryl%2525E2%252580%2525903%25252C5%2525E2%252580%252590diaryl%252Bpyrazines%25253A%252BSynthesis%25252C%252Bbiological%252Bevaluation%252Bagainst%252BMycobacterium%252Btuberculosis%252Band%252Bdocking%252Bstudies%26aulast%3DGangarapu%26aufirst%3DNagaraja%25C2%25A0Reddy%26date%3D2020%26date%3D2020%26volume%3D353%26issue%3D7%26spage%3D1900368" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amanda  Garrido</span>, <span class="hlFld-ContribAuthor ">Alban  Lepailleur</span>, <span class="hlFld-ContribAuthor ">Serge M.  Mignani</span>, <span class="hlFld-ContribAuthor ">Patrick  Dallemagne</span>, <span class="hlFld-ContribAuthor ">Christophe  Rochais</span>. </span><span class="cited-content_cbyCitation_article-title">hERG toxicity assessment: Useful guidelines for drug design. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>195 </em>, 112290. <a href="https://doi.org/10.1016/j.ejmech.2020.112290" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112290</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112290%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DhERG%252Btoxicity%252Bassessment%25253A%252BUseful%252Bguidelines%252Bfor%252Bdrug%252Bdesign%26aulast%3DGarrido%26aufirst%3DAmanda%26date%3D2020%26volume%3D195%26spage%3D112290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rebecca F.  Rogers</span>, <span class="hlFld-ContribAuthor ">Michael I.  Walton</span>, <span class="hlFld-ContribAuthor ">Daniel L.  Cherry</span>, <span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Paul A.  Clarke</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Garrett</span>, <span class="hlFld-ContribAuthor ">Paul  Workman</span>. </span><span class="cited-content_cbyCitation_article-title">CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2020,</strong> <em>80 </em>
                                    (8)
                                     , 1735-1747. <a href="https://doi.org/10.1158/0008-5472.CAN-19-1372" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-19-1372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-19-1372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-19-1372%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DCHK1%252BInhibition%252BIs%252BSynthetically%252BLethal%252Bwith%252BLoss%252Bof%252BB-Family%252BDNA%252BPolymerase%252BFunction%252Bin%252BHuman%252BLung%252Band%252BColorectal%252BCancer%252BCells%26aulast%3DRogers%26aufirst%3DRebecca%2BF.%26date%3D2020%26date%3D2020%26volume%3D80%26issue%3D8%26spage%3D1735%26epage%3D1747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lexian  Tong</span>, <span class="hlFld-ContribAuthor ">Pinrao  Song</span>, <span class="hlFld-ContribAuthor ">Kailong  Jiang</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Tingting  Jin</span>, <span class="hlFld-ContribAuthor ">Peipei  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaobei  Hu</span>, <span class="hlFld-ContribAuthor ">Sui  Fang</span>, <span class="hlFld-ContribAuthor ">Anhui  Gao</span>, <span class="hlFld-ContribAuthor ">Yubo  Zhou</span>, <span class="hlFld-ContribAuthor ">Tao  Liu</span>, <span class="hlFld-ContribAuthor ">Jia  Li</span>, <span class="hlFld-ContribAuthor ">Yongzhou  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (R)-5-((5-(1-methyl-1H-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a novel CHK1 inhibitor for hematologic malignancies. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>173 </em>, 44-62. <a href="https://doi.org/10.1016/j.ejmech.2019.03.062" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.062</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.062%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%252529-5-%252528%2525285-%2525281-methyl-1H-pyrazol-4-yl%252529-4-%252528methylamino%252529pyrimidin-2-yl%252529amino%252529-3-%252528piperidin-3-yloxy%252529picolinonitrile%25252C%252Ba%252Bnovel%252BCHK1%252Binhibitor%252Bfor%252Bhematologic%252Bmalignancies%26aulast%3DTong%26aufirst%3DLexian%26date%3D2019%26volume%3D173%26spage%3D44%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xuan-Xuan  Du</span>, <span class="hlFld-ContribAuthor ">Quan-Xing  Zi</span>, <span class="hlFld-ContribAuthor ">Yu-Meng  Wu</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Sheng-Jiao  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">An environmentally benign multi-component reaction: regioselective synthesis of fluorinated 2-aminopyridines using diverse properties of the nitro group. </span><span class="cited-content_cbyCitation_journal-name">Green Chemistry</span><span> <strong>2019,</strong> <em>21 </em>
                                    (6)
                                     , 1505-1516. <a href="https://doi.org/10.1039/C8GC03698E" title="DOI URL">https://doi.org/10.1039/C8GC03698E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8GC03698E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8GC03698E%26sid%3Dliteratum%253Aachs%26jtitle%3DGreen%2520Chemistry%26atitle%3DAn%252Benvironmentally%252Bbenign%252Bmulti-component%252Breaction%25253A%252Bregioselective%252Bsynthesis%252Bof%252Bfluorinated%252B2-aminopyridines%252Busing%252Bdiverse%252Bproperties%252Bof%252Bthe%252Bnitro%252Bgroup%26aulast%3DDu%26aufirst%3DXuan-Xuan%26date%3D2019%26date%3D2019%26volume%3D21%26issue%3D6%26spage%3D1505%26epage%3D1516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Tian</span>, <span class="hlFld-ContribAuthor ">Zifei  Han</span>, <span class="hlFld-ContribAuthor ">Yuanxin  Li</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Jiajia  Yang</span>, <span class="hlFld-ContribAuthor ">Xiaowei  Wang</span>, <span class="hlFld-ContribAuthor ">Zhili  Zhang</span>, <span class="hlFld-ContribAuthor ">Junyi  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>151 </em>, 836-848. <a href="https://doi.org/10.1016/j.ejmech.2018.03.075" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.03.075</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.03.075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.03.075%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B2%25252C6-disubstituted-9H-purine%25252C%252B2%25252C4-disubstitued-thieno%25255B3%25252C2-d%25255Dpyrimidine%252Band%252B-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Banalogues%252Bas%252Bnovel%252BCHK1%252Binhibitors%26aulast%3DTian%26aufirst%3DChao%26date%3D2018%26volume%3D151%26spage%3D836%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ian  Collins</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Garrett</span>. </span><span class="cited-content_cbyCitation_article-title">Preclinical Profiles and Contexts for CHK1 and CHK2 Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 241-276. <a href="https://doi.org/10.1007/978-3-319-75836-7_10" title="DOI URL">https://doi.org/10.1007/978-3-319-75836-7_10</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-75836-7_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-75836-7_10%26sid%3Dliteratum%253Aachs%26atitle%3DPreclinical%252BProfiles%252Band%252BContexts%252Bfor%252BCHK1%252Band%252BCHK2%252BInhibitors%26aulast%3DCollins%26aufirst%3DIan%26date%3D2018%26date%3D2018%26spage%3D241%26epage%3D276%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DTargeting%252Bthe%252BDNA%252BDamage%252BResponse%252Bfor%252BAnti-Cancer%252BTherapy%26aulast%3DPollard%26aufirst%3DJohn%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monique  Zangarini</span>, <span class="hlFld-ContribAuthor ">Philip  Berry</span>, <span class="hlFld-ContribAuthor ">Julieann  Sludden</span>, <span class="hlFld-ContribAuthor ">Florence I  Raynaud</span>, <span class="hlFld-ContribAuthor ">Udai  Banerji</span>, <span class="hlFld-ContribAuthor ">Paul  Jones</span>, <span class="hlFld-ContribAuthor ">David  Edwards</span>, <span class="hlFld-ContribAuthor ">Gareth J  Veal</span>. </span><span class="cited-content_cbyCitation_article-title">Development and validation of a LC–MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma. </span><span class="cited-content_cbyCitation_journal-name">Bioanalysis</span><span> <strong>2017,</strong> <em>9 </em>
                                    (13)
                                     , 1001-1010. <a href="https://doi.org/10.4155/bio-2017-0043" title="DOI URL">https://doi.org/10.4155/bio-2017-0043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/bio-2017-0043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Fbio-2017-0043%26sid%3Dliteratum%253Aachs%26jtitle%3DBioanalysis%26atitle%3DDevelopment%252Band%252Bvalidation%252Bof%252Ba%252BLC%2525E2%252580%252593MS%25252FMS%252Bmethod%252Bfor%252Bthe%252Bquantification%252Bof%252Bthe%252Bcheckpoint%252Bkinase%252B1%252Binhibitor%252BSRA737%252Bin%252Bhuman%252Bplasma%26aulast%3DZangarini%26aufirst%3DMonique%26date%3D2017%26volume%3D9%26issue%3D13%26spage%3D1001%26epage%3D1010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0001.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Summary of the evolution of the oral inhibitor tool compound <b>1</b><a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and oral clinical development candidate <b>4</b>.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0002.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Relationship of hERG inhibition to calculated AlogP and HBD count for 4-amino-substituted methyl 6-((5-cyanopyrazin-2-yl)amino)nicotinates including examples specified in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0003.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Detail of the crystal structure (PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N">5F4N</a>) showing <b>12</b> (green) bound in the CHK1 ATP site with key residues (gray) and water molecules (red spheres) shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0004.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Relationship of efficacy and selectivity in SW620 colon cancer cells to molecular weight for 5-((4-((morpholin-2-ylmethyl)amino)pyridin-2-yl)amino)pyrazine-2-carbonitriles with <i>C</i>-5 substituents of various sizes, exemplified in <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Points are color-coded by CHK1 cellular selectivity (red, low; green, high) and labeled with compound identifiers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0005.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Inhibition of gemcitabine (60 mg/kg iv) induced pSer296 CHK1 autophosphorylation at 24 h by 300 mg/kg po of (A) <b>38</b>, (B) <b>41</b>, and (C) <b>4</b> in SW620 human colon cancer xenografts. Dashed line indicates where Western blot image has been cut. (D) Total inhibitor concentrations of <b>38</b>, <b>41</b>, and <b>4</b> in plasma and SW620 tumor xenografts at 24 h after a single 300 mg/kg po dose (mean ± SD, <i>n</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0006.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antitumor efficacies of <b>41</b> (150 mg/kg po) and <b>4</b> (150 mg/kg po) in combination with gemcitabine (100 mg/kg iv) in HT29 colon cancer xenografts. The CHK1 inhibitors were administered as suspensions in DMSO–Tween80–PEG400–water (0.05:0.2:0.65:0.1) 24 and 48 h after gemcitabine in each of three weekly treatment cycles. Inset: body weights of cohorts as described in main figure. <i>N</i> = 4–6 per cohort.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0007.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. <b>4</b> (150 mg/kg po) potentiates the tumor growth delay of gemcitabine in allograft KPC1 p53- and KRAS-deficient mouse pancreatic adenocarcinomas.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a><i>N</i> = 8 per cohort. Red arrow = gemcitabine dosed; blue arrow = <b>4</b> dosed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0008.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. <b>4</b> (150 mg/kg po UID for 7 d) inhibits tumor growth in the TH-MYCN GEMM of neuroblastoma.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> (A) Comparison of tumor weights for vehicle- and compound-treated cohorts (mean ± SEM, <i>n</i> = 8). (B) Pre- and post-treatment T<sub>2</sub>-weighted MRI<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> assessment of an abdominal tumor in a single mouse treated with <b>4</b>. k = kidney.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Preparation of Compounds <b>3</b>, <b>5</b>–<b>15</b>, and <b>21</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) R<sup>1</sup>NH<sub>2</sub>, Et<sub>3</sub>N, <sup><i>n</i></sup>BuOH, 120 °C (microwave irradiation), 1.5 h; (ii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, NaO<sup><i>t</i></sup>Bu, toluene, 130 °C (microwave irradiation), 30 min; (iii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 130 °C (microwave irradiation), 30 min; (iv) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (v) NaOH, H<sub>2</sub>O, MeOH, rt, 3 h; (vi) MeNH<sub>2</sub> (2M, THF), HATU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt, 18 h; (vii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene/DMF (1:1), 130 °C (microwave irradiation), 120 min; (viii) (a) LiOH, H<sub>2</sub>O, <sup><i>t</i></sup>BuOH, rt, 4 d, (b) R<sup>2</sup>NH<sub>2</sub>, TBTU, rt, 18 h; (ix) (a) LiI, pyridine, 150 °C (microwave irradiation), 2.5 h, (b) <i>N</i>′-hydroxyacetimidamide, HATU, <sup><i>i</i></sup>Pr<sub>2</sub>NEt, DMF, rt, 18 h, (c) pyridine, 120 °C (microwave irradiation), 1 h.</p></p></figure><figure data-id="sch2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0010.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of Compounds <b>16</b>–<b>20</b> and <b>22</b>–<b>38</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) ICl, KOAc, AcOH, 70 °C, 5 h; (ii) R<sup>1</sup>Br or R<sup>1</sup>OTs, NaH, DMF, 80 °C, 2 h; (iii) R<sup>2</sup>B(OR)<sub>2</sub>, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub> (0.5M, H<sub>2</sub>O), MeCN, 100 °C (microwave irradiation), 20 min; (iv) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, toluene, 150 °C (microwave irradiation), 1 h; (v) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (vi) 5-methyl-2-(tributylstannyl)thiazole, (Ph<sub>3</sub>P)<sub>4</sub>Pd, toluene, 90 °C, 18 h; (vii) HCl, dioxane, rt, 1 h; (viii) R<sup>3</sup>CCH, CuI, Pd(Ph<sub>3</sub>P)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, DMF, 120 °C (microwave irradiation), 10 min; (ix) H<sub>2</sub>, 10% Pd/C, EtOH, rt, 18 h.</p></p></figure><figure data-id="sch3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0011.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Preparation of Compounds <b>39</b> and <b>40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>tert</i>-butyl (<i>rac</i>)-2-(aminomethyl)morpholine-4-carboxylate, Et<sub>3</sub>N, <sup><i>n</i></sup>BuOH, 120 °C (microwave irradiation), 1.5 h; (ii) (CF<sub>3</sub>CO)<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 30 min; (iii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, K<sub>3</sub>PO<sub>4</sub>, dioxane, 150 °C (microwave irradiation), 1 h; (iv) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (v) cyclopropylboronic acid pinacol ester, (Ph<sub>3</sub>P)<sub>4</sub>Pd, Na<sub>2</sub>CO<sub>3</sub> (0.5M, H<sub>2</sub>O), MeCN, 130 °C (microwave irradiation), 1.5 h; (vi) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 130 °C (microwave irradiation), 45 min.</p></p></figure><figure data-id="sch4" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/medium/jm-2015-019385_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0012.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Preparation of Compounds <b>4</b>, <b>41</b>, and <b>42</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-11/acs.jmedchem.5b01938/20160629/images/large/jm-2015-019385_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01938&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) <i>tert</i>-butyl (<i>R</i>)-2-((tosyloxy)methyl)morpholine-4-carboxylate, NaH, DMF, 80 °C, 2.5 h; (ii) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, xantphos, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 150 °C (microwave irradiation), 60 min; (iii) CF<sub>3</sub>CO<sub>2</sub>H, CH<sub>2</sub>Cl<sub>2</sub>, rt; (iv) diphenyl phosphorazidate, Et<sub>3</sub>N, <sup><i>t</i></sup>BuOH, toluene, 105 °C, 5 h; (v) 5-aminopyrazine-2-carbonitrile, Pd<sub>2</sub>(dba)<sub>3</sub>, BINAP, Cs<sub>2</sub>CO<sub>3</sub>, dioxane, 150 °C (microwave irradiation), 1 h; (vi) CF<sub>3</sub>CO<sub>2</sub>H, <sup><i>i</i></sup>Pr<sub>3</sub>SiH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1 h.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i33">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77800" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77800" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Dai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S.</span><span> </span><span class="NLM_article-title">New insights into checkpoint kinase 1 in the DNA damage response signalling network</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">376</span><span class="NLM_x">–</span> <span class="NLM_lpage">383</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-09-1029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-09-1029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20068082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktF2qsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=376-383&author=Y.+Daiauthor=S.+Grant&title=New+insights+into+checkpoint+kinase+1+in+the+DNA+damage+response+signalling+network&doi=10.1158%2F1078-0432.CCR-09-1029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">New insights into checkpoint kinase 1 in the DNA damage response signaling network</span></div><div class="casAuthors">Dai, Yun; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">376-383</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  The DNA damage response (DDR) represents a complex network of multiple signaling pathways involving cell cycle checkpoints, DNA repair, transcriptional programs, and apoptosis, through which cells maintain genomic integrity following various endogenous (metabolic) or environmental stresses.  In cancer treatment, the DDR occurs in response to various genotoxic insults by diverse cytotoxic agents and radiation, representing an important mechanism limiting chemotherapeutic and radiotherapeutic efficacy.  This has prompted the development of agents targeting DDR signaling pathways, particularly checkpoint kinase 1 (Chk1), which contributes to all currently defined cell cycle checkpoints, including G1/S, intra-S-phase, G2/M, and the mitotic spindle checkpoint.  Although numerous agents have been developed with the primary goal of enhancing the activity of DNA-damaging agents or radiation, the therapeutic outcome of this strategy remains to be detd.  Recently, new insights into DDR signaling pathways support the notion that Chk1 represents a core component central to the entire DDR, including direct involvement in DNA repair and apoptotic events in addn. to checkpoint regulation.  Together, these new insights into the role of Chk1 in the DDR machinery could provide an opportunity for novel approaches to the development of Chk1 inhibitor strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP9oCivdYOLbVg90H21EOLACvtfcHk0li4KRupSKqveg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktF2qsb8%253D&md5=37b8cf16a1a136372f1c1ee6d42b6988</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-09-1029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-09-1029%26sid%3Dliteratum%253Aachs%26aulast%3DDai%26aufirst%3DY.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DNew%2520insights%2520into%2520checkpoint%2520kinase%25201%2520in%2520the%2520DNA%2520damage%2520response%2520signalling%2520network%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D376%26epage%3D383%26doi%3D10.1158%2F1078-0432.CCR-09-1029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Smith, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tho, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillespie, D. A.</span><span> </span><span class="NLM_article-title">The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer</span> <span class="citation_source-journal">Adv. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">112</span><span class="refDoi"> DOI: 10.1016/B978-0-12-380888-2.00003-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2FB978-0-12-380888-2.00003-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21034966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXitlSlug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2010&pages=73-112&author=J.+Smithauthor=L.+M.+Thoauthor=N.+Xuauthor=D.+A.+Gillespie&title=The+ATM-Chk2+and+ATR-Chk1+pathways+in+DNA+damage+signaling+and+cancer&doi=10.1016%2FB978-0-12-380888-2.00003-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer</span></div><div class="casAuthors">Smith, Joanne; Tho, Lye Mun; Xu, Naihan; Gillespie, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">73-112</span>CODEN:
                <span class="NLM_cas:coden">ACRSAJ</span>;
        ISSN:<span class="NLM_cas:issn">0065-230X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  DNA damage is a key factor both in the evolution and treatment of cancer.  Genomic instability is a common feature of cancer cells, fuelling accumulation of oncogenic mutations, while radiation and diverse genotoxic agents remain important, if imperfect, therapeutic modalities.  Cellular responses to DNA damage are coordinated primarily by two distinct kinase signaling cascades, the ATM-Chk2 and ATR-Chk1 pathways, which are activated by DNA double-strand breaks (DSBs) and single-stranded DNA resp.  Historically, these pathways were thought to act in parallel with overlapping functions; however, more recently it has become apparent that their relationship is more complex.  In response to DSBs, ATM is required both for ATR-Chk1 activation and to initiate DNA repair via homologous recombination (HRR) by promoting formation of single-stranded DNA at sites of damage through nucleolytic resection.  Interestingly, cells and organisms survive with mutations in ATM or other components required for HRR, such as BRCA1 and BRCA2, but at the cost of genomic instability and cancer predisposition.  By contrast, the ATR-Chk1 pathway is the principal direct effector of the DNA damage and replication checkpoints and, as such, is essential for the survival of many, although not all, cell types.  Remarkably, deficiency for HRR in BRCA1- and BRCA2-deficient tumors confers sensitivity to cisplatin and inhibitors of poly(ADP-ribose) polymerase (PARP), an enzyme required for repair of endogenous DNA damage.  In addn., suppressing DNA damage and replication checkpoint responses by inhibiting Chk1 can enhance tumor cell killing by diverse genotoxic agents.  Here, we review current understanding of the organization and functions of the ATM-Chk2 and ATR-Chk1 pathways and the prospects for targeting DNA damage signaling processes for therapeutic purposes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyKlkmzDBDD7Vg90H21EOLACvtfcHk0lgXL2v2EqgsXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXitlSlug%253D%253D&md5=f9d9d807519bb88afed9ecffc85bd99f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-380888-2.00003-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-380888-2.00003-0%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DJ.%26aulast%3DTho%26aufirst%3DL.%2BM.%26aulast%3DXu%26aufirst%3DN.%26aulast%3DGillespie%26aufirst%3DD.%2BA.%26atitle%3DThe%2520ATM-Chk2%2520and%2520ATR-Chk1%2520pathways%2520in%2520DNA%2520damage%2520signaling%2520and%2520cancer%26jtitle%3DAdv.%2520Cancer%2520Res.%26date%3D2010%26volume%3D108%26spage%3D73%26epage%3D112%26doi%3D10.1016%2FB978-0-12-380888-2.00003-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Clarke, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, P. R.</span><span> </span><span class="NLM_article-title">DNA-dependent phosphorylation of CHK1 and claspin in human cell-free system</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">388</span><span class="NLM_x">, </span> <span class="NLM_fpage">705</span><span class="NLM_x">–</span> <span class="NLM_lpage">712</span><span class="refDoi"> DOI: 10.1042/BJ20041966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1042%2FBJ20041966" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2005&pages=705-712&author=C.+A.+Clarkeauthor=P.+R.+Clarke&title=DNA-dependent+phosphorylation+of+CHK1+and+claspin+in+human+cell-free+system&doi=10.1042%2FBJ20041966"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1042%2FBJ20041966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20041966%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DC.%2BA.%26aulast%3DClarke%26aufirst%3DP.%2BR.%26atitle%3DDNA-dependent%2520phosphorylation%2520of%2520CHK1%2520and%2520claspin%2520in%2520human%2520cell-free%2520system%26jtitle%3DBiochem.%2520J.%26date%3D2005%26volume%3D388%26spage%3D705%26epage%3D712%26doi%3D10.1042%2FBJ20041966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Xiao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gunasekera, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fesik, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span> </span><span class="NLM_article-title">Chk1 mediates S and G2 arrests through Cdc25A degradation in response to DNA-damaging agents</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">21767</span><span class="NLM_x">–</span> <span class="NLM_lpage">21773</span><span class="refDoi"> DOI: 10.1074/jbc.M300229200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1074%2Fjbc.M300229200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=21767-21773&author=Z.+Xiaoauthor=Z.+Chenauthor=A.+H.+Gunasekeraauthor=T.+J.+Sowinauthor=S.+H.+Rosenbergauthor=S.+Fesikauthor=H.+Zhang&title=Chk1+mediates+S+and+G2+arrests+through+Cdc25A+degradation+in+response+to+DNA-damaging+agents&doi=10.1074%2Fjbc.M300229200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M300229200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M300229200%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGunasekera%26aufirst%3DA.%2BH.%26aulast%3DSowin%26aufirst%3DT.%2BJ.%26aulast%3DRosenberg%26aufirst%3DS.%2BH.%26aulast%3DFesik%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DH.%26atitle%3DChk1%2520mediates%2520S%2520and%2520G2%2520arrests%2520through%2520Cdc25A%2520degradation%2520in%2520response%2520to%2520DNA-damaging%2520agents%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D21767%26epage%3D21773%26doi%3D10.1074%2Fjbc.M300229200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Sorensen, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hansen, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dziegielewski, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Syljuasen, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lundin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helleday, T.</span><span> </span><span class="NLM_article-title">The cell-cycle checkpoint kinase chk1 is required for mammalian homologous recombination repair</span> <span class="citation_source-journal">Nat. Cell Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">195</span><span class="NLM_x">–</span> <span class="NLM_lpage">201</span><span class="refDoi"> DOI: 10.1038/ncb1212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fncb1212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15665856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXpt1CjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=195-201&author=C.+S.+Sorensenauthor=L.+T.+Hansenauthor=J.+Dziegielewskiauthor=R.+G.+Syljuasenauthor=C.+Lundinauthor=J.+Bartekauthor=T.+Helleday&title=The+cell-cycle+checkpoint+kinase+chk1+is+required+for+mammalian+homologous+recombination+repair&doi=10.1038%2Fncb1212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair</span></div><div class="casAuthors">Sorensen, Claus Storgaard; Hansen, Lasse Tengbjerg; Dziegielewski, Jaroslaw; Syljuasen, Randi G.; Lundin, Cecilia; Bartek, Jiri; Helleday, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Nature Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">195-201</span>CODEN:
                <span class="NLM_cas:coden">NCBIFN</span>;
        ISSN:<span class="NLM_cas:issn">1465-7392</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The essential checkpoint kinase Chk1 is required for cell-cycle delays after DNA damage or blocked DNA replication.  However, it is unclear whether Chk1 is involved in the repair of damaged DNA.  Here we establish that Chk1 is a key regulator of genome maintenance by the homologous recombination repair (HRR) system.  Abrogation of Chk1 function with small interfering RNA or chem. antagonists inhibits HRR, leading to persistent unrepaired DNA double-strand breaks (DSBs) and cell death after replication inhibition with hydroxyurea or DNA-damage caused by camptothecin.  After hydroxyurea treatment, the essential recombination repair protein RAD51 is recruited to DNA repair foci performing a vital role in correct HRR.  We demonstrate that Chk1 interacts with RAD51, and that RAD51 is phosphorylated on Thr 309 in a Chk1-dependent manner.  Consistent with a functional interplay between Chk1 and RAD51, Chk1-depleted cells failed to form RAD51 nuclear foci after exposure to hydroxyurea, and cells expressing a phosphorylation-deficient mutant RAD51T309A were hypersensitive to hydroxyurea.  These results highlight a crucial role for the Chk1 signalling pathway in protecting cells against lethal DNA lesions through regulation of HRR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraSb0kSyc0XLVg90H21EOLACvtfcHk0lgXL2v2EqgsXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXpt1CjsA%253D%253D&md5=27d6e602266199bad4ff44e2d13b491d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fncb1212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncb1212%26sid%3Dliteratum%253Aachs%26aulast%3DSorensen%26aufirst%3DC.%2BS.%26aulast%3DHansen%26aufirst%3DL.%2BT.%26aulast%3DDziegielewski%26aufirst%3DJ.%26aulast%3DSyljuasen%26aufirst%3DR.%2BG.%26aulast%3DLundin%26aufirst%3DC.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DHelleday%26aufirst%3DT.%26atitle%3DThe%2520cell-cycle%2520checkpoint%2520kinase%2520chk1%2520is%2520required%2520for%2520mammalian%2520homologous%2520recombination%2520repair%26jtitle%3DNat.%2520Cell%2520Biol.%26date%3D2005%26volume%3D7%26spage%3D195%26epage%3D201%26doi%3D10.1038%2Fncb1212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Middleton, F. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curtin, N. J.</span><span> </span><span class="NLM_article-title">Targeting the S and G2 checkpoint to treat cancer</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">194</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1016/j.drudis.2011.12.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.drudis.2011.12.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=22192883" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC38Xjs1Gnu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=194-202&author=T.+Chenauthor=P.+A.+Stephensauthor=F.+K.+Middletonauthor=N.+J.+Curtin&title=Targeting+the+S+and+G2+checkpoint+to+treat+cancer&doi=10.1016%2Fj.drudis.2011.12.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the S and G2 checkpoint to treat cancer</span></div><div class="casAuthors">Chen, Tao; Stephens, Peter A.; Middleton, Fiona K.; Curtin, Nicola J.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">5-6</span>),
    <span class="NLM_cas:pages">194-202</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Cell survival following DNA damage depends on activating checkpoints to arrest proliferation.  Most cancer cells have dysregulated G1 checkpoints making them dependent on their S and G2 checkpoints, which are activated by ATR/Chk1 signalling.  Thus, inhibiting ATR or Chk1 should selectively sensitize cancer cells to DNA damage.  Genetic inactivation of ATR and Chk1 abrogates cell cycle arrest and enhances cytotoxicity following exposure to DNA-damaging agents.  Similar effects were seen with small-mol. Chk1 inhibitors in preclin. studies, and clin. trial data are starting to emerge.  Recently, potent ATR inhibitors have been identified that also sensitize cancer cells in vitro.  ATR and Chk1 inhibitors might also cause synthetic lethality' in tumor cells defective in defined DNA repair pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk-ZLlmsYspbVg90H21EOLACvtfcHk0lgXL2v2EqgsXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xjs1Gnu7s%253D&md5=23724baf6f2ba1a2e622e2f6b44b2e40</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2011.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2011.12.009%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DT.%26aulast%3DStephens%26aufirst%3DP.%2BA.%26aulast%3DMiddleton%26aufirst%3DF.%2BK.%26aulast%3DCurtin%26aufirst%3DN.%2BJ.%26atitle%3DTargeting%2520the%2520S%2520and%2520G2%2520checkpoint%2520to%2520treat%2520cancer%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2012%26volume%3D17%26spage%3D194%26epage%3D202%26doi%3D10.1016%2Fj.drudis.2011.12.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Anticancer therapy with checkpoint inhibitors: what, when and where?</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">308</span><span class="NLM_x">–</span> <span class="NLM_lpage">316</span><span class="refDoi"> DOI: 10.1016/j.tips.2011.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.tips.2011.02.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2011&pages=308-316&author=M.+D.+Garrettauthor=I.+Collins&title=Anticancer+therapy+with+checkpoint+inhibitors%3A+what%2C+when+and+where%3F&doi=10.1016%2Fj.tips.2011.02.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2011.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2011.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DAnticancer%2520therapy%2520with%2520checkpoint%2520inhibitors%253A%2520what%252C%2520when%2520and%2520where%253F%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2011%26volume%3D32%26spage%3D308%26epage%3D316%26doi%3D10.1016%2Fj.tips.2011.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ma, C. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janetka, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piwnica-Worms, H.</span><span> </span><span class="NLM_article-title">Death by releasing the breaks: Chk1 inhibitors as cancer therapeutics</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.molmed.2010.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.molmed.2010.10.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21087899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=88-96&author=C.+X.+Maauthor=J.+W.+Janetkaauthor=H.+Piwnica-Worms&title=Death+by+releasing+the+breaks%3A+Chk1+inhibitors+as+cancer+therapeutics&doi=10.1016%2Fj.molmed.2010.10.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics</span></div><div class="casAuthors">Ma, Cynthia X.; Janetka, James W.; Piwnica-Worms, Helen</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Molecular Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">88-96</span>CODEN:
                <span class="NLM_cas:coden">TMMRCY</span>;
        ISSN:<span class="NLM_cas:issn">1471-4914</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Defects in p53 function, which occur frequently in human cancers due to mutations in TP53 or disruptions in the p53 regulatory pathway, render cells dependent on CHK1 (Checkpoint Kinase 1) to activate cell cycle checkpoints.  In the presence of DNA damage or replication stress, inhibition of CHK1 leads to "mitotic catastrophe" and cell death in p53-deficient tumors while sparing p53-proficient cells.  CHK1 inhibitors sensitize tumors to a variety of DNA-damaging agents or antimetabolites in preclin. models and are being evaluated in early phase clin. trials.  In this review, we summarize recent advances and controversies in the development and application of CHK1 inhibitors as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAxtqrXv9ZqbVg90H21EOLACvtfcHk0lgXTz8sGuwKYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhvFWgsro%253D&md5=e53c01cf0016d5be069913a041d67a08</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.molmed.2010.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmed.2010.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DJanetka%26aufirst%3DJ.%2BW.%26aulast%3DPiwnica-Worms%26aufirst%3DH.%26atitle%3DDeath%2520by%2520releasing%2520the%2520breaks%253A%2520Chk1%2520inhibitors%2520as%2520cancer%2520therapeutics%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2011%26volume%3D17%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.molmed.2010.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cole, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huggins, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laquaglia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulderman, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Russell, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosse, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diskin, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attiyeh, E. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennett, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudenslager, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayes, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jagannathan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosse, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maris, J. M.</span><span> </span><span class="NLM_article-title">RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">3336</span><span class="NLM_x">–</span> <span class="NLM_lpage">3341</span><span class="refDoi"> DOI: 10.1073/pnas.1012351108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1073%2Fpnas.1012351108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21289283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXislGgtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=3336-3341&author=K.+A.+Coleauthor=J.+Hugginsauthor=M.+Laquagliaauthor=C.+E.+Huldermanauthor=M.+R.+Russellauthor=K.+Bosseauthor=S.+J.+Diskinauthor=E.+F.+Attiyehauthor=R.+Sennettauthor=G.+Norrisauthor=M.+Laudenslagerauthor=A.+C.+Woodauthor=P.+A.+Mayesauthor=J.+Jagannathanauthor=C.+Winterauthor=Y.+P.+Mosseauthor=J.+M.+Maris&title=RNAi+screen+of+the+protein+kinome+identifies+checkpoint+kinase+1+%28CHK1%29+as+a+therapeutic+target+in+neuroblastoma&doi=10.1073%2Fpnas.1012351108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma</span></div><div class="casAuthors">Cole, Kristina A.; Huggins, Jonathan; Laquaglia, Michael; Hulderman, Chase E.; Russell, Mike R.; Bosse, Kristopher; Diskin, Sharon J.; Attiyeh, Edward F.; Sennett, Rachel; Norris, Geoffrey; Laudenslager, Marci; Wood, Andrew C.; Mayes, Patrick A.; Jagannathan, Ayanti; Winter, Cynthia; Mosse, Yael P.; Maris, John M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3336-3341, S3336/1-S3336/7</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Neuroblastoma is a childhood cancer that is often fatal despite intense multimodality therapy.  In an effort to identify therapeutic targets for this disease, we performed a comprehensive loss-of-function screen of the protein kinome.  Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the cell cycle checkpoint kinase 1 (CHK1/CHEK1) being the most potent.  CHK1 mRNA expression was higher in MYC-Neuroblastoma-related (MYCN)-amplified (P < 0.0001) and high-risk (P = 0.03) tumors.  Western blotting revealed that CHK1 was constitutively phosphorylated at the ataxia telangiectasia response kinase target site Ser345 and the autophosphorylation site Ser296 in neuroblastoma cell lines.  This pattern was also seen in six of eight high-risk primary tumors but not in control nonneuroblastoma cell lines or in seven of eight low-risk primary tumors.  Neuroblastoma cells were sensitive to the two CHK1 inhibitors SB21807 and TCS2312, with median IC50 values of 564 nM and 548 nM, resp.  In contrast, the control lines had high micromolar IC50 values, indicating a strong correlation between CHK1 phosphorylation and CHK1 inhibitor sensitivity (P = 0.0004).  Furthermore, cell cycle anal. revealed that CHK1 inhibition in neuroblastoma cells caused apoptosis during S-phase, consistent with its role in replication fork progression.  CHK1 inhibitor sensitivity correlated with total MYC(N) protein levels, and inducing MYCN in retinal pigmented epithelial cells resulted in CHK1 phosphorylation, which caused growth inhibition when inhibited.  These data show the power of a functional RNAi screen to identify tractable therapeutical targets in neuroblastoma and support CHK1 inhibition strategies in this disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5veQlVyIXEbVg90H21EOLACvtfcHk0lgXTz8sGuwKYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXislGgtL0%253D&md5=650a9bbb555bc05eefa19f2b22acd476</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1012351108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1012351108%26sid%3Dliteratum%253Aachs%26aulast%3DCole%26aufirst%3DK.%2BA.%26aulast%3DHuggins%26aufirst%3DJ.%26aulast%3DLaquaglia%26aufirst%3DM.%26aulast%3DHulderman%26aufirst%3DC.%2BE.%26aulast%3DRussell%26aufirst%3DM.%2BR.%26aulast%3DBosse%26aufirst%3DK.%26aulast%3DDiskin%26aufirst%3DS.%2BJ.%26aulast%3DAttiyeh%26aufirst%3DE.%2BF.%26aulast%3DSennett%26aufirst%3DR.%26aulast%3DNorris%26aufirst%3DG.%26aulast%3DLaudenslager%26aufirst%3DM.%26aulast%3DWood%26aufirst%3DA.%2BC.%26aulast%3DMayes%26aufirst%3DP.%2BA.%26aulast%3DJagannathan%26aufirst%3DJ.%26aulast%3DWinter%26aufirst%3DC.%26aulast%3DMosse%26aufirst%3DY.%2BP.%26aulast%3DMaris%26aufirst%3DJ.%2BM.%26atitle%3DRNAi%2520screen%2520of%2520the%2520protein%2520kinome%2520identifies%2520checkpoint%2520kinase%25201%2520%2528CHK1%2529%2520as%2520a%2520therapeutic%2520target%2520in%2520neuroblastoma%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2011%26volume%3D108%26spage%3D3336%26epage%3D3341%26doi%3D10.1073%2Fpnas.1012351108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Höglund, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muralidharan, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hasvold, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudelius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolova, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keller, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, J. A.</span><span> </span><span class="NLM_article-title">Therapeutic implications for the induced levels of Chk1 in Myc expressing cancer cells</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">7067</span><span class="NLM_x">–</span> <span class="NLM_lpage">7079</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-11-1198</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-11-1198" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21933891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3MbpvFyluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=7067-7079&author=A.+H%C3%B6glundauthor=L.+M.+Nilssonauthor=S.+V.+Muralidharanauthor=L.+A.+Hasvoldauthor=P.+Mertaauthor=M.+Rudeliusauthor=V.+Nikolovaauthor=U.+Kellerauthor=J.+A.+Nilsson&title=Therapeutic+implications+for+the+induced+levels+of+Chk1+in+Myc+expressing+cancer+cells&doi=10.1158%2F1078-0432.CCR-11-1198"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells</span></div><div class="casAuthors">Hoglund Andreas; Nilsson Lisa M; Muralidharan Somsundar Veppil; Hasvold Lisa A; Merta Philip; Rudelius Martina; Nikolova Viktoriya; Keller Ulrich; Nilsson Jonas A</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7067-79</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  The transcription factor c-Myc (or "Myc") is a master regulator of pathways driving cell growth and proliferation.  MYC is deregulated in many human cancers, making its downstream target genes attractive candidates for drug development.  We report the unexpected finding that B-cell lymphomas from mice and patients exhibit a striking correlation between high levels of Myc and checkpoint kinase 1 (Chk1).  EXPERIMENTAL DESIGN:  By in vitro cell biology studies as well as preclinical studies using a genetically engineered mouse model, we evaluated the role of Chk1 in Myc-overexpressing cells.  RESULTS:  We show that Myc indirectly induces Chek1 transcript and protein expression, independently of DNA damage response proteins such as ATM and p53.  Importantly, we show that inhibition of Chk1, by either RNA interference or a novel highly selective small molecule inhibitor, results in caspase-dependent apoptosis that affects Myc-overexpressing cells in both in vitro and in vivo mouse models of B-cell lymphoma.  CONCLUSION:  Our data suggest that Chk1 inhibitors should be further evaluated as potential drugs against Myc-driven malignancies such as certain B-cell lymphoma/leukemia, neuroblastoma, and some breast and lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSKm-xnHGUIDGgRQsDqrjW_fW6udTcc2ebTpnHO2TeOT7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MbpvFyluw%253D%253D&md5=03f3e4e0366e0d05147dd6381bf0016c</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-11-1198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-11-1198%26sid%3Dliteratum%253Aachs%26aulast%3DH%25C3%25B6glund%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DL.%2BM.%26aulast%3DMuralidharan%26aufirst%3DS.%2BV.%26aulast%3DHasvold%26aufirst%3DL.%2BA.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DRudelius%26aufirst%3DM.%26aulast%3DNikolova%26aufirst%3DV.%26aulast%3DKeller%26aufirst%3DU.%26aulast%3DNilsson%26aufirst%3DJ.%2BA.%26atitle%3DTherapeutic%2520implications%2520for%2520the%2520induced%2520levels%2520of%2520Chk1%2520in%2520Myc%2520expressing%2520cancer%2520cells%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D7067%26epage%3D7079%26doi%3D10.1158%2F1078-0432.CCR-11-1198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Brooks, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oakes, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leo, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavey, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pinder, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beamish, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mukhopadhyay, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lambie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabrielli, B.</span><span> </span><span class="NLM_article-title">A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">796</span><span class="refDoi"> DOI: 10.1038/onc.2012.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fonc.2012.72" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=788-796&author=K.+Brooksauthor=V.+Oakesauthor=B.+Edwardsauthor=M.+Ranallauthor=P.+Leoauthor=S.+Paveyauthor=A.+Pinderauthor=H.+Beamishauthor=P.+Mukhopadhyayauthor=D.+Lambieauthor=B.+Gabrielli&title=A+potent+Chk1+inhibitor+is+selectively+cytotoxic+in+melanomas+with+high+levels+of+replicative+stress&doi=10.1038%2Fonc.2012.72"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.72%26sid%3Dliteratum%253Aachs%26aulast%3DBrooks%26aufirst%3DK.%26aulast%3DOakes%26aufirst%3DV.%26aulast%3DEdwards%26aufirst%3DB.%26aulast%3DRanall%26aufirst%3DM.%26aulast%3DLeo%26aufirst%3DP.%26aulast%3DPavey%26aufirst%3DS.%26aulast%3DPinder%26aufirst%3DA.%26aulast%3DBeamish%26aufirst%3DH.%26aulast%3DMukhopadhyay%26aufirst%3DP.%26aulast%3DLambie%26aufirst%3DD.%26aulast%3DGabrielli%26aufirst%3DB.%26atitle%3DA%2520potent%2520Chk1%2520inhibitor%2520is%2520selectively%2520cytotoxic%2520in%2520melanomas%2520with%2520high%2520levels%2520of%2520replicative%2520stress%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D788%26epage%3D796%26doi%3D10.1038%2Fonc.2012.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Albiges, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goubar, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vicier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lefèbvre, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alsafadi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Commo, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saghatchian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dessen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delaloge, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">André, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quidville, V.</span><span> </span><span class="NLM_article-title">Chk1 as a new therapeutic target in triple-negative breast cancer</span> <span class="citation_source-journal">Breast</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">250</span><span class="NLM_x">–</span> <span class="NLM_lpage">258</span><span class="refDoi"> DOI: 10.1016/j.breast.2014.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.breast.2014.02.004" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2014&pages=250-258&author=L.+Albigesauthor=A.+Goubarauthor=V.+Scottauthor=C.+Vicierauthor=C.+Lef%C3%A8bvreauthor=S.+Alsafadiauthor=F.+Commoauthor=M.+Saghatchianauthor=V.+Lazarauthor=P.+Dessenauthor=S.+Delalogeauthor=F.+Andr%C3%A9author=V.+Quidville&title=Chk1+as+a+new+therapeutic+target+in+triple-negative+breast+cancer&doi=10.1016%2Fj.breast.2014.02.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.breast.2014.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.breast.2014.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DAlbiges%26aufirst%3DL.%26aulast%3DGoubar%26aufirst%3DA.%26aulast%3DScott%26aufirst%3DV.%26aulast%3DVicier%26aufirst%3DC.%26aulast%3DLef%25C3%25A8bvre%26aufirst%3DC.%26aulast%3DAlsafadi%26aufirst%3DS.%26aulast%3DCommo%26aufirst%3DF.%26aulast%3DSaghatchian%26aufirst%3DM.%26aulast%3DLazar%26aufirst%3DV.%26aulast%3DDessen%26aufirst%3DP.%26aulast%3DDelaloge%26aufirst%3DS.%26aulast%3DAndr%25C3%25A9%26aufirst%3DF.%26aulast%3DQuidville%26aufirst%3DV.%26atitle%3DChk1%2520as%2520a%2520new%2520therapeutic%2520target%2520in%2520triple-negative%2520breast%2520cancer%26jtitle%3DBreast%26date%3D2014%26volume%3D23%26spage%3D250%26epage%3D258%26doi%3D10.1016%2Fj.breast.2014.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">McNeely, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beckmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bence Lin, A. K.</span><span> </span><span class="NLM_article-title">CHEK again: revisiting the development of CHK1 inhibitors for cancer therapy</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span><span class="refDoi"> DOI: 10.1016/j.pharmthera.2013.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.pharmthera.2013.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=24140082" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2014&pages=1-10&author=S.+McNeelyauthor=R.+Beckmannauthor=A.+K.+Bence+Lin&title=CHEK+again%3A+revisiting+the+development+of+CHK1+inhibitors+for+cancer+therapy&doi=10.1016%2Fj.pharmthera.2013.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy</span></div><div class="casAuthors">McNeely, S.; Beckmann, R.; Bence Lin, A. K.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-10</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  CHEK1 encodes the serine/threonine kinase CHK1, a central component of the DNA damage response.  CHK1 regulates cell cycle checkpoints following genotoxic stress to prevent the entry of cells with damaged DNA into mitosis and coordinates various aspects of DNA repair.  Accordingly, CHK1 has become a target of considerable interest in oncol.  CHK1 inhibitors potentiate the efficacy of DNA-damaging chemotherapeutics by abrogating CHK1-mediated cell cycle arrest and preventing repair of damaged DNA.  In addn., CHK1 inhibitors interfere with the biol. role of CHK1 as a principal regulator of the cell cycle that controls the initiation of DNA replication, stabilizes replication forks, and coordinates mitosis.  Since these functions of CHK1 facilitate progression through an unperturbed cell cycle, CHK1 inhibitors are being developed not only as chemopotentiators, but also as single-agent therapies.  This review is intended to provide information on the current progress of CHK1 inhibitors in pre-clin. and clin. development and will focus on mechanisms of single-agent activity and potential strategies for patient tailoring and combinations with non-genotoxic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAnRvVVC1dCbVg90H21EOLACvtfcHk0li0C8bE-TJ83A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWqtr8%253D&md5=38db1812b9cd93c1f210c4985b53b4b5</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2013.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2013.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DMcNeely%26aufirst%3DS.%26aulast%3DBeckmann%26aufirst%3DR.%26aulast%3DBence%2BLin%26aufirst%3DA.%2BK.%26atitle%3DCHEK%2520again%253A%2520revisiting%2520the%2520development%2520of%2520CHK1%2520inhibitors%2520for%2520cancer%2520therapy%26jtitle%3DPharmacol.%2520Ther.%26date%3D2014%26volume%3D142%26spage%3D1%26epage%3D10%26doi%3D10.1016%2Fj.pharmthera.2013.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallsworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">CCT244747 is a novel, potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5661</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1322</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1078-0432.CCR-12-1322" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=22929806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC38bitVCksg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=5650-5661&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+De+Haven+Brandonauthor=G.+Boxauthor=A.+Hallsworthauthor=E.+L.+Smithauthor=K.+J.+Boxallauthor=M.+Lainchburyauthor=T.+P.+Matthewsauthor=Y.+Jaminauthor=S.+P.+Robinsonauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=L.+Cheslerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=I.+Collinsauthor=M.+D.+Garrett&title=CCT244747+is+a+novel%2C+potent+and+selective+CHK1+inhibitor+with+oral+efficacy+alone+and+in+combination+with+genotoxic+anticancer+drugs&doi=10.1158%2F1078-0432.CCR-12-1322"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs</span></div><div class="casAuthors">Walton Mike I; Eve Paul D; Hayes Angela; Valenti Melanie R; De Haven Brandon Alexis K; Box Gary; Hallsworth Albert; Smith Elizabeth L; Boxall Kathy J; Lainchbury Michael; Matthews Thomas P; Jamin Yann; Robinson Simon P; Aherne G Wynne; Reader John C; Chesler Louis; Raynaud Florence I; Eccles Suzanne A; Collins Ian; Garrett Michelle D</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5650-61</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Many tumors exhibit defective cell-cycle checkpoint control and increased replicative stress.  CHK1 is critically involved in the DNA damage response and maintenance of replication fork stability.  We have therefore discovered a novel potent, highly selective, orally active ATP-competitive CHK1 inhibitor, CCT244747, and present its preclinical pharmacology and therapeutic activity.  EXPERIMENTAL DESIGN:  Cellular CHK1 activity was assessed using an ELISA assay, and cytotoxicity a SRB assay.  Biomarker modulation was measured using immunoblotting, and cell-cycle effects by flow cytometry analysis.  Single-agent oral CCT244747 antitumor activity was evaluated in a MYCN-driven transgenic mouse model of neuroblastoma by MRI and in genotoxic combinations in human tumor xenografts by growth delay.  RESULTS:  CCT244747 inhibited cellular CHK1 activity (IC(50) 29-170 nmol/L), significantly enhanced the cytotoxicity of several anticancer drugs, and abrogated drug-induced S and G(2) arrest in multiple tumor cell lines.  Biomarkers of CHK1 (pS296 CHK1) activity and cell-cycle inactivity (pY15 CDK1) were induced by genotoxics and inhibited by CCT244747 both in vitro and in vivo, producing enhanced DNA damage and apoptosis.  Active tumor concentrations of CCT244747 were obtained following oral administration.  The antitumor activity of both gemcitabine and irinotecan were significantly enhanced by CCT244747 in several human tumor xenografts, giving concomitant biomarker modulation indicative of CHK1 inhibition.  CCT244747 also showed marked antitumor activity as a single agent in a MYCN-driven neuroblastoma.  CONCLUSION:  CCT244747 represents the first structural disclosure of a highly selective, orally active CHK1 inhibitor and warrants further evaluation alone or combined with genotoxic anticancer therapies.  Clin Cancer Res; 18(20); 5650-61.  ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSYuNWGWhNoVzMsgLhIoICsfW6udTcc2ebY1XsCAKkaNrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38bitVCksg%253D%253D&md5=ae2b2c532939e201d741d8caf3aac8e2</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1322&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1322%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DE.%2BL.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCCT244747%2520is%2520a%2520novel%252C%2520potent%2520and%2520selective%2520CHK1%2520inhibitor%2520with%2520oral%2520efficacy%2520alone%2520and%2520in%2520combination%2520with%2520genotoxic%2520anticancer%2520drugs%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D5650%26epage%3D5661%26doi%3D10.1158%2F1078-0432.CCR-12-1322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epler, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flagella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelista, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowanetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramiscal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakubiak, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cain, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halladay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span> </span><span class="NLM_article-title">Combination drug scheduling defines a ″window of opportunity″ for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1968</span><span class="NLM_x">–</span> <span class="NLM_lpage">1980</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-1218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-12-1218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=23873850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1968-1980&author=E.+Blackwoodauthor=J.+Eplerauthor=I.+Yenauthor=M.+Flagellaauthor=T.+O%E2%80%99Brienauthor=M.+Evangelistaauthor=S.+Schmidtauthor=Y.+Xiaoauthor=J.+Choiauthor=K.+Kowanetzauthor=J.+Ramiscalauthor=K.+Wongauthor=D.+Jakubiakauthor=S.+Yeeauthor=G.+Cainauthor=L.+Gazzardauthor=K.+Williamsauthor=J.+Halladayauthor=P.+K.+Jacksonauthor=S.+Malek&title=Combination+drug+scheduling+defines+a+%E2%80%B3window+of+opportunity%E2%80%B3+for+chemopotentiation+of+gemcitabine+by+an+orally+bioavailable%2C+selective+ChK1+inhibitor%2C+GNE-900&doi=10.1158%2F1535-7163.MCT-12-1218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900</span></div><div class="casAuthors">Blackwood, Elizabeth; Epler, Jennifer; Yen, Ivana; Flagella, Michael; O'Brien, Tom; Evangelista, Marie; Schmidt, Stephen; Xiao, Yang; Choi, Jonathan; Kowanetz, Kaska; Ramiscal, Judi; Wong, Kenton; Jakubiak, Diana; Yee, Sharon; Cain, Gary; Gazzard, Lewis; Williams, Karen; Halladay, Jason; Jackson, Peter K.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1968-1980</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (ChK1) is a serine/threonine kinase that functions as a central mediator of the intra-S and G2-M cell-cycle checkpoints.  Following DNA damage or replication stress, ChK1-mediated phosphorylation of downstream effectors delays cell-cycle progression so that the damaged genome can be repaired.  As a therapeutic strategy, inhibition of ChK1 should potentiate the antitumor effect of chemotherapeutic agents by inactivating the postreplication checkpoint, causing premature entry into mitosis with damaged DNA resulting in mitotic catastrophe.  Here, we describe the characterization of GNE-900, an ATP-competitive, selective, and orally bioavailable ChK1 inhibitor.  In combination with chemotherapeutic agents, GNE-900 sustains ATR/ATM signaling, enhances DNA damage, and induces apoptotic cell death.  The kinetics of checkpoint abrogation seems to be more rapid in p53-mutant cells, resulting in premature mitotic entry and/or accelerated cell death.  Importantly, we show that GNE-900 has little single-agent activity in the absence of chemotherapy and does not grossly potentiate the cytotoxicity of gemcitabine in normal bone marrow cells.  In vivo scheduling studies show that optimal administration of the ChK1 inhibitor requires a defined lag between gemcitabine and GNE-900 administration.  On the refined combination treatment schedule, gemcitabine's antitumor activity against chemotolerant xenografts is significantly enhanced and dose-dependent exacerbation of DNA damage correlates with extent of tumor growth inhibition.  In summary, we show that in vivo potentiation of gemcitabine activity is mechanism based, with optimal efficacy obsd. when S-phase arrest and release is followed by checkpoint abrogation with a ChK1 inhibitor.  Mol Cancer Ther; 12(10); 1968-80. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2JdTj7IGGxLVg90H21EOLACvtfcHk0ljkdHabkRIxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOhurrO&md5=9698b1e41f9e0710174c00ea80bf68d2</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-1218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-1218%26sid%3Dliteratum%253Aachs%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DEpler%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DFlagella%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DSchmidt%26aufirst%3DS.%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DKowanetz%26aufirst%3DK.%26aulast%3DRamiscal%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DJakubiak%26aufirst%3DD.%26aulast%3DYee%26aufirst%3DS.%26aulast%3DCain%26aufirst%3DG.%26aulast%3DGazzard%26aufirst%3DL.%26aulast%3DWilliams%26aufirst%3DK.%26aulast%3DHalladay%26aufirst%3DJ.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DCombination%2520drug%2520scheduling%2520defines%2520a%2520%25E2%2580%25B3window%2520of%2520opportunity%25E2%2580%25B3%2520for%2520chemopotentiation%2520of%2520gemcitabine%2520by%2520an%2520orally%2520bioavailable%252C%2520selective%2520ChK1%2520inhibitor%252C%2520GNE-900%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1968%26epage%3D1980%26doi%3D10.1158%2F1535-7163.MCT-12-1218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Infante, J. R.; Hollebecque, A.; Postel-Vinay, S.; Bauer, T.; Blackwood, B.; Evangelista, M.; Mahrus, S.; Peale, F.; Lu, X.; Sahasranaman, S.; Zhu, R.; Chen, Y.; Ding, X.; Murray, E.; Schutzman, J.; Lauchle, J.; Soria, J.; LoRusso, P.</span><span> </span><span class="NLM_article-title">Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors</span>. In Proceedings of the 106th Annual Meeting of the American Association for Cancer Research, Philadelphia, PA, April 18–22, 2015; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Philadelphia</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span>. Abstract no.  <span class="NLM_fpage">CT139</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&pages=CT139&author=J.+R.+Infante&author=A.+Hollebecque&author=S.+Postel-Vinay&author=T.+Bauer&author=B.+Blackwood&author=M.+Evangelista&author=S.+Mahrus&author=F.+Peale&author=X.+Lu&author=S.+Sahasranaman&author=R.+Zhu&author=Y.+Chen&author=X.+Ding&author=E.+Murray&author=J.+Schutzman&author=J.+Lauchle&author=J.+Soria&author=P.+LoRusso&title=Phase+I+study+of+GDC-0425%2C+a+checkpoint+kinase+1+inhibitor%2C+in+combination+with+gemcitabine+in+patients+with+refractory+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DInfante%26aufirst%3DJ.%2BR.%26atitle%3DPhase%2520I%2520study%2520of%2520GDC-0425%252C%2520a%2520checkpoint%2520kinase%25201%2520inhibitor%252C%2520in%2520combination%2520with%2520gemcitabine%2520in%2520patients%2520with%2520refractory%2520solid%2520tumors%26jtitle%3DProceedings%2520of%2520the%2520106th%2520Annual%2520Meeting%2520of%2520the%2520American%2520Association%2520for%2520Cancer%2520Research%252C%2520Philadelphia%252C%2520PA%252C%2520April%252018%25E2%2580%259322%252C%25202015%26pub%3DAACR%26date%3D2015%26spage%3DCT139" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Stumpf, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, Z. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reynolds, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angelaud, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girotti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deese, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gazzard, L.</span><span> </span><span class="NLM_article-title">Development of an expedient process for the multi-kilogram synthesis of Chk1 inhibitor GDC-0425</span> <span class="citation_source-journal">Org. Process Res. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">661</span><span class="NLM_x">–</span> <span class="NLM_lpage">672</span><span class="refDoi"> DOI: 10.1021/acs.oprd.5b00105</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.5b00105" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2MXotlChtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2015&pages=661-672&author=A.+Stumpfauthor=Z.+K.+Chengauthor=B.+Wongauthor=M.+Reynoldsauthor=R.+Angelaudauthor=J.+Girottiauthor=A.+Deeseauthor=C.+Guauthor=L.+Gazzard&title=Development+of+an+expedient+process+for+the+multi-kilogram+synthesis+of+Chk1+inhibitor+GDC-0425&doi=10.1021%2Facs.oprd.5b00105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Development of an Expedient Process for the Multi-Kilogram Synthesis of Chk1 Inhibitor GDC-0425</span></div><div class="casAuthors">Stumpf, Andreas; Cheng, Zhigang Ken; Wong, Brian; Reynolds, Mark; Angelaud, Remy; Girotti, James; Deese, Alan; Gu, Christine; Gazzard, Lewis</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">661-672</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A process leading to the multikilogram GMP synthesis of Chk1 inhibitor GDC-0425 (I) was developed.  Highlights of the synthesis include protection of the pyrrole ring of a 1,7-diazacarbazole as Pr Et ether, an efficient Pd catalyzed cyanation of an aryl chloride, aryl ether formation by SNAr fluoride displacement, and development of a controlled crystn. providing the API with the required polymorphic form.  The process delivered high-quality GDC-0425 with low levels of impurities and residual metals in five steps and 31% overall yield.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWjKZthxSBP7Vg90H21EOLACvtfcHk0ljkdHabkRIxuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXotlChtrY%253D&md5=3aa319ef1b9059e30f4b464a1e36be58</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.5b00105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.5b00105%26sid%3Dliteratum%253Aachs%26aulast%3DStumpf%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DZ.%2BK.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DReynolds%26aufirst%3DM.%26aulast%3DAngelaud%26aufirst%3DR.%26aulast%3DGirotti%26aufirst%3DJ.%26aulast%3DDeese%26aufirst%3DA.%26aulast%3DGu%26aufirst%3DC.%26aulast%3DGazzard%26aufirst%3DL.%26atitle%3DDevelopment%2520of%2520an%2520expedient%2520process%2520for%2520the%2520multi-kilogram%2520synthesis%2520of%2520Chk1%2520inhibitor%2520GDC-0425%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2015%26volume%3D19%26spage%3D661%26epage%3D672%26doi%3D10.1021%2Facs.oprd.5b00105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">10229</span><span class="NLM_x">–</span> <span class="NLM_lpage">10240</span><span class="refDoi"> DOI: 10.1021/jm3012933</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012933" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10229-10240&author=M.+Lainchburyauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=K.+J.+Boxallauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+R.+Valentiauthor=A.+K.+de+Haven+Brandonauthor=G.+Boxauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Discovery+of+3-alkoxyamino-5-%28pyridin-2-ylamino%29pyrazine-2-carbonitriles+as+selective%2C+orally+bioavailable+CHK1+inhibitors&doi=10.1021%2Fjm3012933"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm3012933&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012933%26sid%3Dliteratum%253Aachs%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%2BR.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DDiscovery%2520of%25203-alkoxyamino-5-%2528pyridin-2-ylamino%2529pyrazine-2-carbonitriles%2520as%2520selective%252C%2520orally%2520bioavailable%2520CHK1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10229%26epage%3D10240%26doi%3D10.1021%2Fjm3012933" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klair, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scanlon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proisy, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Addison, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellard, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piton, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cherry, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westwood, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Haven Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8328</span><span class="NLM_x">–</span> <span class="NLM_lpage">8342</span><span class="refDoi"> DOI: 10.1021/jm2007326</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007326" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8328-8342&author=J.+C.+Readerauthor=T.+P.+Matthewsauthor=S.+Klairauthor=K.+J.+Cheungauthor=J.+Scanlonauthor=N.+Proisyauthor=G.+Addisonauthor=J.+Ellardauthor=N.+Pitonauthor=S.+Taylorauthor=M.+Cherryauthor=M.+Fisherauthor=K.+Boxallauthor=S.+Burnsauthor=M.+I.+Waltonauthor=I.+M.+Westwoodauthor=A.+Hayesauthor=P.+Eveauthor=M.+Valentiauthor=A.+de+Haven+Brandonauthor=G.+Boxauthor=R.+L.+van+Montfortauthor=D.+H.+Williamsauthor=G.+W.+Aherneauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=M.+D.+Garrettauthor=I.+Collins&title=Structure-guided+evolution+of+potent+and+selective+CHK1+inhibitors+through+scaffold+morphing&doi=10.1021%2Fjm2007326"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing</span></div><div class="casAuthors">Reader, John C.; Matthews, Thomas P.; Klair, Suki; Cheung, Kwai-Ming J.; Scanlon, Jane; Proisy, Nicolas; Addison, Glynn; Ellard, John; Piton, Nelly; Taylor, Suzanne; Cherry, Michael; Fisher, Martin; Boxall, Kathy; Burns, Samantha; Walton, Michael I.; Westwood, Isaac M.; Hayes, Angela; Eve, Paul; Valenti, Melanie; de Haven Brandon, Alexis; Box, Gary; van Montfort, Rob L. M.; Williams, David H.; Aherne, G. Wynne; Raynaud, Florence I.; Eccles, Suzanne A.; Garrett, Michelle D.; Collins, Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8328-8342</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Pyrazolopyridine lead inhibitors with micromolar affinities for the checkpoint kinase CHK1 and selective for CHK1 against CHK2 were refined by fragment-growing and scaffold morphing strategies to generate the isoquinolinylaminopyrazinecarbonitrile I as a potent and selective inhibitor of CHK1 [IC50 (CHK1) = 13 nM, IC50 (CHK2) = > 100 μM] as a potential antitumor agent.  Scaffold morphing was used to improve the CHK1 potency and selectivity, synthetic accessibility, and novelty of the inhibitors; the inhibitor core was changed from pyrimido[2,3-b]azaindole to pyrazinylpyrimidinamine to imidazo[4,5-c]pyridine and isoquinoline.  The toxicities, lipophilicities, and polar surface areas of selected compds. were detd., while ligand efficiencies were detd. for the compds. prepd. and tested; the microsomal stability and oral bioavailability of I in mice were detd.  I potentiated the efficacies of irinotecan and gemcitabine in SW620 human colon carcinoma xenografts in nude mice but had no effect on its own.  The structures of six kinase inhibitors including I bound to the CHK1 kinase domain were detd. by x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNwXjNh9xLdLVg90H21EOLACvtfcHk0liN0FywqzfHbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFSlurjO&md5=927c82ade2efd6df0db154e9009368f8</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm2007326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007326%26sid%3Dliteratum%253Aachs%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DKlair%26aufirst%3DS.%26aulast%3DCheung%26aufirst%3DK.%2BJ.%26aulast%3DScanlon%26aufirst%3DJ.%26aulast%3DProisy%26aufirst%3DN.%26aulast%3DAddison%26aufirst%3DG.%26aulast%3DEllard%26aufirst%3DJ.%26aulast%3DPiton%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%26aulast%3DCherry%26aufirst%3DM.%26aulast%3DFisher%26aufirst%3DM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DWestwood%26aufirst%3DI.%2BM.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DEve%26aufirst%3DP.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3Dde%2BHaven%2BBrandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-guided%2520evolution%2520of%2520potent%2520and%2520selective%2520CHK1%2520inhibitors%2520through%2520scaffold%2520morphing%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8328%26epage%3D8342%26doi%3D10.1021%2Fjm2007326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valenti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven-Brandon, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">89</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0938</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-09-0938" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20053762" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXktVOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=89-100&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=M.+Valentiauthor=A.+De+Haven-Brandonauthor=G.+Boxauthor=K.+J.+Boxallauthor=G.+W.+Aherneauthor=S.+A.+Ecclesauthor=F.+I.+Raynaudauthor=D.+H.+Williamsauthor=J.+C.+Readerauthor=I.+Collinsauthor=M.+D.+Garrett&title=The+preclinical+pharmacology+and+therapeutic+activity+of+the+novel+CHK1+inhibitor+SAR-020106&doi=10.1158%2F1535-7163.MCT-09-0938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106</span></div><div class="casAuthors">Walton, Michael I.; Eve, Paul D.; Hayes, Angela; Valenti, Melanie; De Haven Brandon, Alexis; Box, Gary; Boxall, Kathy J.; Aherne, G. Wynne; Eccles, Suzanne A.; Raynaud, Florence I.; Williams, David H.; Reader, John C.; Collins, Ian; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">89-100</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Genotoxic antitumor agents continue to be the mainstay of current cancer chemotherapy.  These drugs cause DNA damage and activate numerous cell cycle checkpoints facilitating DNA repair and the maintenance of genomic integrity.  Most human tumors lack functional p53 and consequently have compromised G1-S checkpoint control.  This has led to the hypothesis that S and G2-M checkpoint abrogation may selectively enhance genotoxic cell killing in a p53-deficient background, as normal cells would be rescued at the G1-S checkpoint.  CHK1 is a serine/threonine kinase assocd. with DNA damage-linked S and G2-M checkpoint control.  SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.  This compd. abrogates an etoposide-induced G2 arrest with an IC50 of 55 nmol/L in HT29 cells, and significantly enhances the cell killing of gemcitabine and SN38 by 3.0- to 29-fold in several colon tumor lines in vitro and in a p53-dependent fashion.  Biomarker studies have shown that SAR-020106 inhibits cytotoxic drug-induced autophosphorylation of CHK1 at S296 and blocks the phosphorylation of CDK1 at Y15 in a dose-dependent fashion both in vitro and in vivo.  Cytotoxic drug combinations were assocd. with increased γH2AX and poly ADP ribose polymerase cleavage consistent with the SAR-020106-enhanced DNA damage and tumor cell death.  Irinotecan and gemcitabine antitumor activity was enhanced by SAR-020106 in vivo with minimal toxicity.  SAR-020106 represents a novel class of CHK1 inhibitors that can enhance antitumor activity with selected anticancer drugs in vivo and may therefore have clin. utility.  Mol Cancer Ther; 9(1); 89-100.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodRgZ8gsmTGbVg90H21EOLACvtfcHk0liN0FywqzfHbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXktVOhuw%253D%253D&md5=395ce9fc39b4a465597e82d59e413f14</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0938%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DValenti%26aufirst%3DM.%26aulast%3DDe%2BHaven-Brandon%26aufirst%3DA.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DWilliams%26aufirst%3DD.%2BH.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DThe%2520preclinical%2520pharmacology%2520and%2520therapeutic%2520activity%2520of%2520the%2520novel%2520CHK1%2520inhibitor%2520SAR-020106%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D89%26epage%3D100%26doi%3D10.1158%2F1535-7163.MCT-09-0938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, A. T. M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Haven Brandon, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tall, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swales, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lainchbury, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Osborne, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, N. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reader, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raynaud, F. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">2329</span><span class="NLM_x">–</span> <span class="NLM_lpage">2342</span><span class="refDoi"> DOI: 10.18632/oncotarget.4919</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.18632%2Foncotarget.4919" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2329-2342&author=M.+I.+Waltonauthor=P.+D.+Eveauthor=A.+Hayesauthor=A.+T.+M.+R.+Henleyauthor=A.+K.+De+Haven+Brandonauthor=G.+Boxauthor=K.+J.+Boxallauthor=M.+Tallauthor=K.+Swalesauthor=T.+P.+Matthewsauthor=T.+McHardyauthor=M.+Lainchburyauthor=J.+Osborneauthor=J.+E.+Hunterauthor=N.+D.+Perkinsauthor=G.+W.+Aherneauthor=J.+C.+Readerauthor=F.+I.+Raynaudauthor=S.+A.+Ecclesauthor=I.+Collinsauthor=M.+D.+Garrett&title=The+clinical+development+candidate+CCT245737+is+an+orally+active+CHK1+inhibitor+with+preclinical+activity+in+RAS+mutant+NSCLC+and+E%CE%BC-MYC+driven+B-cell+lymphoma&doi=10.18632%2Foncotarget.4919"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.4919&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.4919%26sid%3Dliteratum%253Aachs%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DA.%2BT.%2BM.%2BR.%26aulast%3DDe%2BHaven%2BBrandon%26aufirst%3DA.%2BK.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DTall%26aufirst%3DM.%26aulast%3DSwales%26aufirst%3DK.%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DMcHardy%26aufirst%3DT.%26aulast%3DLainchbury%26aufirst%3DM.%26aulast%3DOsborne%26aufirst%3DJ.%26aulast%3DHunter%26aufirst%3DJ.%2BE.%26aulast%3DPerkins%26aufirst%3DN.%2BD.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DReader%26aufirst%3DJ.%2BC.%26aulast%3DRaynaud%26aufirst%3DF.%2BI.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DThe%2520clinical%2520development%2520candidate%2520CCT245737%2520is%2520an%2520orally%2520active%2520CHK1%2520inhibitor%2520with%2520preclinical%2520activity%2520in%2520RAS%2520mutant%2520NSCLC%2520and%2520E%25CE%25BC-MYC%2520driven%2520B-cell%2520lymphoma%26jtitle%3DOncotarget%26date%3D2016%26volume%3D7%26spage%3D2329%26epage%3D2342%26doi%3D10.18632%2Foncotarget.4919" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Guzi, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paruch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dwyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labroli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanahan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taricani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiswell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seghezzi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penaflor, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bhagwat, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsieh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parry, D.</span><span> </span><span class="NLM_article-title">Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">591</span><span class="NLM_x">–</span> <span class="NLM_lpage">602</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-10-0928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-10-0928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21321066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkslSrt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=591-602&author=T.+J.+Guziauthor=K.+Paruchauthor=M.+P.+Dwyerauthor=M.+Labroliauthor=F.+Shanahanauthor=N.+Davisauthor=L.+Taricaniauthor=D.+Wiswellauthor=W.+Seghezziauthor=E.+Penaflorauthor=B.+Bhagwatauthor=W.+Wangauthor=D.+Guauthor=Y.+Hsiehauthor=S.+Leeauthor=M.+Liuauthor=D.+Parry&title=Targeting+the+replication+checkpoint+using+SCH+900776%2C+a+potent+and+functionally+selective+CHK1+inhibitor+identified+via+high+content+screening&doi=10.1158%2F1535-7163.MCT-10-0928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening</span></div><div class="casAuthors">Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Shanahan, Frances; Davis, Nicole; Taricani, Lorena; Wiswell, Derek; Seghezzi, Wolfgang; Penaflor, Ervin; Bhagwat, Bhagyashree; Wang, Wei; Gu, Danling; Hsieh, Yunsheng; Lee, Suining; Liu, Ming; Parry, David</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">591-602</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Checkpoint kinase 1 (CHK1) is an essential serine/threonine kinase that responds to DNA damage and stalled DNA replication.  CHK1 is essential for maintenance of replication fork viability during exposure to DNA antimetabolites.  In human tumor cell lines, ablation of CHK1 function during antimetabolite exposure led to accumulation of double-strand DNA breaks and cell death.  Here, we extend these observations and confirm ablation of CHK2 does not contribute to these phenotypes and may diminish them.  Furthermore, concomitant suppression of cyclin-dependent kinase (CDK) activity is sufficient to completely antagonize the desired CHK1 ablation phenotypes.  These mechanism-based observations prompted the development of a high-content, cell-based screen for γ-H2AX induction, a surrogate marker for double-strand DNA breaks.  This mechanism-based functional approach was used to optimize small mol. inhibitors of CHK1.  Specifically, the assay was used to mechanistically define the optimal in-cell profile with compds. exhibiting varying degrees of CHK1, CHK2, and CDK selectivity.  Using this approach, SCH 900776 was identified as a highly potent and functionally optimal CHK1 inhibitor with minimal intrinsic antagonistic properties.  SCH 900776 exposure phenocopies short interfering RNA-mediated CHK1 ablation and interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce dsDNA breaks and cell death in tumor cell backgrounds.  Mol Cancer Ther; 10(4); 591-602.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_DnP2RPokHLVg90H21EOLACvtfcHk0lhP68d1-fYi1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkslSrt7o%253D&md5=884137ebd69d0959b583a6338a89b87a</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-10-0928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-10-0928%26sid%3Dliteratum%253Aachs%26aulast%3DGuzi%26aufirst%3DT.%2BJ.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DDwyer%26aufirst%3DM.%2BP.%26aulast%3DLabroli%26aufirst%3DM.%26aulast%3DShanahan%26aufirst%3DF.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DTaricani%26aufirst%3DL.%26aulast%3DWiswell%26aufirst%3DD.%26aulast%3DSeghezzi%26aufirst%3DW.%26aulast%3DPenaflor%26aufirst%3DE.%26aulast%3DBhagwat%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DGu%26aufirst%3DD.%26aulast%3DHsieh%26aufirst%3DY.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DParry%26aufirst%3DD.%26atitle%3DTargeting%2520the%2520replication%2520checkpoint%2520using%2520SCH%2520900776%252C%2520a%2520potent%2520and%2520functionally%2520selective%2520CHK1%2520inhibitor%2520identified%2520via%2520high%2520content%2520screening%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D591%26epage%3D602%26doi%3D10.1158%2F1535-7163.MCT-10-0928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Anderson, V. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walton, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eve, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Antoni, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caldwell, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearl, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliver, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span> </span><span class="NLM_article-title">CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">463</span><span class="NLM_x">–</span> <span class="NLM_lpage">472</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-10-1252</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F0008-5472.CAN-10-1252" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21239475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3MXlsFKmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2011&pages=463-472&author=V.+E.+Andersonauthor=M.+I.+Waltonauthor=P.+D.+Eveauthor=K.+J.+Boxallauthor=L.+Antoniauthor=J.+J.+Caldwellauthor=W.+Aherneauthor=L.+H.+Pearlauthor=A.+W.+Oliverauthor=I.+Collinsauthor=M.+D.+Garrett&title=CCT241533+is+a+potent+and+selective+inhibitor+of+CHK2+that+potentiates+the+cytotoxicity+of+PARP+inhibitors&doi=10.1158%2F0008-5472.CAN-10-1252"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors</span></div><div class="casAuthors">Anderson, Victoria E.; Walton, Michael I.; Eve, Paul D.; Boxall, Katherine J.; Antoni, Laurent; Caldwell, John J.; Aherne, Wynne; Pearl, Laurence H.; Oliver, Antony W.; Collins, Ian; Garrett, Michelle D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">463-472</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">CHK2 is a checkpoint kinase involved in the ATM-mediated response to double-strand DNA breaks.  Its potential as a drug target is still unclear, but inhibitors of CHK2 may increase the efficacy of genotoxic cancer therapies in a p53 mutant background by eliminating one of the checkpoints or DNA repair pathways contributing to cellular resistance.  We report here the identification and characterization of a novel CHK2 kinase inhibitor, CCT241533.  X-ray crystallog. confirmed that CCT241533 bound to CHK2 in the ATP pocket.  This compd. inhibits CHK2 with an IC50 of 3 nmol/L and shows minimal cross-reactivity against a panel of kinases at 1 μmol/L.  CCT241533 blocked CHK2 activity in human tumor cell lines in response to DNA damage, as shown by inhibition of CHK2 autophosphorylation at S516, band shift mobility changes, and HDMX degrdn.  CCT241533 did not potentiate the cytotoxicity of a selection of genotoxic agents in several cell lines.  However, this compd. significantly potentiates the cytotoxicity of two structurally distinct PARP inhibitors.  Clear induction of the pS516 CHK2 signal was seen with a PARP inhibitor alone, and this activation was abolished by CCT241533, implying that the potentiation of PARP inhibitor cell killing by CCT241533 was due to inhibition of CHK2.  Consequently, our findings imply that CHK2 inhibitors may exert therapeutic activity in combination with PARP inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHyOqF2omCBbVg90H21EOLACvtfcHk0lhjvYICaeUM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXlsFKmuw%253D%253D&md5=42af9f0f5543674eab441e5f29f45428</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-10-1252&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-10-1252%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DV.%2BE.%26aulast%3DWalton%26aufirst%3DM.%2BI.%26aulast%3DEve%26aufirst%3DP.%2BD.%26aulast%3DBoxall%26aufirst%3DK.%2BJ.%26aulast%3DAntoni%26aufirst%3DL.%26aulast%3DCaldwell%26aufirst%3DJ.%2BJ.%26aulast%3DAherne%26aufirst%3DW.%26aulast%3DPearl%26aufirst%3DL.%2BH.%26aulast%3DOliver%26aufirst%3DA.%2BW.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26atitle%3DCCT241533%2520is%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520CHK2%2520that%2520potentiates%2520the%2520cytotoxicity%2520of%2520PARP%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2011%26volume%3D71%26spage%3D463%26epage%3D472%26doi%3D10.1158%2F0008-5472.CAN-10-1252" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Carlessi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buscemi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larson, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delia, D.</span><span> </span><span class="NLM_article-title">Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">935</span><span class="NLM_x">–</span> <span class="NLM_lpage">944</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-06-0567</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-06-0567" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=17363488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=935-944&author=L.+Carlessiauthor=G.+Buscemiauthor=G.+Larsonauthor=Z.+Hongauthor=J.+Z.+Wuauthor=D.+Delia&title=Biochemical+and+cellular+characterization+of+VRX0466617%2C+a+novel+and+selective+inhibitor+for+the+checkpoint+kinase+Chk2&doi=10.1158%2F1535-7163.MCT-06-0567"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2</span></div><div class="casAuthors">Carlessi, Luigi; Buscemi, Giacomo; Larson, Gary; Hong, Zhi; Wu, Jim Zhen; Delia, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">935-944</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">VRX0466617 is a novel selective small-mol. inhibitor for Chk2 discovered through a protein kinase screening program.  In this study, we provide a detailed biochem. and cellular characterization of VRX0466617.  We show that VRX0466617 blocks the enzymic activity of recombinant Chk2, as well as the ionizing radiation (IR)-induced activation of Chk2 from cells pretreated with the compd., at doses between 5 and 10 μmol/L.  These doses of VRX0466617 inhibited, to some extent, the phosphorylation of Chk2 Ser19 and Ser33-35, but not of Chk2 Thr68, which is phosphorylated by the upstream ataxia-telangiectasia mutated (ATM) kinase.  Interestingly, VRX0466617 induced the phosphorylation of Chk2 Thr68 even in the absence of DNA damage, arising from the block of its enzymic activity.  VRX0466617 prevented the IR-induced Chk2-dependent degrdn. of Hdmx, concordant with the in vivo inhibition of Chk2.  Anal. of ATM/ATM and Rad3-related substrates Smc1, p53, and Chk1 excluded a cross-inhibition of these kinases.  VRX0466617 did not modify the cell cycle phase distribution, although it caused an increase in multinucleated cells.  Whereas VRX0466617 attenuated IR-induced apoptosis, in short-term assays it did not affect the cytotoxicity by the anticancer drugs doxorubicin, Taxol, and cisplatin.  These results underscore the specificity of VRX0466617 for Chk2, both in vitro and in vivo, and support the use of this compd. as a biol. probe to study the Chk2-dependent pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrYT5RvbJvcIbVg90H21EOLACvtfcHk0lhjvYICaeUM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2nur8%253D&md5=3997c4dbaf75f74fef04a171b8712f25</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-06-0567&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-06-0567%26sid%3Dliteratum%253Aachs%26aulast%3DCarlessi%26aufirst%3DL.%26aulast%3DBuscemi%26aufirst%3DG.%26aulast%3DLarson%26aufirst%3DG.%26aulast%3DHong%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DJ.%2BZ.%26aulast%3DDelia%26aufirst%3DD.%26atitle%3DBiochemical%2520and%2520cellular%2520characterization%2520of%2520VRX0466617%252C%2520a%2520novel%2520and%2520selective%2520inhibitor%2520for%2520the%2520checkpoint%2520kinase%2520Chk2%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D935%26epage%3D944%26doi%3D10.1158%2F1535-7163.MCT-06-0567" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Xiao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ramiscal, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kowanetz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Nagro, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evangelista, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackwood, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, T.</span><span> </span><span class="NLM_article-title">Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2285</span><span class="NLM_x">–</span> <span class="NLM_lpage">2295</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1158%2F1535-7163.MCT-13-0404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=24038068" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarsr3P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=2285-2295&author=Y.+Xiaoauthor=J.+Ramiscalauthor=K.+Kowanetzauthor=C.+Del+Nagroauthor=S.+Malekauthor=M.+Evangelistaauthor=E.+Blackwoodauthor=P.+K.+Jacksonauthor=T.+O%E2%80%99Brien&title=Identification+of+preferred+chemotherapeutics+for+combining+with+a+CHK1+inhibitor&doi=10.1158%2F1535-7163.MCT-13-0404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor</span></div><div class="casAuthors">Xiao, Yang; Ramiscal, Judi; Kowanetz, Kaska; Del Nagro, Christopher; Malek, Shiva; Evangelista, Marie; Blackwood, Elizabeth; Jackson, Peter K.; O'Brien, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2285-2295</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Here we report that GNE-783, a novel checkpoint kinase-1 (CHK1) inhibitor, enhances the activity of gemcitabine by disabling the S- and G2 cell-cycle checkpoints following DNA damage.  Using a focused library of 51 DNA-damaging agents, we undertook a systematic screen using three different cell lines to det. which chemotherapeutics have their activity enhanced when combined with GNE-783.  We found that GNE-783 was most effective at enhancing activity of antimetabolite-based DNA-damaging agents; however, there was a surprisingly wide range of activity within each class of agents.  We, next, selected six different therapeutic agents and screened these in combination with GNE-783 across a panel of cell lines.  This revealed a preference for enhanced chemopotentiation of select agents within tumor types, as, for instance, GNE-783 preferentially enhanced the activity of temozolomide only in melanoma cell lines.  Addnl., although p53 mutant status was important for the overall response to combinations with some agents; our data indicate that this alone was insufficient to predict synergy.  We finally compared the ability of a structurally related CHK1 inhibitor, GNE-900, to enhance the in vivo activity of gemcitabine, CPT-11, and temozolomide in xenograft models.  GNE-900 significantly enhanced activity of only gemcitabine in vivo, suggesting that strong chemopotentiation in vitro can translate into chemopotentiation in vivo.  In conclusion, our results show that selection of an appropriate agent to combine with a CHK1 inhibitor needs to be carefully evaluated in the context of the genetic background and tumor type in which it will be used.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM_vkqyr9s_bVg90H21EOLACvtfcHk0lhjvYICaeUM9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarsr3P&md5=a05096579a878f8c2ff052933292058b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0404%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DY.%26aulast%3DRamiscal%26aufirst%3DJ.%26aulast%3DKowanetz%26aufirst%3DK.%26aulast%3DDel%2BNagro%26aufirst%3DC.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DEvangelista%26aufirst%3DM.%26aulast%3DBlackwood%26aufirst%3DE.%26aulast%3DJackson%26aufirst%3DP.%2BK.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DT.%26atitle%3DIdentification%2520of%2520preferred%2520chemotherapeutics%2520for%2520combining%2520with%2520a%2520CHK1%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D2285%26epage%3D2295%26doi%3D10.1158%2F1535-7163.MCT-13-0404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Jamieson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moir, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rankovic, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wishart, G.</span><span> </span><span class="NLM_article-title">Medicinal chemistry of hERG optimizations: highlights and hang-ups</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">5029</span><span class="NLM_x">–</span> <span class="NLM_lpage">5046</span><span class="refDoi"> DOI: 10.1021/jm060379l</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060379l" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=5029-5046&author=C.+Jamiesonauthor=E.+M.+Moirauthor=Z.+Rankovicauthor=G.+Wishart&title=Medicinal+chemistry+of+hERG+optimizations%3A+highlights+and+hang-ups&doi=10.1021%2Fjm060379l"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Medicinal chemistry of hERG optimizations: Highlights and hang-ups</span></div><div class="casAuthors">Jamieson, Craig; Moir, Elizabeth M.; Rankovic, Zoran; Wishart, Grant</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5029-5046</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  A brief summary of the in silico, in vitro, and in vivo approaches employed to measure blockade of hERG and QT prolongation is detailed.  The discussion aims to summarize the approaches engaged to circumvent activity at hERG, identified through an extensive literature survey.  The optimizations are recorded as pairs of compds., which have been categorized in terms of the tactics employed to diminish hERG activity. Examn. of the properties of the compds. within each category has enabled formulation os some empirical guidelines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv6eM5w53KebVg90H21EOLACvtfcHk0lgQh8GoWPcKZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xns1WqsL8%253D&md5=117c84a010f877c835b7dbc945996b92</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm060379l&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060379l%26sid%3Dliteratum%253Aachs%26aulast%3DJamieson%26aufirst%3DC.%26aulast%3DMoir%26aufirst%3DE.%2BM.%26aulast%3DRankovic%26aufirst%3DZ.%26aulast%3DWishart%26aufirst%3DG.%26atitle%3DMedicinal%2520chemistry%2520of%2520hERG%2520optimizations%253A%2520highlights%2520and%2520hang-ups%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D5029%26epage%3D5046%26doi%3D10.1021%2Fjm060379l" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Matthews, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">621</span><span class="NLM_x">–</span> <span class="NLM_lpage">640</span><span class="refDoi"> DOI: 10.1517/17460441.2013.788496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1517%2F17460441.2013.788496" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=621-640&author=T.+P.+Matthewsauthor=A.+M.+Jonesauthor=I.+Collins&title=Structure-based+design%2C+discovery+and+development+of+checkpoint+kinase+inhibitors+as+potential+anticancer+therapies&doi=10.1517%2F17460441.2013.788496"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1517%2F17460441.2013.788496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.2013.788496%26sid%3Dliteratum%253Aachs%26aulast%3DMatthews%26aufirst%3DT.%2BP.%26aulast%3DJones%26aufirst%3DA.%2BM.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DStructure-based%2520design%252C%2520discovery%2520and%2520development%2520of%2520checkpoint%2520kinase%2520inhibitors%2520as%2520potential%2520anticancer%2520therapies%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2013%26volume%3D8%26spage%3D621%26epage%3D640%26doi%3D10.1517%2F17460441.2013.788496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Tao, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bui, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kovar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Judge, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenberg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sowin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, N. H.</span><span> </span><span class="NLM_article-title">Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">1514</span><span class="NLM_x">–</span> <span class="NLM_lpage">1527</span><span class="refDoi"> DOI: 10.1021/jm061247v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061247v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislags7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=1514-1527&author=Z.+F.+Taoauthor=L.+Wangauthor=K.+D.+Stewartauthor=Z.+Chenauthor=W.+Guauthor=M.+H.+Buiauthor=P.+Mertaauthor=H.+Zhangauthor=P.+Kovarauthor=E.+Johnsonauthor=C.+Parkauthor=R.+Judgeauthor=S.+Rosenbergauthor=T.+Sowinauthor=N.+H.+Lin&title=Structure-based+design%2C+synthesis%2C+and+biological+evaluation+of+potent+and+selective+macrocyclic+checkpoint+kinase+1+inhibitors&doi=10.1021%2Fjm061247v"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors</span></div><div class="casAuthors">Tao, Zhi-Fu; Wang, Le; Stewart, Kent D.; Chen, Zehan; Gu, Wendy; Bui, Mai-Ha; Merta, Philip; Zhang, Haiying; Kovar, Peter; Johnson, Eric; Park, Chang; Judge, Russell; Rosenberg, Saul; Sowin, Thomas; Lin, Nan-Horng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1514-1527</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Based on the crystallog. anal. of a urea-checkpoint kinase 1 (Chk1) complex and mol. modeling, a class of macrocyclic Chk1 inhibitors were designed and their biol. activities were evaluated.  An efficient synthetic methodol. for macrocyclic ureas was developed with Grubbs metathesis macrocyclization as the key step.  The structure-activity relationship studies demonstrated that the macrocyclization retains full Chk1 inhibition activity and that the 4-position of the Ph ring can tolerate a wide variety of substituents.  These Chk1 inhibitors exhibited excellent selectivity over a panel of more than 70 kinases.  Some compds., e.g., I, were identified as ideal Chk1 inhibitors, which showed little or no single-agent activity but significantly potentiate the cytotoxicities of the DNA-damaging antitumor agents doxorubicin and camptothecin.  These Chk1 inhibitors abrogate the doxorubicin-induced G2 and camptothecin-induced S checkpoint arrests, confirming that their potent biol. activities are mechanism-based through Chk1 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1cDFwRBm0rbVg90H21EOLACvtfcHk0lgQh8GoWPcKZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislags7w%253D&md5=43770dab8ec51e661400e9f9c8d4d11a</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061247v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061247v%26sid%3Dliteratum%253Aachs%26aulast%3DTao%26aufirst%3DZ.%2BF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStewart%26aufirst%3DK.%2BD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DGu%26aufirst%3DW.%26aulast%3DBui%26aufirst%3DM.%2BH.%26aulast%3DMerta%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKovar%26aufirst%3DP.%26aulast%3DJohnson%26aufirst%3DE.%26aulast%3DPark%26aufirst%3DC.%26aulast%3DJudge%26aufirst%3DR.%26aulast%3DRosenberg%26aufirst%3DS.%26aulast%3DSowin%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DN.%2BH.%26atitle%3DStructure-based%2520design%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520potent%2520and%2520selective%2520macrocyclic%2520checkpoint%2520kinase%25201%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D1514%26epage%3D1527%26doi%3D10.1021%2Fjm061247v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Jamei, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marciniak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnett, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rostami-Hodjegan, A.</span><span> </span><span class="NLM_article-title">The Simcyp population-based ADME simulator</span> <span class="citation_source-journal">Expert Opin. Drug Metab. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">211</span><span class="NLM_x">–</span> <span class="NLM_lpage">223</span><span class="refDoi"> DOI: 10.1517/17425250802691074</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1517%2F17425250802691074" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19199378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1elu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2009&pages=211-223&author=M.+Jameiauthor=S.+Marciniakauthor=K.+Fengauthor=A.+Barnettauthor=G.+Tuckerauthor=A.+Rostami-Hodjegan&title=The+Simcyp+population-based+ADME+simulator&doi=10.1517%2F17425250802691074"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">The Simcyp Population-based ADME Simulator</span></div><div class="casAuthors">Jamei, Masoud; Marciniak, Steve; Feng, Kairui; Barnett, Adrian; Tucker, Geoffrey; Rostami-Hodjegan, Amin</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Metabolism & Toxicology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-223</span>CODEN:
                <span class="NLM_cas:coden">EODMAP</span>;
        ISSN:<span class="NLM_cas:issn">1742-5255</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  The Simcyp population-based absorption, distribution, metab. and excretion simulator is a platform and database for bottom-up' mechanistic modeling and simulation of the processes of oral absorption, tissue distribution, metab. and excretion of drugs and drug candidates in healthy and disease populations.  It combines exptl. data generated routinely during preclin. drug discovery and development from in vitro enzyme and cellular systems and relevant physicochem. attributes of compd. and dosage form with demog., physiol. and genetic information on different patient populations.  The mechanistic approach implemented in the Simcyp Simulator allows simulation of complex absorption, distribution, metab. and excretion outcomes, particularly those involving multiple drug interactions, parent drug and metabolite profiles and time- and dose-dependent phenomena such as auto-induction and auto-inhibition.  This review describes the framework and organization of the simulator and how it combines the different categories of information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrbau4KimjnBLVg90H21EOLACvtfcHk0lgQh8GoWPcKZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1elu7c%253D&md5=11548b35c66fe6f07a917f0718421427</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1517%2F17425250802691074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17425250802691074%26sid%3Dliteratum%253Aachs%26aulast%3DJamei%26aufirst%3DM.%26aulast%3DMarciniak%26aufirst%3DS.%26aulast%3DFeng%26aufirst%3DK.%26aulast%3DBarnett%26aufirst%3DA.%26aulast%3DTucker%26aufirst%3DG.%26aulast%3DRostami-Hodjegan%26aufirst%3DA.%26atitle%3DThe%2520Simcyp%2520population-based%2520ADME%2520simulator%26jtitle%3DExpert%2520Opin.%2520Drug%2520Metab.%2520Toxicol.%26date%3D2009%26volume%3D5%26spage%3D211%26epage%3D223%26doi%3D10.1517%2F17425250802691074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><div class="note"><p class="first last">Determined at Cyprotex</p></div>: <a href="http://www.cyprotex.com" class="extLink">http://www.cyprotex.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Determined+at+Cyprotex%3A+http%3A%2F%2Fwww.cyprotex.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahire, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wagh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullick, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selvakumar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortes, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putlur, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mandlekar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. M.</span><span> </span><span class="NLM_article-title">Electrophilicity of pyridazine-3-carbonitrile, pyrimidine-2-carbonitrile, and pyridine-carbonitrile derivatives: a chemical model to describe the formation of thiazoline derivatives in human liver microsomes</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">2052</span><span class="NLM_x">–</span> <span class="NLM_lpage">2061</span><span class="refDoi"> DOI: 10.1021/tx500256j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx500256j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsLrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2014&pages=2052-2061&author=S.+Sinhaauthor=D.+Ahireauthor=S.+Waghauthor=D.+Mullickauthor=R.+Sistlaauthor=K.+Selvakumarauthor=J.+C.+Cortesauthor=S.+P.+Putlurauthor=S.+Mandlekarauthor=B.+M.+Johnson&title=Electrophilicity+of+pyridazine-3-carbonitrile%2C+pyrimidine-2-carbonitrile%2C+and+pyridine-carbonitrile+derivatives%3A+a+chemical+model+to+describe+the+formation+of+thiazoline+derivatives+in+human+liver+microsomes&doi=10.1021%2Ftx500256j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Electrophilicity of Pyridazine-3-carbonitrile, Pyrimidine-2-carbonitrile, and Pyridine-carbonitrile Derivatives: A Chemical Model To Describe the Formation of Thiazoline Derivatives in Human Liver Microsomes</span></div><div class="casAuthors">Sinha, Sarmistha; Ahire, Deepak; Wagh, Santosh; Mullick, Dibakar; Sistla, Ramesh; Selvakumar, Kumaravel; Cortes, Janet Caceres; Putlur, Siva Prasad; Mandlekar, Sandhya; Johnson, Benjamin M.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2052-2061</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Certain arom. nitriles are well-known inhibitors of cysteine proteases.  The mode of action of these compds. involves the formation of a reversible or irreversible covalent bond between the nitrile and a thiol group in the active site of the enzyme.  However, the reactivity of these arom. nitrile-substituted heterocycles may lead inadvertently to nonspecific interactions with DNA, protein, glutathione, and other endogenous components, resulting in toxicity and complicating the use of these compds. as therapeutic agents.  In the present study, the intrinsic reactivity and assocd. structure-property relationships of cathepsin K inhibitors featuring substituted pyridazines [6-phenylpyridazine-3-carbonitrile, 6-(4-fluorophenyl)pyridazine-3-carbonitrile, 6-(4-methoxyphenyl)pyridazine-3-carbonitrile, 6-p-tolylpyridazine-3-carbonitrile], pyrimidines [5-p-tolylpyrimidine-2-carbonitrile, 5-(4-fluorophenyl)pyrimidine-2-carbonitrile], and pyridines [5-p-tolylpicolinonitrile and 5-(4-fluorophenyl)picolinonitrile] were evaluated using a combination of computational and anal. approaches to establish correlations between electrophilicity and levels of metabolites that were formed in glutathione- and N-acetylcysteine-supplemented human liver microsomes.  Metabolites that were characterized in this study featured substituted thiazolines that were formed following rearrangements of transient glutathione and N-acetylcysteine conjugates.  Peptidases including γ-glutamyltranspeptidase were shown to catalyze the formation of these products, which were formed to lesser extents in the presence of the selective γ-glutamyltranspeptidase inhibitor acivicin and the nonspecific peptidase inhibitors phenylmethylsulfonyl fluoride and aprotinin.  Of the chem. series mentioned above, the pyrimidine series was the most susceptible to metab. to thiazoline-contg. products, followed, in order, by the pyridazine and pyridine series.  This trend was in keeping with the diminishing electrophilicity across these series, as demonstrated by in silico modeling.  Hence, mechanistic insights gained from this study could be used to assist a medicinal chem. campaign to design cysteine protease inhibitors that were less prone to the formation of covalent adducts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_vAWzUVGE17Vg90H21EOLACvtfcHk0lha6TfJ1pYZ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVKrsLrE&md5=5953c7b27b84330b917c9bf39a3578a2</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Ftx500256j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx500256j%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DAhire%26aufirst%3DD.%26aulast%3DWagh%26aufirst%3DS.%26aulast%3DMullick%26aufirst%3DD.%26aulast%3DSistla%26aufirst%3DR.%26aulast%3DSelvakumar%26aufirst%3DK.%26aulast%3DCortes%26aufirst%3DJ.%2BC.%26aulast%3DPutlur%26aufirst%3DS.%2BP.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DB.%2BM.%26atitle%3DElectrophilicity%2520of%2520pyridazine-3-carbonitrile%252C%2520pyrimidine-2-carbonitrile%252C%2520and%2520pyridine-carbonitrile%2520derivatives%253A%2520a%2520chemical%2520model%2520to%2520describe%2520the%2520formation%2520of%2520thiazoline%2520derivatives%2520in%2520human%2520liver%2520microsomes%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2014%26volume%3D27%26spage%3D2052%26epage%3D2061%26doi%3D10.1021%2Ftx500256j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><div class="note"><p class="first last">Determined at The MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee, UK</p></div>: <a href="http://www.ppu.mrc.ac.uk" class="extLink">http://www.ppu.mrc.ac.uk</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Determined+at+The+MRC+Protein+Phosphorylation+and+Ubiquitylation+Unit%2C+University+of+Dundee%2C+UK%3A+http%3A%2F%2Fwww.ppu.mrc.ac.uk."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Kerkela, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woulfe, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Durand, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vagnozzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kramer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beahm, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Force, T.</span><span> </span><span class="NLM_article-title">Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase</span> <span class="citation_source-journal">Clin. Transl. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1111/j.1752-8062.2008.00090.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1111%2Fj.1752-8062.2008.00090.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20376335" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXntlemtrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=15-25&author=R.+Kerkelaauthor=K.+C.+Woulfeauthor=J.+B.+Durandauthor=R.+Vagnozziauthor=D.+Kramerauthor=T.+F.+Chuauthor=C.+Beahmauthor=M.+H.+Chenauthor=T.+Force&title=Sunitinib-induced+cardiotoxicity+is+mediated+by+off-target+inhibition+of+AMP-activated+protein+kinase&doi=10.1111%2Fj.1752-8062.2008.00090.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protease kinase</span></div><div class="casAuthors">Kerkela, Risto; Woulfe, Kathleen C.; Durand, Jean-Bernard; Vagnozzi, Ronald; Kramer, David; Chu, Tammy F.; Beahm, Cara; Chen, Ming Hui; Force, Thomas</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Translational Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">15-25</span>CODEN:
                <span class="NLM_cas:coden">CTSLCA</span>;
        ISSN:<span class="NLM_cas:issn">1752-8062</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has demonstrated activity against a variety of solid tumors.  Sunitinib is "multitargeted",inhibiting growth factor receptors that regulate both tumor angiogenesis and tumor cell survival.  However, cardiac dysfunction has been assocd. with its use. Identification of the target of sunitinib-assocd. cardiac dysfunction could guide future drug design to reduce toxicity while preserving anticancer activity.  Herein we identify severe mitochondrial structural abnormalities in the heart of a patient with sunitinib-induced heart failure.  In cultured cardiomyocytes, sunitinib induces loss of mitochondrial membrane potential and energy rundown.  Despite the latter, 5' adenosine monophosphate-activated protein kinase (AMPK) activity, which should be increased in the setting of energy compromise, is reduced in hearts of sunitinib-treated mice and cardiomyocytes in culture, and this is due to direct inhibition of AMPK by sunitinib.  Critically, we find that adenovirus-mediated gene transfer of an activated mutant of AMPK reduces sunitinib-induced cell death.  Our findings suggest AMPK inhibition plays a central role in sunitinib cardiomyocyte toxicity, highlighting the potential of off-target effects of TKIs contributing to cardiotoxicity.  While multitargeting can enhance tumor cell killing, this must be balanced against the potential increased risk of cardiac dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMviU6GEMVU7Vg90H21EOLACvtfcHk0lha6TfJ1pYZ1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXntlemtrY%253D&md5=9b7a885241a90b8a28073d89b924acb1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1111%2Fj.1752-8062.2008.00090.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1752-8062.2008.00090.x%26sid%3Dliteratum%253Aachs%26aulast%3DKerkela%26aufirst%3DR.%26aulast%3DWoulfe%26aufirst%3DK.%2BC.%26aulast%3DDurand%26aufirst%3DJ.%2BB.%26aulast%3DVagnozzi%26aufirst%3DR.%26aulast%3DKramer%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DT.%2BF.%26aulast%3DBeahm%26aufirst%3DC.%26aulast%3DChen%26aufirst%3DM.%2BH.%26aulast%3DForce%26aufirst%3DT.%26atitle%3DSunitinib-induced%2520cardiotoxicity%2520is%2520mediated%2520by%2520off-target%2520inhibition%2520of%2520AMP-activated%2520protein%2520kinase%26jtitle%3DClin.%2520Transl.%2520Sci.%26date%3D2009%26volume%3D2%26spage%3D15%26epage%3D25%26doi%3D10.1111%2Fj.1752-8062.2008.00090.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Smyth, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span> </span><span class="NLM_article-title">Measuring and interpreting the selectivity of protein kinase inhibitors</span> <span class="citation_source-journal">J. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">131</span><span class="NLM_x">–</span> <span class="NLM_lpage">151</span><span class="refDoi"> DOI: 10.1007/s12154-009-0023-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1007%2Fs12154-009-0023-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19568781" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=131-151&author=L.+A.+Smythauthor=I.+Collins&title=Measuring+and+interpreting+the+selectivity+of+protein+kinase+inhibitors&doi=10.1007%2Fs12154-009-0023-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Measuring and interpreting the selectivity of protein kinase inhibitors</span></div><div class="casAuthors">Smyth Lynette A; Collins Ian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of chemical biology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">131-51</span>
        ISSN:<span class="NLM_cas:issn">1864-6158</span>.
    </div><div class="casAbstract">Protein kinase inhibitors are a well-established class of clinically useful drugs, particularly for the treatment of cancer.  Achieving inhibitor selectivity for particular protein kinases often remains a significant challenge in the development of new small molecules as drugs or as tools for chemical biology research.  This review summarises the methodologies available for measuring kinase inhibitor selectivity, both in vitro and in cells.  The interpretation of kinase inhibitor selectivity data is discussed, particularly with reference to the structural biology of the protein targets.  Measurement and prediction of kinase inhibitor selectivity will be important for the development of new multi-targeted kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzU9rA5WZcz9FxYDaSSP8XfW6udTcc2ebLXvn8EZ_1Jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1MrkslGqtA%253D%253D&md5=f78ff1202a949a71ffd65e804298c37f</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1007%2Fs12154-009-0023-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12154-009-0023-9%26sid%3Dliteratum%253Aachs%26aulast%3DSmyth%26aufirst%3DL.%2BA.%26aulast%3DCollins%26aufirst%3DI.%26atitle%3DMeasuring%2520and%2520interpreting%2520the%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Chem.%2520Biol.%26date%3D2009%26volume%3D2%26spage%3D131%26epage%3D151%26doi%3D10.1007%2Fs12154-009-0023-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Schneider, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, R. M.</span><span> </span><span class="NLM_article-title">Genetic alterations in pancreatic carcinoma</span> <span class="citation_source-journal">Mol. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">15</span><span class="refDoi"> DOI: 10.1186/1476-4598-2-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1186%2F1476-4598-2-15" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=12605716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BD2czltlyhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=15&author=G.+Schneiderauthor=R.+M.+Schmid&title=Genetic+alterations+in+pancreatic+carcinoma&doi=10.1186%2F1476-4598-2-15"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic alterations in pancreatic carcinoma</span></div><div class="casAuthors">Schneider Gunter; Schmid Roland M</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer of the exocrine pancreas represents the fifth leading cause of cancer death in the Western population with an average survival after diagnosis of 3 to 6 months and a five-year survival rate under 5%.  Our understanding of the molecular carcinogenesis has improved in the last few years due to the development of novel molecular biological techniques.  Pancreatic cancer is a multi-stage process resulting from the accumulation of genetic changes in the somatic DNA of normal cells.  In this article we describe major genetic alterations of pancreatic cancer, mutations in the proto-oncogene K-RAS and the tumor suppressors INK4A, TP53 and DPC4/SMAD4.  The accumulation of these genetic changes leads to a profound disturbance in cell cycle regulation and continuous growth.  The knowledge of the underlying molecular mechanisms will offer new therapeutic and diagnostic options and hopefully improve the outcome of this aggressive disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRvHJ3qSMrH5MzK395ZObgVfW6udTcc2ebLXvn8EZ_1Jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2czltlyhtA%253D%253D&md5=9ae0f252ae8dbf2e7f47977948f25abd</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-2-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-2-15%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DG.%26aulast%3DSchmid%26aufirst%3DR.%2BM.%26atitle%3DGenetic%2520alterations%2520in%2520pancreatic%2520carcinoma%26jtitle%3DMol.%2520Cancer%26date%3D2003%26volume%3D2%26spage%3D15%26doi%3D10.1186%2F1476-4598-2-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Mogi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuwano, H.</span><span> </span><span class="NLM_article-title">TP53 mutations in non-small cell lung cancer</span> <span class="citation_source-journal">J. Biomed. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2011</span><span class="NLM_x">, </span> <span class="NLM_fpage">583929</span><span class="refDoi"> DOI: 10.1155/2011/583929</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1155%2F2011%2F583929" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=21331359" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3M3gsVKgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2011&publication_year=2011&pages=583929&author=A.+Mogiauthor=H.+Kuwano&title=TP53+mutations+in+non-small+cell+lung+cancer&doi=10.1155%2F2011%2F583929"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">TP53 mutations in nonsmall cell lung cancer</span></div><div class="casAuthors">Mogi Akira; Kuwano Hiroyuki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of biomedicine & biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2011</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">583929</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The tumor suppressor gene TP53 is frequently mutated in human cancers.  Abnormality of the TP53 gene is one of the most significant events in lung cancers and plays an important role in the tumorigenesis of lung epithelial cells.  Human lung cancers are classified into two major types, small cell lung cancer (SCLC) and nonsmall cell lung cancer (NSCLC).  The latter accounts for approximately 80% of all primary lung cancers, and the incidence of NSCLC is increasing yearly.  Most clinical studies suggest that NSCLC with TP53 alterations carries a worse prognosis and may be relatively more resistant to chemotherapy and radiation.  A deep understanding of the role of TP53 in lung carcinogenesis may lead to a more reasonably targeted clinical approach, which should be exploited to enhance the survival rates of patients with lung cancer.  This paper will focus on the role of TP53 in the molecular pathogenesis, epidemiology, and therapeutic strategies of TP53 mutation in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkBjLU7AEAUBwLZxei1HN8fW6udTcc2ebLXvn8EZ_1Jrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M3gsVKgtw%253D%253D&md5=61547b78d036d8507b38bbdddf9efa0d</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1155%2F2011%2F583929&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1155%252F2011%252F583929%26sid%3Dliteratum%253Aachs%26aulast%3DMogi%26aufirst%3DA.%26aulast%3DKuwano%26aufirst%3DH.%26atitle%3DTP53%2520mutations%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DJ.%2520Biomed.%2520Biotechnol.%26date%3D2011%26volume%3D2011%26spage%3D583929%26doi%3D10.1155%2F2011%2F583929" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Hingorani, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Multani, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Combs, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deramaudt, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hruban, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rustgi, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span> </span><span class="NLM_article-title">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">469</span><span class="NLM_x">–</span> <span class="NLM_lpage">483</span><span class="refDoi"> DOI: 10.1016/j.ccr.2005.04.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.ccr.2005.04.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15894267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=469-483&author=S.+R.+Hingoraniauthor=L.+Wangauthor=A.+S.+Multaniauthor=C.+Combsauthor=T.+B.+Deramaudtauthor=R.+H.+Hrubanauthor=A.+K.+Rustgiauthor=S.+Changauthor=D.+A.+Tuveson&title=Trp53R172H+and+KrasG12D+cooperate+to+promote+chromosomal+instability+and+widely+metastatic+pancreatic+ductal+adenocarcinoma+in+mice&doi=10.1016%2Fj.ccr.2005.04.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice</span></div><div class="casAuthors">Hingorani, Sunil R.; Wang, Lifu; Multani, Asha S.; Combs, Chelsea; Deramaudt, Therese B.; Hruban, Ralph H.; Rustgi, Anil K.; Chang, Sandy; Tuveson, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">469-483</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">To define the genetic requirements for pancreatic ductal adenocarcinoma (PDA), we have targeted concomitant endogenous expression of Trp53R172H and KrasG12D to the mouse pancreas, revealing the cooperative development of invasive and widely metastatic carcinoma that recapitulates the human disease.  The primary carcinomas and metastases demonstrate a high degree of genomic instability manifested by nonreciprocal translocations without obvious telomere erosion-hallmarks of human carcinomas not typically obsd. in mice.  No mutations were discovered in other cardinal tumor suppressor gene pathways, which, together with previous results, suggests that there are distinct genetic pathways to PDA with different biol. behaviors.  These findings have clear implications for understanding mechanisms of disease pathogenesis, and for the development of detection and targeted treatment strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUqdYCBqe-vrVg90H21EOLACvtfcHk0liDbavjbeyjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkslyitLk%253D&md5=fef745f04506e9e64bbc760a1d6f8cf6</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2005.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2005.04.023%26sid%3Dliteratum%253Aachs%26aulast%3DHingorani%26aufirst%3DS.%2BR.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DMultani%26aufirst%3DA.%2BS.%26aulast%3DCombs%26aufirst%3DC.%26aulast%3DDeramaudt%26aufirst%3DT.%2BB.%26aulast%3DHruban%26aufirst%3DR.%2BH.%26aulast%3DRustgi%26aufirst%3DA.%2BK.%26aulast%3DChang%26aufirst%3DS.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26atitle%3DTrp53R172H%2520and%2520KrasG12D%2520cooperate%2520to%2520promote%2520chromosomal%2520instability%2520and%2520widely%2520metastatic%2520pancreatic%2520ductal%2520adenocarcinoma%2520in%2520mice%26jtitle%3DCancer%2520Cell%26date%3D2005%26volume%3D7%26spage%3D469%26epage%3D483%26doi%3D10.1016%2Fj.ccr.2005.04.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Weiss, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aldape, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohapatra, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bishop, J. M.</span><span> </span><span class="NLM_article-title">Targeted expression of MYCN causes neuroblastoma in transgenic mice</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2985</span><span class="NLM_x">–</span> <span class="NLM_lpage">2995</span><span class="refDoi"> DOI: 10.1093/emboj/16.11.2985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1093%2Femboj%2F16.11.2985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=9214616" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADyaK2sXktlaqu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1997&pages=2985-2995&author=W.+A.+Weissauthor=K.+Aldapeauthor=G.+Mohapatraauthor=B.+G.+Feuersteinauthor=J.+M.+Bishop&title=Targeted+expression+of+MYCN+causes+neuroblastoma+in+transgenic+mice&doi=10.1093%2Femboj%2F16.11.2985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted expression of MYCN causes neuroblastoma in transgenic mice</span></div><div class="casAuthors">Weiss, William A.; Aldape, Ken; Mohapatra, Gayatry; Feuerstein, Burt G.; Bishop, J. Michael</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2985-2995</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The proto-oncogene MYCN is often amplified in human neuroblastomas.  The assumption that the amplification contributes to tumorigenesis has never been tested directly.  The authors have created transgenic mice that over-express MYCN in neuroectodermal cells and develop neuroblastoma.  Anal. of tumors by comparative genomic hybridization revealed gains and losses of at least seven chromosomal regions, all of which are syntenic with comparable abnormalities detected in human neuroblastomas.  In addn., the authors have shown that increases in MYCN dosage or deficiencies in either of the tumor suppressor genes NF1 or RB1 can augment tumorigenesis by the transgene.  Thus, MYCN can contribute to the genesis of neuroblastoma, the genetic events involved in the genesis of neuroblastoma can be tumorigenic in more than one chronol. sequence, and the model could be used for further study of the pathogenesis and therapy of neuroblastoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3hLdZJ6w4wbVg90H21EOLACvtfcHk0liDbavjbeyjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXktlaqu7o%253D&md5=5171e78c0df25a1b329ab56592b21372</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1093%2Femboj%2F16.11.2985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Femboj%252F16.11.2985%26sid%3Dliteratum%253Aachs%26aulast%3DWeiss%26aufirst%3DW.%2BA.%26aulast%3DAldape%26aufirst%3DK.%26aulast%3DMohapatra%26aufirst%3DG.%26aulast%3DFeuerstein%26aufirst%3DB.%2BG.%26aulast%3DBishop%26aufirst%3DJ.%2BM.%26atitle%3DTargeted%2520expression%2520of%2520MYCN%2520causes%2520neuroblastoma%2520in%2520transgenic%2520mice%26jtitle%3DEMBO%2520J.%26date%3D1997%26volume%3D16%26spage%3D2985%26epage%3D2995%26doi%3D10.1093%2Femboj%2F16.11.2985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Jamin, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tucker, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Popov, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boult, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webber, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallsworth, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koh, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pearson, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesler, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, S. P.</span><span> </span><span class="NLM_article-title">Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma</span> <span class="citation_source-journal">Radiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">266</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">140</span><span class="refDoi"> DOI: 10.1148/radiol.12120128</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1148%2Fradiol.12120128" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=266&publication_year=2013&pages=130-140&author=Y.+Jaminauthor=E.+R.+Tuckerauthor=E.+Poonauthor=S.+Popovauthor=L.+Vaughanauthor=J.+K.+Boultauthor=H.+Webberauthor=A.+Hallsworthauthor=L.+C.+Bakerauthor=C.+Jonesauthor=D.+M.+Kohauthor=A.+D.+Pearsonauthor=L.+Cheslerauthor=S.+P.+Robinson&title=Evaluation+of+clinically+translatable+MR+imaging+biomarkers+of+therapeutic+response+in+the+TH-MYCN+transgenic+mouse+model+of+neuroblastoma&doi=10.1148%2Fradiol.12120128"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1148%2Fradiol.12120128&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1148%252Fradiol.12120128%26sid%3Dliteratum%253Aachs%26aulast%3DJamin%26aufirst%3DY.%26aulast%3DTucker%26aufirst%3DE.%2BR.%26aulast%3DPoon%26aufirst%3DE.%26aulast%3DPopov%26aufirst%3DS.%26aulast%3DVaughan%26aufirst%3DL.%26aulast%3DBoult%26aufirst%3DJ.%2BK.%26aulast%3DWebber%26aufirst%3DH.%26aulast%3DHallsworth%26aufirst%3DA.%26aulast%3DBaker%26aufirst%3DL.%2BC.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DKoh%26aufirst%3DD.%2BM.%26aulast%3DPearson%26aufirst%3DA.%2BD.%26aulast%3DChesler%26aufirst%3DL.%26aulast%3DRobinson%26aufirst%3DS.%2BP.%26atitle%3DEvaluation%2520of%2520clinically%2520translatable%2520MR%2520imaging%2520biomarkers%2520of%2520therapeutic%2520response%2520in%2520the%2520TH-MYCN%2520transgenic%2520mouse%2520model%2520of%2520neuroblastoma%26jtitle%3DRadiology%26date%3D2013%26volume%3D266%26spage%3D130%26epage%3D140%26doi%3D10.1148%2Fradiol.12120128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Hosea, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collard, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maurer, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fang, R. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakar, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaumont, K.</span><span> </span><span class="NLM_article-title">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span> <span class="citation_source-journal">J. Clin. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">513</span><span class="NLM_x">–</span> <span class="NLM_lpage">533</span><span class="refDoi"> DOI: 10.1177/0091270009333209</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1177%2F0091270009333209" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=19299532" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2009&pages=513-533&author=N.+A.+Hoseaauthor=W.+T.+Collardauthor=S.+Coleauthor=T.+S.+Maurerauthor=R.+X.+Fangauthor=H.+Jonesauthor=S.+M.+Kakarauthor=Y.+Nakaiauthor=B.+J.+Smithauthor=R.+Websterauthor=K.+Beaumont&title=Prediction+of+human+pharmacokinetics+from+preclinical+information%3A+comparative+accuracy+of+quantitative+prediction+approaches&doi=10.1177%2F0091270009333209"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches</span></div><div class="casAuthors">Hosea, Natilie A.; Collard, Wendy T.; Cole, Susan; Maurer, Tristan S.; Fang, Rick X.; Jones, Hannah; Kakar, Shefali M.; Nakai, Yasuhiro; Smith, Bill J.; Webster, Rob; Beaumont, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">513-533</span>CODEN:
                <span class="NLM_cas:coden">JCPCBR</span>;
        ISSN:<span class="NLM_cas:issn">0091-2700</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">A review.  Quant. prediction of human pharmacokinetics is crit. in assessing the viability of drug candidates and in detg. first-in-human dosing.  Numerous prediction methodologies, incorporating both in vitro and preclin. in vivo data, have been developed in recent years, each with advantages and disadvantages.  However, the lack of a comprehensive data set, both preclin. and clin., has limited efforts to evaluate the optimal strategy (or strategies) that results in quant. predictions of human pharmacokinetics.  To address this issue, the authors conducted a retrospective anal. using 50 proprietary compds. for which in vitro, preclin. pharmacokinetic data and oral single-dose human pharmacokinetic data were available.  Five predictive strategies, involving either allometry or use of unbound intrinsic clearance from microsomes or hepatocytes, were then compared for their ability to predict human oral clearance, half-life through predictions of systemic clearance, vol. of distribution, and bioavailability.  Use of a single-species scaling approach with rat, dog, or monkey was as accurate as or more accurate than using multiple-species allometry.  For those compds. cleared almost exclusively by P 450-mediated pathways, scaling from human liver microsomes was as predictive as single-species scaling of clearance based on data from rat, dog, or monkey.  These data suggest that use of predictive methods involving either single-species in vivo data or in vitro human liver microsomes can quant. predict human in vivo pharmacokinetics and suggest the possibility of streamlining the predictive methodol. through use of a single species or use only of human in vitro microsomal prepns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrg67HcwS4O4LVg90H21EOLACvtfcHk0liDbavjbeyjeQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFWmu74%253D&md5=a0941d53fe43392f8fb1562ee546705e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1177%2F0091270009333209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0091270009333209%26sid%3Dliteratum%253Aachs%26aulast%3DHosea%26aufirst%3DN.%2BA.%26aulast%3DCollard%26aufirst%3DW.%2BT.%26aulast%3DCole%26aufirst%3DS.%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DFang%26aufirst%3DR.%2BX.%26aulast%3DJones%26aufirst%3DH.%26aulast%3DKakar%26aufirst%3DS.%2BM.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DSmith%26aufirst%3DB.%2BJ.%26aulast%3DWebster%26aufirst%3DR.%26aulast%3DBeaumont%26aufirst%3DK.%26atitle%3DPrediction%2520of%2520human%2520pharmacokinetics%2520from%2520preclinical%2520information%253A%2520comparative%2520accuracy%2520of%2520quantitative%2520prediction%2520approaches%26jtitle%3DJ.%2520Clin.%2520Pharmacol.%26date%3D2009%26volume%3D49%26spage%3D513%26epage%3D533%26doi%3D10.1177%2F0091270009333209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span>CardiacProfiler; <span class="NLM_publisher-name">Eurofins Pharma Discovery Services</span>: <span class="NLM_publisher-loc">St. Charles, MO</span>; <a href="http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitro-pharmacology/ion-channels.aspx" class="extLink">http://www.eurofins.com/pharma-services/pharma-discovery-services/services/in-vitro-pharmacology/ion-channels.aspx</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=CardiacProfiler%3B+Eurofins+Pharma+Discovery+Services%3A+St.+Charles%2C+MO%3B+http%3A%2F%2Fwww.eurofins.com%2Fpharma-services%2Fpharma-discovery-services%2Fservices%2Fin-vitro-pharmacology%2Fion-channels.aspx."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DCardiacProfiler%26pub%3DEurofins%2520Pharma%2520Discovery%2520Services" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Hu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kolesnikov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggs, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wesson, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leahy, E. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shrader, W. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sprengeler, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sanford, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjerstad, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabuslay, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, W. B.</span><span> </span><span class="NLM_article-title">Potent 4-amino-5-azaindole factor VIIa inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">4567</span><span class="NLM_x">–</span> <span class="NLM_lpage">4570</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2006.06.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.bmcl.2006.06.016" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=4567-4570&author=H.+Huauthor=A.+Kolesnikovauthor=J.+R.+Riggsauthor=K.+E.+Wessonauthor=R.+Stephensauthor=E.+M.+Leahyauthor=W.+D.+Shraderauthor=P.+A.+Sprengelerauthor=M.+J.+Greenauthor=E.+Sanfordauthor=M.+Nguyenauthor=E.+Gjerstadauthor=R.+Cabuslayauthor=W.+B.+Young&title=Potent+4-amino-5-azaindole+factor+VIIa+inhibitors&doi=10.1016%2Fj.bmcl.2006.06.016"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2006.06.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2006.06.016%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DH.%26aulast%3DKolesnikov%26aufirst%3DA.%26aulast%3DRiggs%26aufirst%3DJ.%2BR.%26aulast%3DWesson%26aufirst%3DK.%2BE.%26aulast%3DStephens%26aufirst%3DR.%26aulast%3DLeahy%26aufirst%3DE.%2BM.%26aulast%3DShrader%26aufirst%3DW.%2BD.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DGreen%26aufirst%3DM.%2BJ.%26aulast%3DSanford%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DM.%26aulast%3DGjerstad%26aufirst%3DE.%26aulast%3DCabuslay%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DPotent%25204-amino-5-azaindole%2520factor%2520VIIa%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D4567%26epage%3D4570%26doi%3D10.1016%2Fj.bmcl.2006.06.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Mineno, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kansui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimitsu, H.</span><span> </span><span class="NLM_article-title">A convergent synthesis of the imidazopyridine scaffold of fluorescent alkaloid ageladine A</span> <span class="citation_source-journal">Tetrahedron Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">3131</span><span class="NLM_x">–</span> <span class="NLM_lpage">3132</span><span class="refDoi"> DOI: 10.1016/j.tetlet.2011.04.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1016%2Fj.tetlet.2011.04.024" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2011&pages=3131-3132&author=T.+Minenoauthor=H.+Kansuiauthor=H.+Yoshimitsu&title=A+convergent+synthesis+of+the+imidazopyridine+scaffold+of+fluorescent+alkaloid+ageladine+A&doi=10.1016%2Fj.tetlet.2011.04.024"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.tetlet.2011.04.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tetlet.2011.04.024%26sid%3Dliteratum%253Aachs%26aulast%3DMineno%26aufirst%3DT.%26aulast%3DKansui%26aufirst%3DH.%26aulast%3DYoshimitsu%26aufirst%3DH.%26atitle%3DA%2520convergent%2520synthesis%2520of%2520the%2520imidazopyridine%2520scaffold%2520of%2520fluorescent%2520alkaloid%2520ageladine%2520A%26jtitle%3DTetrahedron%2520Lett.%26date%3D2011%26volume%3D52%26spage%3D3131%26epage%3D3132%26doi%3D10.1016%2Fj.tetlet.2011.04.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Xds</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1107/S0907444909047337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Xds&doi=10.1107%2FS0907444909047337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lid686f0O-3wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DXds%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132%26doi%3D10.1107%2FS0907444909047337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Evans, P. R.</span><span> </span><span class="NLM_article-title">Scaling and assessment of data quality</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">72</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1107/S0907444905036693</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444905036693" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=16369096" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2006&pages=72-82&author=P.+R.+Evans&title=Scaling+and+assessment+of+data+quality&doi=10.1107%2FS0907444905036693"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Scaling and assessment of data quality</span></div><div class="casAuthors">Evans, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">D62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">72-82</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">The various phys. factors affecting measured diffraction intensities are discussed, as are the scaling models which may be used to put the data on a consistent scale.  After scaling, the intensities can be analyzed to set the real resoln. of the data set, to detect bad regions (e.g. bad images), to analyze radiation damage and to assess the overall quality of the data set.  The significance of any anomalous signal may be assessed by probability and correlation anal.  The algorithms used by the CCP4 scaling program SCALA are described.  A requirement for the scaling and merging of intensities is knowledge of the Laue group and point-group symmetries: the possible symmetry of the diffraction pattern may be detd. from scores such as correlation coeffs. between observations which might be symmetry-related.  These scoring functions are implemented in a new program POINTLESS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGravLSLU62RhLVg90H21EOLACvtfcHk0lid686f0O-3wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlant7jM&md5=293d3876e534c0c57813990515bb3c76</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1107%2FS0907444905036693&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444905036693%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DP.%2BR.%26atitle%3DScaling%2520and%2520assessment%2520of%2520data%2520quality%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2006%26volume%3D62%26spage%3D72%26epage%3D82%26doi%3D10.1107%2FS0907444905036693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">COOT: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span><span class="refDoi"> DOI: 10.1107/S0907444904019158</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=COOT%3A+Model-building+tools+for+molecular+graphics&doi=10.1107%2FS0907444904019158"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lhl34MuuzOCbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCOOT%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132%26doi%3D10.1107%2FS0907444904019158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, W.; Roversi, P.; Sharff, A.; Smart, O. S.; Vonrhein, C.; Womack, T. O.</span>BUSTER, <span class="NLM_edition">version 2.10.1</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=G.+Bricogne&author=E.+Blanc&author=M.+Brandl&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=P.+Roversi&author=A.+Sharff&author=O.+S.+Smart&author=C.+Vonrhein&author=T.+O.+Womack&title=BUSTER"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DBricogne%26aufirst%3DG.%26jtitle%3DBUSTER%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Adams, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afonine, P. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunkóczi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Echols, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Headd, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, L.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapral, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grosse-Kunstleve, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCoy, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriarty, N. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oeffner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richardson, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terwilliger, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwart, P. H.</span><span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">213</span><span class="NLM_x">–</span> <span class="NLM_lpage">221</span><span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.-W.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0lhl34MuuzOCbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.-W.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Smart, O. S.; Womack, T. O.; Sharff, A.; Flensburg, C.; Keller, P.; Paciorek, W.; Vonrhein, C.; Bricogne, G.</span>GRADE, <span class="NLM_edition">version 1.2.1</span>; <span class="NLM_publisher-name">Global Phasing Ltd.</span>: <span class="NLM_publisher-loc">Cambridge, UK</span>,<span class="NLM_x"> </span><span class="NLM_year">2012</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=O.+S.+Smart&author=T.+O.+Womack&author=A.+Sharff&author=C.+Flensburg&author=P.+Keller&author=W.+Paciorek&author=C.+Vonrhein&author=G.+Bricogne&title=GRADE"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DO.%2BS.%26jtitle%3DGRADE%26pub%3DGlobal%2520Phasing%2520Ltd%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Bruno, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kessler, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motherwell, W. D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Purkis, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orpen, A. G.</span><span> </span><span class="NLM_article-title">Retrieval of crystallographically-derived molecular geometry information</span> <span class="citation_source-journal">J. Chem. Inf. Comput. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2133</span><span class="NLM_x">–</span> <span class="NLM_lpage">2144</span><span class="refDoi"> DOI: 10.1021/ci049780b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci049780b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotlalsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2004&pages=2133-2144&author=I.+J.+Brunoauthor=J.+C.+Coleauthor=M.+Kesslerauthor=J.+Luoauthor=W.+D.+S.+Motherwellauthor=L.+H.+Purkisauthor=B.+R.+Smithauthor=R.+Taylorauthor=R.+I.+Cooperauthor=S.+E.+Harrisauthor=A.+G.+Orpen&title=Retrieval+of+crystallographically-derived+molecular+geometry+information&doi=10.1021%2Fci049780b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Retrieval of Crystallographically-Derived Molecular Geometry Information</span></div><div class="casAuthors">Bruno, Ian J.; Cole, Jason C.; Kessler, Magnus; Luo, Jie; Motherwell, W. D. Sam; Purkis, Lucy H.; Smith, Barry R.; Taylor, Robin; Cooper, Richard I.; Harris, Stephanie E.; Orpen, A. Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Computer Sciences</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2133-2144</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">0095-2338</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The crystallog. detd. bond length, valence angle, and torsion angle information in the Cambridge Structural Database (CSD) has many uses.  However, accessing it by conventional substructure searching requires nontrivial user intervention.  In consequence, these valuable data were underused and were not directly accessible to client applications.  The situation was remedied by development of a new program (Mogul) for automated retrieval of mol. geometry data from the CSD.  The program uses a system of keys to encode the chem. environments of fragments (bonds, valence angles, and acyclic torsions) from CSD structures.  Fragments with identical keys are deemed to be chem. identical and are grouped together, and the distribution of the appropriate geometrical parameter (bond length, valence angle, or torsion angle) is computed and stored.  Use of a search tree indexed on key values, together with a novel similarity calcn., then enables the distribution matching any given query fragment (or the distributions most closely matching, if an adequate exact match is unavailable) to be found easily and with no user intervention.  Validation expts. indicate that, with rare exceptions, search results afford precise and unbiased ests. of mol. geometrical preferences.  Such ests. may be used, for example, to validate the geometries of libraries of modeled mols. or of newly detd. crystal structures or to assist structure soln. from low-resoln. (e.g. powder diffraction) x-ray data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8AZn6w-T817Vg90H21EOLACvtfcHk0ligajlvWjY6Lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotlalsr8%253D&md5=a7909c257045351d5bff7b78c7fba2d5</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fci049780b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci049780b%26sid%3Dliteratum%253Aachs%26aulast%3DBruno%26aufirst%3DI.%2BJ.%26aulast%3DCole%26aufirst%3DJ.%2BC.%26aulast%3DKessler%26aufirst%3DM.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DMotherwell%26aufirst%3DW.%2BD.%2BS.%26aulast%3DPurkis%26aufirst%3DL.%2BH.%26aulast%3DSmith%26aufirst%3DB.%2BR.%26aulast%3DTaylor%26aufirst%3DR.%26aulast%3DCooper%26aufirst%3DR.%2BI.%26aulast%3DHarris%26aufirst%3DS.%2BE.%26aulast%3DOrpen%26aufirst%3DA.%2BG.%26atitle%3DRetrieval%2520of%2520crystallographically-derived%2520molecular%2520geometry%2520information%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Comput.%2520Sci.%26date%3D2004%26volume%3D44%26spage%3D2133%26epage%3D2144%26doi%3D10.1021%2Fci049780b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Workman, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aboagye, E. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balkwill, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balmain, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruder, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaplin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Double, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Everitt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farningham, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glennie, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelland, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robinson, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratford, I. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tozer, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wedge, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eccles, S. A.</span><span> </span><span class="NLM_article-title">Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">1555</span><span class="NLM_x">–</span> <span class="NLM_lpage">1577</span><span class="refDoi"> DOI: 10.1038/sj.bjc.6605642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=10.1038%2Fsj.bjc.6605642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=20502460" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;key=1%3ACAS%3A280%3ADC%252BC3czmvFyhsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2010&pages=1555-1577&author=P.+Workmanauthor=E.+O.+Aboagyeauthor=F.+Balkwillauthor=A.+Balmainauthor=G.+Bruderauthor=D.+J.+Chaplinauthor=J.+A.+Doubleauthor=J.+Everittauthor=D.+A.+Farninghamauthor=M.+J.+Glennieauthor=L.+R.+Kellandauthor=V.+Robinsonauthor=I.+J.+Stratfordauthor=G.+M.+Tozerauthor=S.+Watsonauthor=S.+R.+Wedgeauthor=S.+A.+Eccles&title=Committee+of+the+National+Cancer+Research+Institute.+Guidelines+for+the+welfare+and+use+of+animals+in+cancer+research&doi=10.1038%2Fsj.bjc.6605642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Guidelines for the welfare and use of animals in cancer research</span></div><div class="casAuthors">Workman P; Aboagye E O; Balkwill F; Balmain A; Bruder G; Chaplin D J; Double J A; Everitt J; Farningham D A H; Glennie M J; Kelland L R; Robinson V; Stratford I J; Tozer G M; Watson S; Wedge S R; Eccles S A</div><div class="citationInfo"><span class="NLM_cas:title">British journal of cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1555-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Animal experiments remain essential to understand the fundamental mechanisms underpinning malignancy and to discover improved methods to prevent, diagnose and treat cancer.  Excellent standards of animal care are fully consistent with the conduct of high quality cancer research.  Here we provide updated guidelines on the welfare and use of animals in cancer research.  All experiments should incorporate the 3Rs: replacement, reduction and refinement.  Focusing on animal welfare, we present recommendations on all aspects of cancer research, including: study design, statistics and pilot studies; choice of tumour models (e.g., genetically engineered, orthotopic and metastatic); therapy (including drugs and radiation); imaging (covering techniques, anaesthesia and restraint); humane endpoints (including tumour burden and site); and publication of best practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRkVD7D529OLg5nADWVYHg1fW6udTcc2ea-htFDerByhbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3czmvFyhsQ%253D%253D&md5=55f4c62e16fb1ebaa1f05d59caba3989</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6605642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6605642%26sid%3Dliteratum%253Aachs%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBalkwill%26aufirst%3DF.%26aulast%3DBalmain%26aufirst%3DA.%26aulast%3DBruder%26aufirst%3DG.%26aulast%3DChaplin%26aufirst%3DD.%2BJ.%26aulast%3DDouble%26aufirst%3DJ.%2BA.%26aulast%3DEveritt%26aufirst%3DJ.%26aulast%3DFarningham%26aufirst%3DD.%2BA.%26aulast%3DGlennie%26aufirst%3DM.%2BJ.%26aulast%3DKelland%26aufirst%3DL.%2BR.%26aulast%3DRobinson%26aufirst%3DV.%26aulast%3DStratford%26aufirst%3DI.%2BJ.%26aulast%3DTozer%26aufirst%3DG.%2BM.%26aulast%3DWatson%26aufirst%3DS.%26aulast%3DWedge%26aufirst%3DS.%2BR.%26aulast%3DEccles%26aufirst%3DS.%2BA.%26atitle%3DCommittee%2520of%2520the%2520National%2520Cancer%2520Research%2520Institute.%2520Guidelines%2520for%2520the%2520welfare%2520and%2520use%2520of%2520animals%2520in%2520cancer%2520research%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2010%26volume%3D102%26spage%3D1555%26epage%3D1577%26doi%3D10.1038%2Fsj.bjc.6605642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM7','PDB','2YM7'); return false;">PDB: 2YM7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N','PDB','5F4N'); return false;">PDB: 5F4N</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2YM8','PDB','2YM8'); return false;">PDB: 2YM8</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i27"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01938">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_72150"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01938">10.1021/acs.jmedchem.5b01938</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Mouse liver microsome stability of selected compounds; kinase inhibition profile of <b>4</b>; potentiation of genotoxic efficacy in cancer cell lines by <b>4</b>; cardiac ion channel inhibition profile of <b>4</b>; experimental methods for the synthesis of compounds <b>3</b> and <b>5</b>–<b>42</b>; experimental methods for in silico classification model; experimental methods for in vivo procedures; experimental methods for MRI; data collection and refinement statistics for the crystal structure of CHK1 with <b>12</b>; HPLC data for key compounds; <sup>1</sup>H and <sup>13</sup>C NMR spectra for compounds <b>3</b>–<b>42</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_001.pdf">jm5b01938_si_001.pdf (7.78 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01938/suppl_file/jm5b01938_si_002.csv">jm5b01938_si_002.csv (3.52 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB ID code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5F4N">5F4N</a>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01938&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-11%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01938%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01938" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a8254c95a3cca","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
